

56-1 ONE REPORT 2024

DEVELOP & EXPAND



 โรงพยาบาล
ไทรนครินทร์
THAINAKARIN HOSPITAL

THAINAKARIN HOSPITAL PUBLIC COMPANY LIMITED
บริษัท โรงพยาบาลไทรนครินทร์ จำกัด (มหาชน)



Teamwork and staff value
Non-stop learning and improvement
Hospitality and quality care

Thainakarin...

The hospital you can trust

Hospital Policy and Strategy Committee



1



2



3



4



5



6



7



8



9



10



11



12



13



14



15



16



17

1. Charoen Meensook, M.D.
2. Mr. Thiti Sihanatkathakul
3. Prof. Pittayapoom Pattaranutaporn, M.D.
4. Clinical Prof. Seree Tuchinda, M.D.
5. Vinai Viriyakitjar, M.D.
6. Sqn.Ldr. Boonruang Triruangworawat, M.D.
(Distinguished Scholar)
7. Clinical Prof. Emeritus Dhaivadee Dulayajinda, M.D.
8. Clinical Prof. Emeritus Chaiporn Bhadrakom, M.D.
9. Prakasit Chirappapha, M.D.
10. Kacha Ruenkhwan, M.D.
11. Arkom Cheirsilpa, M.D.
12. Clinical Prof. Thipachart Punyaratabandhu, M.D.
13. Phichai Rattanarojsakul, Ph.D.
14. Watson Aphiwatanakoon, M.D.
15. Paitoon Kachornvachara, M.D.
16. Pattarapon Kammuntree, M.D.
17. Miss Malee Boonleechai

Contents

Message from The Chairman of the Board	4
Message from The Chief Executive Officer	5
Technology	6
Part 1 Business Operations and Performance	7
1. Structure and Business Operations	8
1.1 Policy and Overall Business Operations	8
1.2 Nature of Business	10
1.3 Shareholding Structure	23
1.4 Registered Capital and Paid - Up Capital	24
1.5 Other Securities	24
1.6 Dividend Payment Policy	24
2. Risk Management	24
2.1 Risk Management Policy and Plan	25
2.2 Business Risk Factors	25
3. Driving Business For Sustainability	27
3.1 Sustainability Management Policies and Goals	27
3.2 Impact Management to Stakeholders in the Business Value Chain	27
3.3 Sustainability Management In The Environment Dimension	29
3.4 Sustainability Management In Social Dimensions	33
4. Management Discussion and Analysis: MD&A	47
5. General Information and Other Important Information	54
Part 2 Corporate Governance	56
1. Corporate Governance Policy	57
1.1 Overview On Corporate Governance Policy and Guidelines	57
1.2 Code of Conduct	69
1.3 Significant Changes and Development of Corporate Governance Policy, Guidelines and System in the Previous Year	69
2. Corporate Governance Structure	70
2.1 Corporate Governance Structure	70
2.2 Board of Directors	71
2.3 Sub - Committees	73
2.4 Executives	76
2.5 Personnel	78
2.6 Other Important Information	79
3. Significant Performance on Corporate Governance	81
Part 3 Financial Statement	88
Part 4 Certification of Accuracy	130
Attachment	132
Attachment 1 Details of Directors, Executives, the Person taking the highest responsibility in accounting and finance, the Person supervision accounting, Company Secretary and coordinator for foreign investors	133
Attachment 2 Details of Directors of Subsidiaries	153
Attachment 3 Details of the Head of Internal Audit and the Head of Compliance	154
Attachment 4 Business Assets and Details on asset Valuation	155
Attachment 5 Policy and Guidelines for Corporate Governance and Code of Conduct	156
Attachment 6 Report of the Audit Committee	157

MESSAGE FROM THE CHAIRMAN OF THE BOARD

In 2024, Thainakarin Hospital has entered its 31st year. This is an important step and many changes have occurred. The hospital has taken various actions including modifying services. In order to be consistent with changing consumer behavior and to be able to respond to the highest satisfaction of consumers by Thainakarin Hospital as a health service provider who has gained confidence in the potential and readiness to treat various diseases from the people of Eastern Bangkok and the Eastern region of Thailand. Currently, the hospital has more than 30 centers and service departments, including Cancer and Radiotherapy Centers that cancer patients can access to effective cancer treatment under the supervision of specialized doctors and a multidisciplinary team through the Eastern Cancer Network, which consists of Thainakarin Hospital, Samrong Medical Hospital, Cancer Alliance Sriracha Hospital (CAH) and Saha Clinic Chachoengsao (SCC). This network is an important part that makes the hospital is one of the private hospital options that are accepted by people in the Bangkok area Eastern and Eastern regions.

On the occasion of the 31st anniversary of Thainakarin Hospital, to service recipients for good health both physically and mentally and receive maximum benefit, the hospital has increased medical services with various medical equipment imported for the purpose of examining and treating diseases to save time and quickly diagnose the disease in the initial stages to increase treatment efficiency as follows:

- Using AI to help doctors screen for colon cancer
- Robots in knee replacement surgery
- Treating enlarged prostate with REZUM steam

In addition to the medical technology mentioned above, Thainakarin Hospital also plans to open a new center 'Healthy Weight Center' to provide preventive health care services (Prevention) to reduce the chance of chronic non-communicable diseases. And in the 4th quarter, the hospital plans to open a Scope Center to provide specialist medical services in the field of gastrointestinal tract. Both in terms of diagnosis medical treatment and patient care with a team of doctors and nurses with specialized expertise.

All business operations, Thainakarin Hospital does not focus on generating only income and profits but still want to create positive change for the health of people in Eastern Bangkok and Eastern regions of Thailand. The hospital adhere to the mission of the organization, committed to providing the best health care for all service recipients as trusted by the hospital always being a health care provider. In 2024, Thainakarin Hospital received the honorary award 'Allianz Ayudhya Best Collaboration Award' (Best Medical Cooperation and Coordination Award), number one, Group A. This award is a collaboration award between Allianz Ayudhya Assurance Public Company Limited and Thainakarin Hospital from working together to achieve goals and perfectly responds to the needs of customers and service recipients. This honor is another award of pride and confirm the service standards of Thainakarin Hospital and we remain committed to continuously improving the quality of our services and cooperation for the good health of all service recipients forever.

Finally, as the Chairman of Thainakarin Hospital Public Company Limited, I would like to thank shareholders, service recipients, and our business partners as well as all stakeholders who have always given confidence and trust in supporting the Company's business operations and thanks to the doctors, nurses, and medical personnel and all personnel who lead this organization to grow to success together. I believe that today's small step will be a solid step which make Thainakarin Hospital successful according to the intended results and create medical sustainability in the future.



Charoen Meensook, M.D.

Chairman of the Board

MESSAGE FROM THE CHIEF EXECUTIVE OFFICER



A handwritten signature in black ink, appearing to read 'Thiti Sihanatkathakul'.

Mr. Thiti Sihanatkathakul

Chief Executive Officer

As of 2024, Thainakarin Hospital has been operating in providing health services for 31 years and still maintains its leadership as a health service provider to service recipients in the East of Bangkok and expand its coverage to neighboring areas in the East which has a distribution of the population residences, business zones and industrial estates and still tends to expand continuously. Last year, the Company opened Saha Clinic Chachoengsao; the first branch clinic of Thainakarin Hospital in Chachoengsao province to take care of the health of the people of Chachoengsao province from general disease diagnosis, health check and disease prevention, vaccination services. In cases the difficulty and complex diseases are found; the service recipients can consult via Telemedicine with doctors at Thainakarin Hospital. This concept is for Chachoengsao people who come to the medical services at the clinic are able to get the same standard service as coming to a hospital.

In the new decade of Thainakarin Hospital, the Company will not stop at just being the Hospital of Choice in Eastern Bangkok & Eastern Thailand, but the Company has plans to create an organization for sustainable growth. The readiness to penetrate the international market, especially Chinese service recipients and the CLMV group (Cambodia, Laos, Myanmar and Vietnam). In 2024, the number of foreign service recipients of Thainakarin Hospital has increased. Part of this comes from receiving quality certification according to AACI (American Accreditation Commission International) international standards for breast cancer in the past year 2023, it has created confidence in the quality of treatment and service. Currently, Thainakarin Hospital has 80% of Thai patients and 20% of foreign patients.

In the future it is expected that Foreign service recipients will increase. Both foreign service recipients working in Thailand (EXPAT) and service recipients who travel from abroad to receive treatment (Fly-in / Medical Tourism) with the strengths of Thainakarin Hospital that is ready to treat patients by specialist doctors in every field with modern medical technology and a multidisciplinary team with expertise in various fields creates the highest efficiency in care and reasonable price including adding personnel who can communicate in many languages. Newly renovated locations and amenities to create a good service experience for foreign service recipients. This will make Thainakarin Hospital becomes the Hospital of Choice in ASEAN in the future.

Thainakarin Hospital Committed to delivering quality care to all service recipients under outstanding operations from the medical side, treatment technology, and services according to strategic plans which leads to business growth. Finally, on behalf of the CEO of Thainakarin Hospital Public Company Limited, I would like to thank the shareholders, executives, doctors, nurses, and medical personnel and all personnel as well as the business partners for the supportive, trustworthy and always believed in the Company's operations, including being an important force and work together to create success, create good operating results and sustainable growth forever.

TECHNOLOGY

For 2024, Thainakarin Hospital still pay attention to medical tools and equipment. In addition to the expertise and services, the goal of Thainakarin Hospital is being a leader of private hospital that is trusted by people in the Eastern Bangkok area and the Eastern region of Thailand (Hospital of Choice in Eastern Bangkok & Eastern Thailand). Modern medical tools and equipment are one of the important factors that enable medical teams and interdisciplinary teams to provide holistic care to patients or service recipients starting from searching, analyzing, preventing, treating, and controlling disease, as well as restoring health and promoting health. In 2024, medical tools have been added as follows.

Laser machine for the treatment of pigmentation disorders and tattoo removal (ENLIGHTEN SR).

The Enlighten SR is a PICOSECOND LASER type Nd:YAG laser light generator that can adjust the laser light emitting time (Pulse Duration) not less than 750 picoseconds (ps) to treat pigment abnormalities. Or used to remove tattoos by the Enlighten SR machine can produce wavelengths of 532 and 1064 nanometers, which covers both light and dark tattoo removal and treats pigment abnormalities such as

- Treat blemishes, freckles, dark spots (Pigmented Lesion)
- Tighten pores, makes the skin smoother (Rejuvenation)
- Treat acne pits, acne marks, scars (Acne scar)
- Treats skin cracks (Stretch marks)



High-frequency heart monitoring machine (Echocardiography)

From the report of the Ministry of Public Health as many, in 2023, the cumulative number of patients diagnosed with cardiovascular diseases exceeded 250,000 with as 40,000 people will die from cardiovascular diseases or an average of 5 people per hour. The cause is a narrowing of the blood supply to the heart, lack of flexibility. This is due to the accumulation of fat, protein, and inflammation on the inner walls of blood vessels. Important risk factors associated with heart disease and coronary artery disease are age, gender, and family history, high blood pressure levels, high blood sugar levels, high blood fat levels, Obesity and overweight, smoking, drinking alcohol, etc. Most people don't know they have heart disease. This is because the disease often shows no symptoms. Checking heart health to see if there are any abnormalities or not with an ultrasound of the heart. It will help prevent or treat heart abnormalities before it's too late.

High-frequency heart monitoring machine (Echocardiography) is a measuring device to measure the efficiency of the heart's work, such as the contraction of the heart muscle, size of the heart chambers, blood flow in the heart, heart valve function and check the position of various blood vessels that goes in and out of the heart, etc. It is a test by creating an image of the heart from the reflection of high-frequency sound waves sent from the probe. It passes through the chest wall to the heart. When sound waves pass through tissues or organs, different signals are reflected according to tissue composition. The computer then takes these signals and converts them into digital images that can be seen on the screen during the examination (Real-time). This test shows the shape, size, and function of the heart muscles and heart valves. This test is safe and painless, helps doctors diagnose work and diseases related to the heart and blood vessels.

PART

1

Business Operations and Performance

- ① Structure and Business Operations
- ② Risk Management
- ③ Driving Business For Sustainability
- ④ Management Discussion and Analysis: MD&A
- ⑤ General Information and Other Important Information

1 Structure and Business Operations



1.1 Policy and Business Overview

Policy and Commitment of Thainakarin Hospital

Thainakarin Hospital Public Company Limited was incorporated on August 8, 1988, initially under the name “L.J. Enterprise Co., Ltd.” by the Company’s co-founders, a group of businessmen and doctors who had foreseen that there were no quality and affordable private hospitals accessible to the general public. Later, it was registered to change its name to “Thainakarin Hospital Co., Ltd.” and established as private hospital to enable people with medical care at an affordable price and good quality of service. On June 14, 1993, the Company commenced its operation as the “Thainakarin Hospital”.

The Thainakarin Hospital has received a great number of positive feedbacks from the people who come to use the service, and extended more services in response to the increasing number of medical services available. And in order for the Company’s business operations to be able to enhance its potential and compete with the growing number of other private hospital operators, the Company became a public limited company on October 11, 2004, by listed on the MAI Stock Exchange, with its first trading commencement on December 16, 2005. Currently, the Company has a total registered capital which has been issued and paid-up capital of 180 million baht.

The Thainakarin Hospital remains commitment in conducting business with the strength to lead the Hospital to an era of change and competition. The Thainakarin Hospital has implemented the Hospital’s strategic plan, which means to strive for excellence in medical care and services to become the number one hospital in Bangkok Eastern area and Eastern Regions of Thailand and stand firmly and sustainably in this business.

1.1.1 Vision

Hospital of Choice in Eastern Bangkok & Eastern Thailand

Dedicated to being the most trust hospital in Eastern Bangkok and Eastern Region in terms of medical expertise, technology, quality, international standards, warm service, and care like family

Mission

- To develop personnel competency, satisfaction and pride in the company.
- To elevate the health care quality with international standard.
- To progressive proceed with continuous and sustainable development of the company.
- To achieve the best hospitality with a warm and family-like treatment that creates lasting impressions.
- To manage in accordance with the corporate governance.

Business Goal and Strategies

The Company aims to drive an enterprise-wide sustainable development program, with 6 business strategies as follows:

1. To operate with transparency, morality, ethics and responsibility to stakeholders and the society;
2. To operate by providing proper and quality medical care matching international standards;
3. To operate with sincerity, attentiveness and understanding toward patients and service users as if they are family members;
4. To operate with emphasis on personnel, the valuable asset, by taking good care of them and building a favorable work environment to promote happiness and organizational pride;

5. To operate with social responsibility by attaining efficient resources management and good environmental management in all the processes;
6. To operate with emphasis on enhancement of personnel and service quality in order to achieve continual and steady growth of the organization.

Long-term Goal

The Company focusses on the long term goal to build the Thainakarin Hospital 2. In the first phase, the company constructs the car park building and Linac Center buildings have been completed and available for service. in the next period, there will be construction of 1 more building for car park buliding 3.

1.1.2 Significant changes and Development

Thainakarin Hospital has been operating since June 14, 1993, with positive feedbacks from patients throughout, the Hospital provided well-developed various services to meet the needs of its recipients and the changes circumstances as follows;

Service

- **2020** Launch the Rehabilitation Center
- **2021** Launch the Kidney Transplant Center
- **2022** Launch Wellness Center
- **2023** Launch Linac building and renovation various service areas such as Lasik Center, Pediatrics Department and Coffee & Library Zone, 3rd Floor, Including providing service at Saha Clinic Chachoengsao (SCC), located in Chachoengsao province.
- **2024** Launch Lasik Center, 12nd Floor by expanding the area to enhance convenience and accommodate more clients. Including improvements to the service area around the Dental Center.

Awards



- 1** 2021: Claim Service Excellence Award, Bangkok Life Smart Hospital Awards 2021, Bangkok Life Assurance PCL.
- 2** 2022, the Company received a plaque for a hospital-certified 5-star Stroke Center from the Ministry of Public Health.
- 3** 2022: Hospital Accreditation (HA) for the 5th times (Re-Accreditation #5)
- 4** 2023, the Company received AACI (American Accreditation Commission International) and standard breast cancer certification from the United States.
- 5** 2023, the Company received Commitment to Success Silver Award, MUANG THAI LIFE ASSURANCE HOSPITAL AWARDS 2022
- 6** 2023, was selected as one of the 11 best Thai public companies in Asia, Forbes Asia's Best Under a Billion, among 200 best companies from across the Asia-Pacific region with revenues not exceeding USD 1,000 million in 2023 from Forbes.com.
- 7** 2024, Honor award.1st Place group A "Best Collaboration Award", Allianz Ayudhya Hospital Service Awards 2023

Crowdfunding on purpose


- None -

Obligations for offering of securities

- None -

1.2 Nature of Business

Thainakarin Hospital Public Company Limited is situated at 345 Debaratna Road km.3.5, Bangna Nuea, Bangna, Bangkok commenced, on 14 June 1993 under the name “Thainakarin Hospital” after that changed the name to “Thainakarin Hospital, Large General Hospital”, and have license to operate Health Facility establishment business. Being the private hospital in eastern Bangkok, it renders inpatient, outpatient and 24-hour emergency medical services by a multidisciplinary team of specialized doctors with state-of-the-art and standard facilities. Currently staffed by approximately 442 full-time and part-time doctors and 524 nursing staffs, the Hospital has an inpatient bed capacity of 190 and daily outpatient capacity of 2,000, with an after-hour clinic in service until 24.00 hrs. Medical services can be divided by types of patients into 2 groups, which are outpatient services (OPD) that accounts for 58% of the Company’s revenue, and inpatient services (IPD) for 42%.



	2024		2023		2022	
	Amount (MB)	Proportion (%)	Amount (MB)	Proportion (%)	Amount (MB)	Proportion (%)
Revenue from medical services						
OPD	1,559.52	57.39	1,406.76	58.14	1,420.02	54.52
IPD	1,146.70	42.20	997.28	41.22	1,166.88	44.80
Total revenue from medical services	2,706.22	98.59	2,404.04	99.36	2,586.90	99.32
Other revenue	11.29	0.41	15.51	0.64	17.74	0.68
Total revenue	2,717.51	100.00	2,419.55	100.00	2,604.64	100.00

1.2.1 Types of Products and Services

Outpatient service is available from the following departments and centers:

- Heart Center
- Bone & Joint Center
- Holistic Oncology Center
- Breast Care Center
- Hemodialysis Center
- Check-up Center
- Skin & Laser Center
- Dental Center
- Gastrointestinal Center
- Lasik Center

- | | |
|--|--|
| 11. Brain and Neurology Center | 21. Pediatrics Department |
| 12. Rehabilitation Center | 22. Obstetrics and Gynecology Department |
| 13. Kidney transplant Center | 23. Ear, Nose and Throat Department |
| 14. Wellness Center | 24. Eye Department |
| 15. Diabetes & Endocrinology Department | 25. Emergency Department |
| 16. Traditional Chinese Medical Department | 26. ARI Clinic |
| 17. Mental Health Department | 27. Linac Department |
| 18. Hepato-Biliary & Pancreas Department | 28. Laboratory Department |
| 19. Medicine Department | 29. X-ray Department |
| 20. Surgery Department | 30. Physical Therapy Department |

Patient's room types:

- | | |
|------------------------------|-----------------------------|
| 1. Operating Room (OR) | 6. Coronary Care Unit (CCU) |
| 2. Anesthesia Induction Room | 7. Stroke Unit |
| 3. Delivery/Labor Room | 8. Ward |
| 4. Cath Lab Department | 9. Nursery Department |
| 5. Intensive Care Unit (ICU) | |

Besides medical services and treatments, the Company also made available at its premises access to high-speed internet connection, 24-hour convenience stores, Automated teller machine, fruit cup vending machine, florist shops, coffee & bakery shops, maternity shops, optical shop, food center, a Buddhist prayer room and a Muslim prayer room to offer superior convenience to patients and visitors.

Capacity Utilization

Capacity utilization is assessed based on a comparison between the actual service capacity and projected maximum capacity, divided into OPD and IPD groups. The Hospital's service utilization has obviously increased as a result of marketing activities to build brand awareness and enhance image among both Thai and International patients, including patients who pay for their own treatment or insurance. The company has received a positive response, largely due to the quality of specialized medical expertise, excellent service, and cost-effective treatment options. In addition, the company has expanded its patient base to international clients following the country's reopening to foreign tourists, leading to an increase in the number of international customers utilizing its services.

OPD	2024	2023	2022
Capacity per day (times)	2,000	2,000	2,000
Capacity per annum (times)	732,000	730,000	730,000
Service per annum (times)	477,530	446,965	509,752
Capacity utilization (%)	65.24	61.23	69.83

IPD	2024	2023	2022
Bed in service per day (beds)	190	190	190
Total capacity per annum (beds)	69,540	69,350	69,350
Bed in service per annum (beds)	46,588	42,181	42,577
Bed occupancy rate (%)	66.99	60.82	61.39

1.2.2 Market and Competition

1. Overview of Private Hospital Industry in Thailand

TTB Economic Analysis Center (TTB analytics) evaluates the private hospital business in 2024 will generate revenue of 3.22 hundred billion baht, based on challenges that are beginning to face limitations from the trend of a declining population and the concept of using services has changed from treatment to prevention. To reduce the risk of receiving services in the hospital, this made the business model of private hospitals is different from before.

The private hospital business is a business that has grown exponentially over the past 10 years due to the population structure and increasing illness rates includes legal regulations that require entrepreneurs to register their employees as insured. As a result, hospitals have additional income from the social security system with insured persons with medical treatment rights reaching up to 13.7 million people, including group insurance benefits provided by private companies to employees in the amount of more than 2.6 million insurance policies.

In addition to the dimension of the amount of demand that has increased in the past the hospital business is a service business group that is not sensitive to price and income since it is a service business that is necessary and cannot be replaced in terms of quality and length of treatment. As a result, private hospital businesses have the power to easily pass on service prices and private hospital service fees have continued to increase in the past period. The market value of the private hospital business can continue to expand and in 2024, the private hospital business has total revenue of up to 3.22 billion baht, expanding by 4% from 2023 with a total income of 3.14 billion baht. However, when considering since 2022, the private hospital business has recovered and received positive results from the COVID-19 crisis as revenue grew by 29%.

In 2023, the private hospital business began to see signs of growth that were more limited than in the past. This is partly due to the unique characteristics of the demand for service users in private hospitals that are unpredictable or in other words: services will be used when get sick. For this reason, it need an increasing of large population amount rate to be able to create the number of patients at the desired rate on the condition that the hospital admission rate is constant. Therefore, in the year 2023, the population amount decreased, regarding to trend of increased awareness of health care to avoid illness from the high medical costs compared with income.

Even though they have the right to medical expenses from health insurance, it is still found that many times, service users still have to pay excess amounts of treatment costs, thus the rate of hospital admissions in the future may tend to decrease affects to overview of whole private hospital business began to face challenges. The growth of private hospitals will be in a K-Shape, divided into groups as follows:

- The group that continues to maintain good growth rates is private hospitals that focus on foreign customers, whose revenue in 2023 can still expand by approximately 15.3% from the ability to expand the market to increase the number of people receiving services from the quality of medical care high at an accessible price, countries in the Middle East where Thailand has an advantage of lower prices when compared to the same or higher quality including high-income demand groups in the ASEAN region such as Cambodia, Myanmar, Laos, etc., Thailand has an advantage of higher standard quality of its public health system.
- The group that is beginning to face limitations in expansion is the private hospital group that focuses on Thai customers with total revenue decreasing 18.3% in 2023, starting to face constraints from a decrease of outpatients number. From the report of the survey of visits to hospitals and private nursing homes in 2022, there were 58.5 million outpatients, compared to 58.8 million in 2017, and when considering the context that the Thai population is entering a period of decline. As a result, the amount of demand from service users has begun to have limitations in expanding including in the past period, medical expenses have tended to increase at a higher proportion than the increase of income. Pressure to change the behavior of the new generation who are more health conscious to reduce the risk of various diseases in long-term.

Therefore, in the situation where the demand for services by users in the country who receive medical care tends to decrease. Including in the foreign user market, there is still room for expansion, whether from the number of users and prices that are still increasing from comparative prices that are still lower than the country of origin in some countries. But in the long run, growth depends on the context in which foreign markets are beginning to reach saturation. Traditional medical care may begin to face limitations, which ttb analytics is of the opinion that starting from 2024, it will be the beginning of a changing business model of private hospital groups in various forms as follows.

- 1) Using technology to increase service utilization rates due to a part of the current income structure of private hospital groups comes from the health insurance system, such as group insurance with a number of policies as high as 2.6 million. According to statistics, group insured people receive hospital services on average 5.7 times per year. However, using hospital services, even without having to pay medical expenses, has other hidden costs such as travel expenses and time off work that may affect the evaluation results of work efficiency each year. As a result, sometimes people who come to the service with minor illnesses may choose not to receive service even though they have the right to receive treatment. As a result, the use of technology such as Telemedicine can increase the frequency of service visits even though there may not be an increase in the number of service recipients.
- 2) Increasing the specific needs of medical services to reduce limitations on the unpredictable demand of service users to create a special needs to receive medical services. For example, in hospitals and specialized clinics such as therapy, beauty treatments or even the trend to avoid illness through preventative care where income grows at an accelerating rate at an average over the past 3 years of 30.2%. The expected revenue in 2024 is approximately 4.2 billion baht from the ability to respond to specific needs other than receiving services for treatment purposes with a low frequency of service use and limitations in marketing from the inability to predict the use of the service.
- 3) Focusing on creating recurring income to create a revenue base that can grow regularly from predictable users. By adding special needs to change the perspective from the original service for treatment towards a contemporary perspective that receives services in the form of preventive care. This creates a new service model with higher frequency, such as rehabilitation medicine, health services or dietary supplement group. Including expanding service formats in the elderly care business that answers the problems of Thailand, which is about to enter a Super Aged Society. In the context of smaller families, this is an additional factor supporting the elderly care business in a direction that can expand continuously.

Resource: TerraBKK.com - <https://www.terrabkk.com/articles/202367>

2. Industry Trends

Thainakarin Hospital has proactive strategic planning. The goal is to be a leading private hospital that is trusted by people in Eastern Bangkok area, Eastern coast and Eastern regions of Thailand. That has the ability to provide medical services from finding, analyzing, preventing, treating and controlling disease, restoring health and promoting health. In 2023, the hospital raised the quality of treatment by opening a cancer center. It covers diagnosis, treatment and rehabilitation of both body and mind (Comprehensive Cancer Center). For that treatment services will range from surgical treatment (Surgery), cancer chemotherapy (Chemotherapy), use of specific cancer drugs (Target Therapy), radiotherapy. In addition, the hospital has built a radiotherapy building, equipped with a high-energy particle accelerator irradiation machine (Linear Accelerator; Linac) and a computerized tomography treatment simulator for more efficiency in caring of cancer patients.

Thainakarin Hospital has developed the quality of treatment and holistic health care under the concept of Personalized Healthcare, reassure on every treatment which aims to be Hospital of Choice, the number one hospital for people in Bangkok, the East Coast and the Eastern region. For the Eastern Cancer Network Project, it is a collaborative network for treating cancer patients in the Eastern Region of Thailand for patient referrals. Using equipment together provides maximum benefit and value in terms of treatment and costs including cooperation in transferring academic knowledge between networks, the strengths of medical expertise quality and standard technology, warm and attentive service like family members leading to design treatment and services in a specific, individual manner for good treatment results create a good experience for service recipients.

In addition, the hospital medical tools and technology are available to help increase the efficiency of patient treatment, including 3D mammography (Digital Mammogram With Tomosynthesis) to increase the accuracy of diagnosis. This makes breast cancer detection more effective as it can clearly differentiate between normal tumors and breast cancer tumors. Reduce the rate of calling patients back for repeat examinations (Reduce Recall Rate) and helps increase efficiency in screening patients for breast biopsies. Currently, AI is being used in conjunction with colonoscopy to screen for colon cancer with AI-Assisted Colonoscopy technology to detect polyps and read the mucosa in biopsies. AI plays an important role as a virtual assistant. For doctor and allow doctors to perform examinations and treatment more efficiently the Hospitals provides minimally invasive spinal surgery (Full Endoscopies Surgery) which reduce the length of stay in the hospital, reduce complications resulting from surgery and better quality of patients life.

The hospital also focuses on providing kidney transplant center and heart center to support providing services to patients who need a kidney transplant and patients with heart problems. The hospital also focuses on services related to laparoscopic surgery by using a camera and small tools to perform surgery. The surgical wound is small, this reduces the length of stay in the hospital. Reduce complications resulting from surgery and improve the better quality of patients life as well as giving advice about diseases and other medical treatments. There are plans to build on strengths and expertise in this area to reach all groups of service recipients. By expanding the service base on preventive health examinations in an off-site format (Mobile Checkup) to general service recipients and groups of service recipients who are contracting companies to continue to provide health promotion services (Health Promotion & Wellness) for the group of service recipients who do not have any symptoms of illness but are concerned about their health and want to promote good health to provide a better quality of life. It is holistic health care which has received cooperation from a team of doctors and medical personnel with specialists from various professional fields such as occupational medicine doctors, Anti-aging medicine doctor, Rehabilitation doctors, psychiatrists, physical therapists, and nutritionists, etc.

Major Customer

Over a period of 31 years, the Company has enhanced its medical care capacity and service strengths in pursuit of service and academic excellence, as follows:

1. **Corporate:** Customers who are the employees of the contractual corporate making an agreement to define its employees to exercise medical welfare right at Thainakarin Hospital with expense of such corporate.
2. **Insurance:** Customers who are general customers and employees of the company providing welfare to its employees for receiving medical services at Thainakarin Hospital through health insurance with expenses of the insurance company based on coverage and conditions of each policy made by the insurance company.
3. **Self-pay:** General customers who pay for medical fee by themselves in the form of debit card, credit card or cash. Most of them live in the nearby areas while others are customers who live far from the hospital but are confident with quality and standards of Thainakarin Hospital as well as patients transferred from other hospitals.

Performance Highlights

Over a period of 31 years, the Company has enhanced its medical care capacity and service strengths in pursuit of service and academic excellence, as follows:

- 1. Promptness of Professional Treatment and Services:** Both medical and supporting personnel of the Hospital use knowledge and expertise in best performing their duties to ensure that the service recipients receive appropriate medical care and highest possible satisfactory services. Improvement and rectification of problems shall be readily and regularly carried out.
- 2. Promptness of Physicians, Nurses and Multi-disciplinary Team:** Accessibility for patients and service recipients to comprehensive, swift and precise medical care is enabled by the promptness of our proficient medical team through 24-hours emergency units, namely.
 - 2.1 24-hours Emergency Heart Center, thus capable of treating all irregular conditions of acute and chronic heart diseases.
 - 2.2 24-hour Emergency Brain and Neurology Center fully-equipped with medical and surgical equipment, thus capable of treating acute and chronic brain diseases, both of which help reduce mortality or disability rate of patients to a great extent.
 - 2.3 A team of pediatricians takes care of pediatric emergency patients 24 hours a day. Thainakarin Hospital is ready to provide care for pediatric patients by providing services 24 hours a day. General pediatricians and specialists are prepared to care for children from birth to 15 years of age.

Such emergency medical services significantly reduce the rate of death or disability of patients.

- 3. Assured Trustworthiness of Medical Care and Hospitable Services:** The Hospital is always be regarded with trust and widely accepted in order to ensure that service recipients are assured to receive quality treatment and services from personnel who understands the true principles of service. The evidence shown from the Annual Honorary Award, Allianz Ayudhya Hospital 2023, organized by Allianz Ayudhya Life Assurance PCL. the Hospital won the first Award in Group A “Best Collaboration Award” (Best Medical Cooperation and Coordination Award). It reinforces the development of treatment service standards and promotes the development of hospital service standards.
- 4. International Standard Quality:** The Hospital’s medical care has been monitored and controlled in compliance with standards of relevant quality accreditation institutes.
 - In 2003, it received quality accreditation from the Healthcare Accreditation Institute. (Public Organization). Thainakarin Hospital is considered one of the first rank private hospitals in Thailand. to receive this quality certification. The hospital has always had its accreditation renewed. At this time, Thainakarin Hospital has renewed its quality process accreditation (Hospital Re-Accreditation) for the 5th time. The certification period is from 10 September 2022 - 9 September 2025.
 - In May 2023, Thainakarin Hospital received AACI (American Accreditation Commission International) accreditation for breast cancer treatment. It demonstrates our commitment to improving quality and safety for patients and those receiving services in breast cancer to be accepted at the AACI standard level. On May 31, 2024, Thainakarin Hospital underwent a follow up survey and monitoring visit, achieving a score of 99.45%.

1.2.3 Procurement of Products or Services

- **Medical Personnel**

The Company has a policy to recruit doctors in various specialties, including other medical personnel such as nurses, etc., in order to deliver full-range and quality services. Up to now, it has succeeded in recruiting and retaining proficient medical personnel through appropriate remuneration and fringe benefits, favorable workplace environment, along with constant seminars and training schemes for doctors, nurses and medical personnel for their skills development and up-to-date knowledge to ensure of safety services.

- **Medicines and Medical Supplies**

As medicines and medical supplies are essential raw materials for hospital business, the Company adopts a procurement process that is stringent in every step, from order placement where details of medicines shall be screened and decided by a committee consisting of doctors, pharmacists and procurement staff established to oversee appropriate medicine procurement, as well as inventory control.

Almost all medicines and medical supplies of the Company are procured domestically, hence no risk of shortage. To ensure availability of supplies, moreover, the Company establishes effective procurement and inventory management systems, alongside assessment of price suitability, efficiency and quality of products.

- **Medical Equipment and Tools**

Due to increasing complexity of diseases nowadays, the Company needs latest medical equipment and tools to provide patients with quality services. As it is a large sum of investment, the Company takes into meticulous consideration the necessity and quality of the equipment and tools that can meet adequacy and utilization requirements

For the period 2023 - 2024, the Company has purchased high-value medical equipment, such as a set of laser machines to treat pigment abnormalities and remove tattoos. To increase the potential for treatment and focus on health and beauty care customers; the Company has been purchased an ultrasound heart monitoring machine with high potential for fast and accurate processing in order to increase the potential of medical treatment.

The Company has usually made purchases from domestic distributors and also secured clear terms and conditions on prices and after-sales services for the cost-effectiveness and best utilization benefit.

- **Supply of medicines, medical supplies, medical equipment and devices from suppliers (Suppliers)**

The supply of medicines, medical supplies and consumables, medical equipment and devices used in medical treatment each year is as follows:

(Unit: Million Baht)

Order List				
No.	Year	Medical Device	Medicine	Medical supplies and medical consumables
1	Aug 2021 - Jul 2022	64.58	252.04	219.47
2	Aug 2022 -Jul 2023	33.05	255.78	133.46
3	Aug 2023 -Jul 2024	31.26	321.72	149.44

Purchase orders for medicines, medical supplies and consumables, medical equipment and devices used in medical treatment were ordered from domestic manufacturers or distributors. The committee was required to consider imports to Hospital in order to be as cost-effective and appropriate as possible.

1.2.4 Operating Assets

- **Core Assets**

The Company's core assets of various types as of July 31, 2024 are as follows:

(Unit: Million Baht)

Asset	Book Value	Type of Ownership
Land and land improvement	236.69	Owner
Building, construction and work in process	509.62	Owner / Leasehold
Operating systems	352.47	Owner
Office equipment and furniture	186.20	Owner
Medical equipment and tools	754.69	Owner
Vehicles	18.17	Owner
Total	2,057.84	
Less: Accumulated depreciation	1,071.57	Please see notes
Total Net	986.27	

Notes : As of July 31, 2024, the Company has contributed to the renovation of the building, and a number of equipment and tools, which have been completely depreciated, but are still in use. Book value before deduction of accumulated depreciation of such assets is approximately Baht 742.85 million. (2023: 690.49 million Baht)

- **Land and Buildings use in Operation**

As of July 31, 2024, the Company's land and buildings used in the business operation were as follows:

Land and Buildings used in the operations	Ownership Characteristic	Net Book Value (Million Baht)
Thainakarin Hospital Building 345 Debaratna Rd., km.3.5, Bangna Nuea, Bangna, Bangkok 10260 Land: 6-2-42 Rai Building: Usable area of about 64,325 square meters	The term of the lease is 30 years from 9 November 2018 to 8 November 2048.	Building and Building improvements 48.89 used in 547.07
Thainakarin Hospital 2 Project Land: 38 deed 16-3-19.5 Rai		
Linac Center Building 759 Debaratna Rd., Bangna Nuea, Bangna, Bangkok 10260 Land: 3-0-92 Rai Building: Usable area of about 1,809 square meters	Owner	120.63

Land and Buildings used in the operations	Ownership Characteristic	Net Book Value (Million Baht)
Car Parking Building 2 799 Debaratna Rd., Bangna Nuea, Bangna, Bangkok 10260 Land: 1-1-10 Rai Building: Usable area of about 9,958 square meters	Owner	118.70
In progress Land: 12-1-17.5 Rai	Owner	148.08
Land in Chachoengsao Province Land: 4 deed 0-3-98 Rai		
Saha Clinic Chachoengsao (SCC) 107/1,7 Bang Phra, Mueang Chachoengsao, Chachoengsao 24000 Land: 51 square two-meters Building: Usable area of about 684 square meters	Owner	12.73
In progress Land: 0-3-47 Rai	Owner	10.41
Total Land, Building and right of use, used in the operations		1,006.51

1.2.5 Important Contract

1. Collaboration Contract

Party to contract	1. Cancer Alliance Company Limited 2. S.MEDICAL ENTERPRISE COMPANY LIMITED 3. Saha Clinic Chachoengsao
Term of contract	1 March 2023, onwards. Any party may terminate the contract at any time. However, it requires providing written notice to all parties with a minimum of 15 days in advance.
Essence of the contract	The objective is to improve access to effective cancer treatment for patients, ensuring it aligns with medical standards and prioritizes patient safety, appropriateness, and comfort. To achieve this goal, both parties have agreed to initiate the Eastern Cancer Network Project, a collaborative medical venture for sharing academic and medical expertise.

2. Lasik Center Establishment Contract

Party to contract	R.X. Company Limited
Term of contract	1 September 2024 - 31 January 2031
Essence of the contract	The R.X. company has committed to supplying the hospital with the WaveLight Excimer Laser EX500 machine and WaveLight Femtosecond Laser FS200 with all essential treatment equipment to support the delivery of medical care to patients or service recipients.

3. Sales and service contracts for various tools and equipment

Party to contract	Z-Medic Company Limited
Term of contract	4 January 2021 - 3 January 2024
Essence of the contract	This preparation is aimed at effectively countering the potential outbreak of viruses such as Influenza A/B, Dengue, HPV, Zika, and Chikungunya. It enables us to obtain genetic testing results within a swift timeframe of 4-6 hours from specimen receipt.

4. Insurance Contract

4.1 Industrial All Risks Insurance

Type of contract	Industrial All Risks Insurance
Insurer	MSIG Insurance (Thailand) Public Company Limited
Location of property insured	345 Debaratna Rd., Bangna Nuea, Bangna, Bangkok 10260
Protection	This insurance policy provides coverage for loss or damage to insured property resulting directly from various events, including fire, lightning, explosions, collisions with vehicles, smoke, aircraft, water-related hazards like floods, windstorms, earthquakes, volcanic eruption underwater waves, tsunamis and hail danger. Additionally, it covers risks such as strikes, riots, malicious acts, and accidents from unspecified or excluded external factors, as defined in the property risk insurance policy.
Period of insurance	9 November 2023 - 9 November 2024
Total sum insured	800,000,000 Baht

Insured property

Part 1: The insurance coverage extends to all structures (including their foundations), fences, walls, gates, improvements, and additions. However, it excludes tools, machinery, spare parts, equipment, and medical appliances used for treatment. The coverage also includes the elevator system, sanitation system, fire extinguishing system, wastewater disposal system, water supply system, chiller system, electrical system, air conditioning system, and generator equipment, with a total insured sum of 500,000,000 baht.

Part 2: This coverage includes movable assets such as furniture, decorative items, computer systems, communication equipment, telephone systems, air-conditioned rooms with temperature control, refrigerators, tools, machinery, and medical appliances, including all types of medical treatment facilities, various medical supplies, and medications. It encompasses all movable property within the building, with a total insured sum of 300,000,000 baht.

- The Thai Red Cross Society is the only beneficiary of Part 1.

4.2 Industrial All Risks Insurance (Car Parking Building 2 and Linac Building)

Type of contract	Industrial All Risks Insurance
Insurer	MSIG Insurance (Thailand) Public Company Limited
Location of property issued	759 and 799 Debaratna Rd., Bangna Nuea, Bangna, Bangkok 10260
Protection	This insurance policy provides coverage for loss or damage to insured property resulting directly from various events, including fire, lightning, explosions, collisions with vehicles, smoke, aircraft, water-related hazards like floods, windstorms, earthquakes, volcanic eruption, underwater waves, tsunamis) and hail danger. Additionally, it covers risks such as strikes, riots, malicious acts, and accidents from unspecified or excluded external factors, as defined in the property risk insurance policy.
Period of insurance	23 September 2023 - 23 September 2024
Total sum insured	348,450,000 Baht
Insured property	<ul style="list-style-type: none"> • Car Parking Building 2: Address 799 The building consists of 9 stories, including an underground floor, and features a passenger elevator system, water system, and electrical system, with a total insured sum of 113,450,000 baht. • Linac Building : Address 759 The 4-story building, along with its perimeter features like fences, walls, gates, and renovation items, is insured for a total of 89,000,000 baht. This coverage extends to furniture, fixtures, and additional improvements, including utility systems such as fire extinguishing, water supply, electrical, electric transformer, MDB mains cabinet, and emergency mains cabinet. It also covers the passenger elevator system, communication system, air conditioning, temperature control, cold room, computer systems and equipment, machinery, and medical appliances, including equipment for medical treatment, is insured for a total of 146,000,000 baht.

4.3 Industrial All Risks Insurance (Saha Clinic Chachoengsao (SCC))

Type of contract	Industrial All Risks Insurance
Insurer	MSIG Insurance (Thailand) Public Company Limited
Location of property issued	107/1, 7 Siri Sothon Rd., Bang Phra, Mueang Chachoengsao, Chachoengsao
Protection	This insurance policy provides coverage for loss or damage to insured property resulting directly from various events, including fire, lightning, explosions, collisions with vehicles, smoke, aircraft, water-related hazards like floods, windstorms, earthquakes, volcanic eruption, underwater waves, tsunamis) and hail danger. Additionally, it covers risks such as strikes, riots, malicious acts, and accidents from unspecified or excluded external factors, as defined in the property risk insurance policy.
Period of insurance	28 October 2023 - 28 October 2024
Total sum insured	16,500,000 Baht
Insured property	<p>Part 1: 4-story building (including foundation), concrete floor, tiled roof, including walls, doors, improvements and additions as of 11,000,000 baht.</p> <p>Part 2: Furniture, decorative fixtures, fixtures, additions, sanitary systems, water supply systems, water pump systems, sanitary ware systems, electrical systems, electrical transformers, MDB mains cabinets, emergency mains cabinets, lighting systems, air conditioning systems. Temperature control system, cold room, passenger elevator system, communication systems, computer systems, along with equipment, machinery, tools, and medical appliances Medical treatment equipment as of 5,500,000 baht</p>

4.4 Public Liability Insurance (Thainakarin Hospital)

Type of contract	Public Liability Insurance
Insurer	MSIG Insurance (Thailand) Public Company Limited
Location of property issued	345 Debaratna Rd., Bangna Nuea, Bangna, Bangkok 10260
Protection	legal liability arising from the Business and happening within or caused by the Insured Premises
Period of insurance	1 January 2024 - 1 January 2025
Total sum insured	25,000,000 Baht

4.5 Public Liability Insurance (Car Parking Building 2 and Linac Building)

Type of contract	Public Liability Insurance
Insurer	MSIG Insurance (Thailand) Public Company Limited
Location of property issued	759 and 799 Debaratna Rd., Bangna Nuea, Bangna, Bangkok 10260
Protection	legal liability arising from the Business and happening within or caused by the Insured Premises
Period of insurance	28 September 2023 - 23 September 2024
Total sum insured	15,000,000 Baht

4.6 Public Liability Insurance (Saha Clinic Chachoengsao (SCC))


Type of contract	Public Liability Insurance
Insurer	MSIG Insurance (Thailand) Public Company Limited
Location of property issued	107/1, 7 Siri Sothon Rd., Bang Phra, Mueang Chachoengsao, Chachoengsao
Protection	legal liability arising from the Business and happening within or caused by the Insured Premises
Period of insurance	28 September 2023 - 23 September 2024
Total sum insured	5,000,000 Baht

1.2.6 Unfinished Jobs

- None -

1.3 Shareholding Structure

1.3.1 Shareholding Structure of Thainakarin Hospital Public Company Limited as of July 31, 2024



1.3.2 Persons with Potential Conflicts of Interest Holding Shares in a Subsidiary or Associate

- None -

1.3.3 Relationship with Major Shareholders' Business Group

The Company has a relationship with the business group of the significant shareholder, Vibhavadi Medical Center Public Company Limited, a shareholder who operates the same business in the same region.

1.3.4 Shareholder

Shareholding and Management Structure

• Company's Securities

The Company's total registered capital is Baht 180 million. The capital is fully paid and has 180 million total shares at the par value of Baht 1 per share.

List of top 10 major shareholders of the Company as of July 31, 2024.

Shareholder

Names of Shareholders		Number of Shares	Proportion of shares (%)
1.	Siam Property Development Company Limited	50,000,000	27.78
2.	Vibhavadi Medical Center Public Company Limited	31,893,000	17.72
3.	Mr. Jatuporn Sihanatkathakul	21,540,000	11.97
4.	Mr. Thiti Sihanatkathakul	5,485,000	3.05
5.	Mrs. Nilnate Mahatthanarak	4,704,000	2.61
6.	Mrs. Vaewta Looareesuan	4,435,700	2.46
7.	Mrs. Nipapat Sihanatkathakul	3,000,000	1.67
8.	Ms. Jane Olaric	3,000,000	1.67
9.	Mr. Charoen Meensook	2,500,000	1.39
10.	Mrs. Hataya Meensook	2,285,500	1.27

Source: Thailand Securities Depository Co., Ltd.

The major shareholders having material influence on the Company's decisions on policies, management and operations are as follows:

1. The Sihanatkathakul family, which includes Mr. Jatuporn Sihanatkathakul, Mr. Suchart Sihanatkatakul, Mrs. Nipapat Sihanatkathakul, Mr. Thiti Sihanatkathakul, Mr. Pitipat Sihanatkathakul, Miss Onaree Sihanatkathakul and Mr. Tosaporn Sihanatkathakul, holds approximately 18.67 percent shareholding in the Company.
2. Members of the Sihanatkathakul family hold shares in Siam Property Development Company Limited and are authorized directors of Siam Property Development Company Limited

1.4 Registered and Paid-up Capital

As of July 31, 2024, the Company has a registered capital of 180 million baht, fully paid up of 180 million baht, which is 180 million ordinary shares with a par value of 1 baht per share. The Company does not issue other types of shares other than ordinary shares.

1.5 Other type of securities

- None -

1.6 Dividend Policy

According to the Company's dividend policy, the dividend payment shall be at least 60 percent of the net profit after corporate income tax. Nonetheless, the payout ratio may be lower than the said level if the Company finds it necessary to allocate the net profit to its business expansion.


On 26 September 2024, the Board of Directors, in its meeting no. 3/2024, resolved to propose the 2024 annual dividend payment (from the operating results of the period between 1 August 2023 and 31 July 2024) at the rate of Baht 0.60 per share, totaling Baht 108,000,000 (One hundred and Eight million baht) to the annual general meeting of shareholders 2024 for approval.

Past dividend payment records are shown in the table below:

	2023	2022	2021
Earnings per share (Baht)	350,293,631	424,829,940	293,415,820
Dividend per share (Baht)	0.60	0.60	0.50
Dividend payment per net profit (%)	30.83	25.42	30.67

2 Risk Management

Risk Management Structure



2.1 Risk Management Policy

The Company has applied the principles of risk management. Through risk management, there is a systematic and continuous organizational process to help the organization reduce each potential risk to an acceptable level and consistent with patient safety. It follows rules according to Hospital Accreditation (HA) standards, which the hospital continuously certifies and renews (Re-Accreditation).

2.2 Business Risk Factors

Thainakarin Hospital Public Company Limited places importance on risk management throughout the organization and at every level in order to cover awareness and participation on risk management includes work at the operational level along with training on risks and risk management. To drive the organization towards sustainable growth according to various objectives, goals and strategic plans, risk factors in the Company's business operations can be classified as follows:

1. Risk from shortage of medical personnel. Hospital business is a business that focuses on providing services by medical personnel. At present, there is an expansion of more medical service business which creates a need for qualified personnel with knowledge, abilities and experience in providing treatment services to patients. Therefore, there is a risk of a shortage of medical personnel including recruiting personnel with knowledge and expertise, such as specialized doctors, professional nurses with knowledge expertise for newly opened specialized services, etc. Due to the increasing demand for these professional personnel in private and public hospitals.

2. Strategic and Business Risks. The hospital business and medical services today are more competitive. Each hospital has developed and improved services, the hospital environment including the use of modern medical technology in treatment. Therefore, it is the reason for the Company gradually improve the place and patient rooms including the purchase of effective medical equipment and prepare the medical and interdisciplinary teams. To aim for excellence in treatment (Excellence Center) and the readiness to provide medical services in all aspects to meet the needs of service recipients in the midst of increased competition in the hospital business.

In addition to improving the location, the investment in medical equipment and medical personnel, the Company has adjusted its strategy by increasing its penetration into foreign markets especially for foreign service recipients in the CLMV group (Cambodia, Laos, Myanmar and Vietnam).

3. Risks related to preparing personnel potential for internationalization. There is a goal to expand the base of foreign service recipients and there has been an increase in providing treatment services for foreign patients. In addition to the interpreter which is an important mechanism for communication, for sustainability and in line with the direction of serving foreigners, the company has established an international marketing department to carry out marketing to foreign patients and coordination between hospitals with foreign patients who come to use the service specifically.

4. Risk of loss of personnel resources. The hospital business is a highly competitive business. In Bangna area and nearby areas is becoming an important location for the health business in the future. When a new medical facility or hospital is opened and offers a better rate of return. As a result, there has been a transfer of personnel's work locations. Therefore, the Company has taken both proactive and defensive actions. To reduce such risks by setting the compensation structure to be consistent with the labor market in the business group. Private hospital providing welfare, compensation and various training to motivate personnel to stay with the organization. Including creating a system for developing leaders of important work groups within the hospital. When there is resignation or retirement, remaining personnel

will be able to continue their work without affecting the service recipient and the organization. In addition, it also builds bonds between personnel and the organization through various activities, including organizing activities to create intimacy for personnel to have the opportunity to meet and talk and exchange opinions with hospital administrators every quarter. This make the administrators can be informed and help solve various problems of personnel and of the hospital. Reducing the risk of losing personnel resources.

5. Risks from changes in government policies. Government measures, and government policy-making related to medical services, such as the “Universal Coverage for Emergency Patients” (UCEP). The policy allows people suffering from critical emergencies to receive free medical care in the nearest public and private hospitals or free medical services for patients infected with COVID - 19 (Only for critical emergency patients’ red group symptoms). It allows the hospital to reimburse medical expenses from the National Health Security Fund or other related funds. The rates imposed by the government, which are inconsistent with the actual cost of the hospital, or the policy that sets medicines and medical supplies as regulated goods, have a considerable impact on the operation of private hospitals. It is because private hospitals do not receive any support from the government or for hospitals to sell medicines and medical supplies at controlled prices that do not correspond to the actual cost of medical care. These policies directly affect the Company's business income.

6. Information technology (IT) risks: In the current era, where technology is rapidly changing, most hospital business groups have increasingly adopted artificial intelligence (AI) and machine learning technology in their information systems. Therefore, organizations must understand threats, attack techniques, security systems, deployment of automated security technologies, etc. It is to deal with events promptly, reduce the impact of attacks, and reduce the risk of threats; information officers must also know how to deploy consistent security across multiple IT environments as they evolve and expand. It will define a separate but interoperable security solution framework. It combines Machine Learning (ML), container management and control software, automation, and 3rd party software. Therefore, everyone in the organization's culture and expected behavior has been created to be aware of possible risks. An appropriate information security policy is established, roles and responsibilities are appropriately defined, and risks are continuously monitored, including ensuring that there are personnel in the organization with sufficient knowledge and expertise, as well as enhancing knowledge and understanding of technology regularly.

7. Cyber Threat Risk. Violations of patient rights and information health service system is a service system that is very important because it is directly related to people's health. Today, medical technology is more advanced and people are relying more on health-related technology. Therefore, various technologies are being applied to medical and health care services, such as digital watches, wristbands, robots, artificial intelligence (AI), applications, etc. Cybercriminals look for vulnerabilities that arise from the use of these technologies by espionage or leaking information, using the data without permission from the data owner or patient or violate privacy or seek illegal benefits, such as ransomware, etc., The risk of data espionage or the risk of information leakage may not only be caused by a cyber attack but it also stems from the way data is managed. Measures for storing and accessing information supervision of personnel involved or accessing information or the readiness of software and IT equipment of each organization, etc.



3 Driving Business For Sustainability

3.1 Sustainability Management Policies and Goals

The Company attaches great importance to development in every aspect to drive the business to grow and move forward sustainably. They cover economic, environmental, and social aspects under the principles of good corporate governance, considering the participation of all stakeholder groups. In addition, the Company has planned proactive strategies for future operations to be the most efficient for growth goals. It focuses on investment in treatment technology and state-of-the-art medical equipment to become “Expert Healthcare” to provide more variety of medical care and health care for people in East Bangkok. In addition to standardized medical treatment, expert doctors and modern treatment techniques regarding facilities are also crucial to the Company. Because of the stable business growth, the customer must be impressed by the excellent experience in the service.




3.2 Impact Management to Stakeholders in the Business Value Chain



3.2.1 Business Value Chain

For Company to continue its business sustainably, all stakeholders, whether inside or outside the organization, are essential factors. The Company, therefore, places importance on the comprehensive business value chain management of stakeholders from upstream to downstream. These are 1. Shareholders, 2. Personnel, 3. Community and society, 4. Suppliers, 5. Business Competitors, 6. Service recipients by regularly engaging with all groups of stakeholders to create value for the Company's services to meet the expectations of stakeholders.

3.2.2 Analysis of Stakeholders in the Business Value Chain

Stakeholders	Engagement	Expectation	Response
1 Shareholder 	<ul style="list-style-type: none"> The Company arranges for the annual general meeting of shareholders. Prepare One report one time per year The Company has disclosed essential information to invest in listed securities to investors through the SET Link system and the Company's website. The Company has a variety of channels to contact investor relations such as telephone, email, and fax. 	<ul style="list-style-type: none"> The Company has good operating results, stable growth, and business profits, including paying dividends to shareholders. Updating important information and getting accurate, complete, and fast communication. Good corporate governance, transparency, and verifiable. 	<ul style="list-style-type: none"> Develop potential, and expand the business to grow continuously Disclosure of information to the Stock Exchange is correct, complete, and timely for decision-making. Operate business under the principles of good corporate governance with transparency and fairness.

Stakeholders	Engagement	Expectation	Response
2 Personnel 	<ul style="list-style-type: none"> • Compensation, welfares, and benefits are reasonable and fairly. • The Company has surveyed the satisfaction and commitment of personnel. • The Company organizes an orientation for new personnel every month. • Personnel Training and Development (both specialized personnel and general personnel) • Organizing meetings and seminars within the organization. • Updating news and information for personnel to be informed and up-to-date through various channels such as email, the Company's intranet media, the Company's Open Chat Line . • Receiving personnel complaints through complaints channels or notifying directly to the Head office. 	<ul style="list-style-type: none"> • Compensation review and appropriate welfares. • Growth, stability, and advancement in the position. • Developing competencies and fostering the learning and potential required for work. • Treating personnel fairly and equally • Contribute to comments and suggestions. 	<ul style="list-style-type: none"> • Fair compensation and benefits appropriate and satisfactory to the personnel. • 79.20% personnel engagement rate survey. • Personnel have learned the Company's policy, vision, and mission. • Develop knowledge and ability of personnel through training from internal and external agencies which averages 24.00 hours of training per person per year. • Activities to meet and communicate between personnel and executives regularly (Town Hall) • Projects for social to promote social responsibility and promote good relationships. • Provide a safe channel for providing feedback and complaints for personnel.
3 Community and Society 	<ul style="list-style-type: none"> • The Company participates in community and social development and organizes activities to support and join the hospital, the community, and society. • The Company organizes health education programs and assists in various fields with community and society. 	<ul style="list-style-type: none"> • There is an integrated management of wastewater and waste disposal treatment that meets standards and does not affect the community and the environment. • Promote the community's and society's health by organizing health check-up activities and providing medical knowledge. 	<ul style="list-style-type: none"> • Manage the waste disposal system according to the legal guidelines. • Organize activities to help, share and promote community health, such as providing medical supplies, and vaccinating local monks.
4 Suppliers 	<ul style="list-style-type: none"> • The Company met with partners to hear opinions and guidelines for joint practice. 	<ul style="list-style-type: none"> • There is a process for procurement, contracting, and memorandum of agreement that is fair, transparent • The agreed conditions are fulfilled correctly and on time. 	<ul style="list-style-type: none"> • Selection of quality and moral partners. • Comply with the procurement purchase and sale agreements with trading partners with transparency, fairness, and clarity. • Make payments on terms and on time.

Stakeholders	Engagement	Expectation	Response
5 Business Competitors 	<ul style="list-style-type: none"> Meeting and exchanging opinions with competitors 	<ul style="list-style-type: none"> Conduct business competitions with honesty, without distorting facts. Comply with the rules of good competition and within the framework of the law. 	<ul style="list-style-type: none"> Attending meetings about businesses related to private hospitals. Treat competitors with honesty, fairness, and transparency.
6 Service recipients 	<ul style="list-style-type: none"> The Company surveyed satisfaction, opinions, and patient experience in receiving services. Treatment services with standards and safety. Organize activities and public relations marketing to meet customers There are many communication channels such as telephone, email, letter, fax, Facebook, and Line Official. 	<ul style="list-style-type: none"> Receive comfort in treatment and medical services from specialized medical personnel in various fields. Use innovation and technology that is of standard and modern in medical treatment. There is an easy-to-access, clear, and reasonably priced medical service communication channel. 	<ul style="list-style-type: none"> The satisfaction survey results of the service recipients were satisfied at 93.61% Serving customers following the measures to improve the quality of medical care and providing services to maintain quality medical care under the hospital quality standards and related rules. Use new information technology to keep up-to-date in communication with service recipients.

3.2.3 Environment Policies and Practices

The Company is committed to conducting business with safety and environmental impact considerations. It includes setting up environmental management policies and encouraging personnel to be aware of the importance of the environment to achieve sustainability. It also sets a policy to reduce unnecessary use of resources and energy, such as reducing the use of documents by printing documents as needed or reducing electricity consumption such as turning off the lights and the air conditioners in some departments during lunch breaks.

3.3 Sustainability Management in the Environment Dimension

The Company has taken environmental actions to cover all dimensions, including:

3.3.1 Energy and Utilities Management

- Determine appropriate guidelines for the use of utility systems, such as turning off the lights in some departments during lunch breaks to be following the plan to control the use of energy appropriately while taking into account that it does not affect the quality and good service. The Company has created 2 electrical energy conservation projects as follows:
 - Project to change the type of electric bulbs 18 × 3 watt lamps to 18 watt for 20 LED lamps at OPD on G floor- 4th floor and patient rooms. The result is a saving of 6,745 Kilowatt-hours/year, equivalent to 32,242 baht/year.
 - Project to change the type of 14 watt incandescent light bulbs to 9 watt for 40 LED bulbs at the Pediatrics Department, L floor. The result is a saving of 876 Kilowatt-hours/year, equivalent to 4,187 baht/year.

The overall result is a reduced energy saving of 0.072%. In the future there will be additional measures to reduce energy to more than 0.1%.

3.3.2 Solid waste management, Hazardous materials and wastewater

- Manual for storage and disposal of hazardous materials, such as blades and needles handling. Training programs on infection prevention and control as well as waste sorting are constantly arranged for personnel related to patient care and housekeeping
- Hazardous materials and waste management plan.
- Prepare a list of chemicals used in hospitals, put chemical type stickers according to the Globally Harmonized System for Classification and labeling of Chemicals (GSH), create Safety Data Sheets, communicate in the Intranet system for convenience and speed in use.
- Manual for protection against chemical substances, together with practice guidelines for prevention and management against risk from chemical exposure at work.
- Create work guidelines managing biological and chemical spills
- Prepare, organize training and practice using equipment. Managing biological and chemical spills.
- Arrange practice for using the Spill Kit equipment for chemotherapy.
- Wastewater treatment system has put in place by Sequence Batch Reactor (SBR).
- The new chiller system with environmentally-friendly refrigerant is used.
- Awareness is raised throughout the Hospital about waste reduction, focusing on reuse and efficient use of resources with a sense of eco-friendliness.
- Encourage to have good behavior about waste separation and waste littering.
- Send waste for disposal according to the correct type of waste, such as general waste, hazardous waste, toxic waste, and recyclable waste.
- Introduce the campaign on “zero use” of plastic bags and foam.

3.3.3 Management of safety in the workplace

- Building inspection is performed by internal units and external experts certified by the Department of Public Works and Town & Country Planning on an annual basis, with due structural improvement in compliance with the Building Control Act B.E. 2522 and other relevant laws in order to affirm and ensure service users and staff of solid and safe building structures.
- Relevant measurement are conducted in accordance with the Occupational Safety, Health and Environment Act, B.E. 2554 with reference to the Ministerial Regulations on standards for management and execution of occupational safety, health and environment for work involving heat, light and noise.
- Adjusting the area to provide appropriate treatment services for patients infected with COVID-19

3.3.4 Building quality inspection

- Fire extinguishing system and equipment are inspected 30th of every month and a full-scale inspection shall be conducted once every 6 months in accordance with the Ministerial Regulation Prescribing Standards for Administration, Management and Execution of Occupational Safety, Health and Environment in Relation to Fire Prevention and Control.
- Basic fire prevention and prevention knowledge is provided every year for personnel.
- Annual fire evacuation drill is conducted once a year. In addition, basic fire extinguishing drills are arranged for high-risk working units, such as Nutrition Department, cafeteria, etc. so that the staff gain knowledge, understanding and awareness of fire hazard and can respond according to the Fire Prevention and Extinguishing Plan in the event of fire incident. Any flaws detected during the drills shall be used for developing a more efficient fire prevention and extinguishing system.
- Contingency plan against brawl incident in the Hospital's premises and surrounding communities.

3.3.5 Providing safety education to personnel

- Personnel Health Promotion: The Company focuses on personnel for good physical and mental health. It provides full support to the health care of personnel by providing annual personnel health check benefits, medical expenses benefits, and influenza vaccination. It equips personnel

with COVID-19 prevention equipment, including Personal Protective Equipment (PPE), Surgical Mask, Goggle/Face Shield, and COVID-19 Vaccination. It also includes the annual health check-up data of the personnel for analysis to find ways to prevent various diseases for personnel in the risk group as well.

3.3.6 Measures to prevent epidemics and communicable disease under surveillance

From the current situation of the spread of coronavirus disease 2019, it is found that the rate of spread of the disease has decreased worldwide. At the same time, the World Health Organization has announced the end of the public health emergency of coronavirus disease 2019 from May 2023, along with the severity of the disease decreasing in both morbidity and death rates. Therefore, the hospital has adjusted measures to provide patient care services and the medical treatment process to suit the situation according to the guidelines for providing care for patients with coronavirus disease 2019 for healthcare facilities, 3rd revised edition, dated 3 July, 2023 as follows:

1. Screening for infection when a patient has respiratory infection symptoms;
2. Emphasis on wearing a surgical mask for everyone at all times, both patients and their followers, Medical personnel, and other officials;
3. Emphasis on washing hands on necessary and appropriate occasions;
4. Wearing personal protective equipment depends on the risks of each activity according to the recommendations;
5. For providing services to patients with respiratory symptoms, space in the building is organized by zoning it from general outpatients;
6. Among infected patients, separate areas are provided in specific areas and provide One Stop Service;
7. Arrangement of service areas at each service point to allow for social distancing while waiting for service, including cleaning measures in service areas, patient rooms, medical equipment, ambulances, wheelchairs, and various touch points in Hospitals, such as escalator handrails, elevator buttons, etc.

This is due to the epidemic situation of emerging infectious diseases such as monkeypox has spread from animals to people and is transmitted from person to person. The channels of infection spread are Droplet Precautions and Contact Precautions, and infections are increasing in the country. In December 2023, the Hospital Infectious Disease Control Committee Measures were taken according to the clinical practice guidelines for caring for monkeypox patients, Ministry of Public Health, second revised edition, November 9, 2023, to control and prevent the spread of infection in hospitals as follows:

1. Prepare an area for separating patients when receiving services. Specifying the use of emergency department isolation rooms
2. Provide One Stop Service
3. Create a guidelines to follow when suspecting a patient with monkeypox infection.
4. On January 19, 2024, there was the practise of 1st guidelines rehearsal and Root Cause Analysis to identify the reasons for non-compliance with the guidelines and to improve the guideline for more efficiency work.
5. On February 28, 2024, there was a second practise of guidelines rehearsal to provide more efficient services.
6. Prepare equipment for examinations and procedures ready for use.
7. Specimen has been sent for testing to the Ministry of Public Health and follow up on examination results within 24 hours after submitting the examination during business hours and report the results to the treating doctor who will inform the results to the patient.
8. There is surveillance to follow treatment in patients for 20 days (Home Isolation) until the spread of infection has passed.
9. Coordinate with public health service centers in patient areas to find closed contact who may be at risk of infection.

3.3.7 Energy Management

1. Fuel Consumption

Energy Management of Fuel Oil and Liquefied Petroleum Gas, the Company has established measures and guidelines for fuel use, including a fuel reserve plan to continue operating its business and comply with the law.

The Company has the following fuel consumption data:

	2023	2022	2021
Fuel (liter)	802	448	575
Liquefied Petroleum Gas (kg)	163,381	182,841	182,441

2. Electricity Consumption

The Company conserves energy consumption by defining a policy on energy management and communicating to personnel at all levels to know and follow the energy conservation measures. In addition, the Company has participated in developing energy management under Thai law with the Department of Alternative Energy Development and Efficiency.

The Company has the following information on electricity consumption:

	2023	2022	2021
Electricity consumption (kilowatt-hour)	7,882,000	8,399,935	8,911,458

3. Water Consumption

The Company manages to have a 24-hour on-demand water supply. Water quality monitoring is carried out, water sources are tested, and test results are recorded regularly. Extra Tap water is also available in designated high-risk areas with the plan to reduce the risk when tap water becomes contaminated or cannot supply.

However, the Company is committed to efficient water usage by regularly inspecting and controlling the water drainage system for cleaning the cooling tower to maintain it at an appropriate level.

The Company has information on water consumption as follows:

	2023	2022	2021
Tap water consumption (cubic meter)	147,236	149,093	151,676.50

4. Effluent quality analysis in the wastewater treatment system

In 2023, the Company had an effluent quality analysis by the laboratory of Life & Environment Company Limited. The result of the effluent quality analysis for the Company's wastewater treatment system is within the standard.

5. Management of the disposal of waste

The Company has segregated waste into two main categories: general waste (comprising general waste and recyclable waste) and hazardous waste (Contains chemical waste, sharp waste, and infectious waste). With Krungthep Thanakom Company Limited and Bangkok, garbage trucks come to pick up general and hazardous waste every day for disposal. Including the promotion of waste segregation and the sale of recyclable waste, which is purchased by ECG Co., Ltd.

Statistics on the amount of waste volume each year are as follows:

	2023	2022	2021
General waste volume (kg)	358,480	383,800	367,410
Hazardous waste volume (kg)	25,600	26,500	26,000
Total volume (kg)	384,080	410,300	393,410

Occupational Safety, Health and Environment Policy

The Company is committed to act responsibly toward the environment, safety and the society, thereby facilitating the safety and wellbeing of its staff, patients and visitors. This commitment has been adopted as policy and annual action plan under the supervision of the Hospital's Occupational Safety, Health and Environmental Committee, comprised of management-level representatives and personnel as representatives of operating-level staff. The organization's physical, environmental and safety structures are managed in accordance with the Hospital and Healthcare Services Standards No. 5 of The Healthcare Accreditation Institute (Public Organization), Bureau of Disaster Prevention and Mitigation's standards for mega high-rise buildings, and those of other agencies etc. These standards provide frameworks for planning, supervision and control. Meanwhile, pertinent information and indicators are used in analyzing and identifying causes in order to consistently take preventive and corrective actions on major physical, environmental and safety structures.

Number of accidents classified by nature and gravity, during August 2023 - July 2024

Nature of Accident	Number of Personnel Exposed to Danger, and Gravity (Person)					
	Death	Disability	Leave, Over 3 days	Leave, 3 days or less	No Leave	Total
Sharp force	-	-	-	1	1	2
Puncture wound	-	-	-	-	6	6
Slip/Trip/Fall	-	-	-	2	1	3
Chemical/secretions splashes	-	-	-	1	-	1
Total	-	-	-	4	8	12

3.4 Sustainability Management in Social Dimensions

3.4.1 Social Policies and Practices

Throughout 31 years in business, Thainakarin Hospital Public Company Limited. has provided quality and high-standard medical care under the vision of **“Dedicated to being the most trust hospital in Eastern Bangkok and Eastern Region in terms of medical expertise, technology, quality, international standards, warm service, and care like family.”** alongside the code of professional ethics. The Executives always holds that hospital business is not about profit-making only, but also the commitment to give best care for the health and quality of life of people, communities, the society and the environment. It is the Company's firm belief that corporate social responsibility contributes to sustainable and robust business growth.

In this regard, the 5 core missions are set forth as follows:

1. To develop personnel competency, satisfaction and pride in the company;
2. To elevate the health care quality with international standard;
3. To progressively proceed with continuous and sustainable development of the company;
4. To achieve the best hospitality with a warm and family-like treatment that creates lasting impressions;
5. To manage in accordance with the corporate governance.

The Company has pursued the core missions through numerous projects and activities to attain business stability. The Hospital has also devised good corporate governance principles and provision of quality services in order to uplift quality of life and the society whilst helping preserve and restore the environment.

Thainakarin Hospital's CSR scheme is carried out on the following basis:

1. Fair business conduct

The Company adheres to fair business conduct based on ethical principles, transparency, honesty and accountability, in tandem with avoidance of monopoly and piracy. Practices include:

- **Giving all vendors equal opportunity to tender** in order to prohibit monopoly and price discrimination.
- **Comparing prices of products and services** in order to promote transparency in procurement and to reduce operating costs, resulting in reasonable prices for customers.
- **Set out rules and procedures for procurement** in order to uphold business ethics, to refrain from soliciting and offering any benefits, and to protect interests in collaboration with suppliers and creditors.

2. Non-infringement of Intellectual Property Rights

The Company seeks to purchase copyrighted computer software, images, fonts including any other intellectual property rights for legitimate use by the organization. It has prohibited all directors, executives and staff from reproducing, modifying, altering or executing any other acts which are an infringement of copyrights or rights in the aforementioned intellectual properties, and imposed penalties on persons infringing intellectual property rights according to Thainakarin Hospital's Information Security Policy to ensure fairness to the intellectual property right owners.

The Company sets guidelines on non-infringement of intellectual properties as follows:

1. The Company requires that all directors, executives and personnel respect intellectual property rights of other persons. It shall seek prior permission of the legal owners of such intellectual properties.
2. The Company does not support the use of any works characterized as infringement of other persons' intellectual properties, whether in form of reproduction, modification, alteration, advertising, republication, exhibition or any other acts characterized as support of works that infringe other persons' intellectual properties.
3. The Company prohibits all directors, executives and staff from executing any acts characterized as infringement of other persons' intellectual properties, whether in form of reproduction, modification, alteration, advertising, republication or any acts characterized as infringement of the owners' of intellectual property rights

3. Respect for human rights

Appreciating that human rights are the basic rights inherent to all human beings, Thainakarin Hospital embraces respect for human rights under the following practices:

3.1 Overall process of services rendered to patients and customers

Thainakarin Hospital recognizes its duty as a medical care service provider with a responsibility to respect the customers' rights and complied with Personal Data Protection Act B.E. 2562. For this reason, staffs of all units have been inculcated with full regard for patients' rights according to the Declaration of Patients' Rights and Patients' Duties issued and certified by 6 professional federations on 12th August 2015, namely.

Patients Rights

1. All patients have the fundamental right to receive healthcare services as specified under the Constitution.
2. Patients seeking healthcare services have the right to receive accurate and sufficient information from healthcare providers, in words the patients can easily understand, about the illness, medical examination, treatment, advantages and disadvantages of such examination and treatment so that they can make a well-informed decision on whether to consent to or refuse treatment from healthcare providers, except in case of life-threatening emergency.
3. Patients in life-threatening conditions have the right to receive immediate attention from healthcare providers as necessary, whether or not the patients requested so.
4. Patients have the right to know names, surnames and professional status of the healthcare providers delivering services to them.
5. Patients have the right to seek a second opinion from other healthcare providers and to request for the change of healthcare service provider and establishment.
6. Patients have the right to receive from healthcare providers the strict protection of their personal information, except upon the patients' consent or by legal requirements.
7. Patients have the right to receive complete information for making decision to participate in or withdraw from an experimental research conducted by healthcare providers.
8. Patients have the right to receive information, upon request, about their own treatments as appeared in the medical records, provided that such information does not violate personal rights of a third party.
9. For patients under the age of 18 or with physical or mental impairment who are unable to exercise their rights, their father, mother or legal representatives may exercise such rights on their behalf

Patients' Duties

1. Inquire to gain an understanding of all information and possible risks before placing their signature to consent to or refuse medical diagnosis or treatment.
2. Provide accurate and complete facts and information regarding their health to healthcare providers in the course of treatment.
3. Cooperate with and follow treatment-related advice of healthcare providers, and notify the healthcare providers in case they are unable to follow such advice.
4. Cooperate and comply with hospital rules and regulations
5. Treat healthcare providers, other patients as well as visitors with respect and politeness, and avoid causing disturbance to others.
6. Inform relevant personnel of the Hospital about their healthcare rights along with documents thereof.
7. Patients should acknowledge medical facts and information as follows:

- 7.1 Healthcare providers who work according to professional standards and ethics are duly protected by laws and entitled to protection against unjust accusations.
- 7.2 “Medical practice” is hereby defined as modern medical practice that has been scientifically proven by the body of knowledge at that time to be of benefit rather than harm to the patients.
- 7.3 Medical practice is unable to diagnose, prevent or cure every disease or condition.
- 7.4 Every type of medical treatment carries possible risks of undesirable effects. Apart from that, inevitable events can occur even when healthcare providers have exerted sufficient care under conditions and circumstances of such medical treatment.
- 7.5 Examination for the purpose of screening, diagnosis and follow-up may have varying results due to limitations of technology and other uncontrollable factors beyond operating standards.
- 7.6 Healthcare providers have the right to exercise their discretion to select treatment process according to medical principles, their capabilities and limitations, as well as the given conditions and circumstances, and to provide consultations and transfers for the patients’ rights and benefits in general.
- 7.7 For the interest of patients, healthcare providers may give advice or suggest transfers in order that the patients receive proper treatment, provided that such patients are not in emergency and life-threatening conditions.
- 7.8 Patients’ concealment of their health-related information and medical facts from healthcare providers may adversely affect medical treatment process.
- 7.9 Hospital emergency rooms are for patients under emergency and life-threatening conditions.

With respect to this, Thainakarin Hospital has posted up the Declaration of Patients’ Rights and Patients’ Duties in all services areas for customers’ acknowledgement, promoted ethical conducts of service providers, and focused on active fulfillment of customer needs.

3.2 Information

All data in medical records is a kind of health information. Thainakarin Hospital has set a clear policy on privacy and confidentiality of patients. A good medical record management system is implemented across the whole process, with chief concern for fundamental rights and best interests of the patients. Medical records of the Hospital can be divided as follows:

1. Paper-based medical record: Information is kept in document form and into medical record files. The Medical Record Development Committee has a responsibility to set pertinent formats and processes, including preparation of new patients’ medical records, and determination of information necessary for providing medical care. Important data shall be compiled by personnel in related units, e.g. basic information, benefit-related information by registration officer, patient care information by nurses, diagnostic and treatment information by physicians, etc.
2. Electronic medical record: Relevant data is recorded into the system by all service-providing personnel according to their respective access authorizations and duties. The Medical Record Development Committee, the Information Committee and other related parties are responsible for defining such authorizations, duties as well as information useful for arranging services compliant with recognized standards, such as Hospital Accreditation (HA) etc.

All data, in whatever format, is known to be crucial and clear guidelines must be established regarding access authority to each medical record. Thainakarin Hospital staffs of all levels have acknowledged policy and complied persistently.

To develop the healthcare services, the key element of business relies partly on systematic utilization of intra-organizational information in support of management and operations. For example, healthcare information is presented via electronics channels such as “Mobile Application” with the aim of generating maximum benefits for service recipient. Statistical data can be utilized by working units as a tool for efficient internal management, where the Business Intelligence (BI) system is developed for use in data analysis to boost organizational development efficiency. In addition to security system improvement and a clear policy on confidentiality and security of service recipients data.

3.3 Corporate Social and Environmental Responsibility in Medical Record Execution and Management

The Medical Record Development Committee and multidisciplinary units have jointly formulated a policy on the Company’s medical record management system, taking into account the rights of patients, the communications of information to health service colleagues, as well as the creation of a medical record keeping culture. The use of information for medical treatment purpose shall cover the provision of important information for medical treatment to other hospitals in compliance with acceptable standards of practices, namely Hospital Accreditation (HA), and with reference to international standards, such as Joint Commission International (JCI), the National Safety and Quality Health Service Standards (NSQHS), etc.

Social Responsibility: High priority is given to the consideration of the rights of patients and related persons in the medical record information. Examining physicians nurses and service staff shall record all important factual information, access to which is granted only to the permitted requestors, authorized representatives and approving persons. Duplication of the approved medical history record must be in accordance with the specified procedures in order to safeguard the confidentiality and safety of patients’ information according to the Declaration of Patients’ Rights and Patients’ Duties, including related laws such as the Personal Data Protection Act. B.E. 2562 and National Health Act, B.E. 2550.

Environmental Responsibility Medical record documentation and files involve the use of a large quantity of paper. The Company has established guidelines for destruction of medical records of patients having lost contact for over 5 consecutive years. The patients’ record documents shall be shredded to prevent the patients’ information from being exploited, and then be recycled for useful purposes. Accordingly, the Company takes part in helping the environment and indirectly contributes to less cutting down of trees for paper making. At the same time, the hospital has the policy to promote and develop an electronic medical record system that will significantly reduce the use of resources in the process.

4. Personnel

The Company has placed importance on human resource management in driving the organization towards success and taking care of personnel so that they are committed to the organization. It uses various tools, including human resource development and creating a safe working environment. Also, it includes promoting and supporting the cultivation of awareness among all personnel to be aware of environmental safety, surveillance, prevention, and health promotion for personnel and service recipients. Training activities on occupational health and working environment, essential fire prevention, and suppression are organized for personnel to support their work and enhance their knowledge even more by the Committee on Safety, Occupational Health and Working Environment (ENV).

In addition, the Company places importance on providing knowledge and understanding in preventing and controlling infectious diseases, as well as appropriate surveillance and tracking systems to prevent infection and control contagious diseases safely.

5. Anti-Corruption

The Company seeks to promote the significance and awareness of anti-corruption among employees of all levels, as well as taking internal control measures against corruption and bribery-related conducts of all forms.

Under the Company's business philosophy, all its business associates must act in a forthright, honest, accountable and non-corrupt manner in compliance with relevant laws and corporate anti-corruption policy, without bringing disgrace on or undermining the Company's reputation. Pertinent practices are adopted as follows:

1. Never commit corruption and be cautious in the course of high-risk operations;
2. Never disregard or ignore any acts of corruption related to the Company when witnessing one, must report the case to the supervisor or responsible person, and cooperate in the fact-finding investigation as well.
3. Giving or accepting of financial donations and sponsorships must be carried out with transparency in accordance with the Company's regulations and governing laws. It must be ensured that such donations or sponsorships are not used for bribery.
4. Be duly careful when conducting business transactions with any persons, juristic persons or organizations suspected of corruption.

6. Fair Labor Practices

The Company adheres to the principle of treating all personnel fairly and equally and under the protection of the law, whereby the Company operates by the law and ethical principles and respects personal rights by setting various operating policies as follows:

Compensation and benefits

1. The Company will determine appropriate compensation and treat all personnel equally, without discrimination, regarding nationality, race, religion, and gender.
2. The Company considers fair wage adjustments to suit the knowledge, abilities, responsibilities, efficiency, and performance of different workers by setting criteria according to the performance evaluation regulations.
3. The Company has a transparent and auditable recording and reporting system.

The Company implements a policy for managing wages and personnel compensation with the principles of fairness and appropriateness according to knowledge, abilities, duties, responsibilities, and performance. It is compared with the labor market and companies in the same industry, with annual wage increases, performance-based incentive payments, and special financial adjustments for personnel with high potential and good performance.

Welfare

The Company provides welfare and benefits to ensure that personnel have a good life and are physically and mentally happy. In addition to the welfare provided by law, the Company also offers other welfare, for example:

1. Living expenses welfare, such as promotions for special price tickets for food centers, personnel uniforms, travel allowances, financial assistance in the event of flooding, fire, or death, and special rights for family members of personnel to receive medical treatment;
2. Future stability Welfare, such as a provident fund;
3. Health welfare by providing knowledge through activities to prevent and control infectious diseases and annual health examinations such as chest x-rays, checking for diabetes levels, lipids, blood pressure, and vaccines to prevent coronavirus 2019, etc;
4. Boosting morale and honoring personnel welfare, such as awarding money to doctors and personnel who have completed 5, 10, 15, 20, 25 and 30 years of service.

Fair employment and labor management

The Company complies with the law and various regulations and shall protect the rights of personnel equally.

1. The Company provides an employment system with legal contracts and precise employment agreements.
2. The Company hires disabled people to work to promote and support the quality of life of disabled people by considering their physical and mental suitability as important.
3. The Company provides opportunities for personnel to participate in management through the welfare committee. Personnel can express their opinions and participate in decision-making.
4. The Company provides a grievance system to create understanding and good relationships and ensure fairness in employment.

Working Hours

1. The Company determines regular working hours and overtime hours as required by law.
2. Overtime work must be voluntary by personnel, with personnel agreeing to work overtime as required by law.
3. The Company has set rest times on working days, weekly holidays, and annual leave.

Child Labor

The Company has a policy of not hiring anyone under 15 years of age as company personnel.

7. Responsibility to Personnel

The Company sets strategies and directions for human resource management to align with the Company's business operations direction. It includes human resource management policies and systems by the principles of good corporate governance, labor law requirements, respect for human rights principles, and well-being.

The Company gives importance to the manpower planning process, recruiting and selecting appropriate personnel, training, and developing personnel to learn, take responsibility, and grow with the organization, managing fair compensation, maintaining personnel, and inculcating organizational values and culture.

8. Responsibilities towards Consumers

From the current situation of the spread of coronavirus disease 2019, it is found that the rate of spread of the disease has decreased worldwide. At the same time, the World Health Organization has announced the end of the public health emergency of coronavirus disease 2019 from May 2023, along with the severity of the disease decreasing in both morbidity and death rates. Therefore, the hospital has adjusted measures to provide patient care services and the medical treatment process to suit the situation according to the guidelines for providing care for patients with coronavirus disease 2019 for healthcare facilities, 3rd revised edition, dated 3 July 2023 as follows:

1. Screening for infection when a patient has respiratory infection symptoms;
2. Emphasis on wearing a surgical mask for everyone at all times, both patients and their followers, Medical personnel, and other officials;
3. Emphasis on washing hands on necessary and appropriate occasions;
4. Wearing personal protective equipment depends on the risks of each activity according to the recommendations;
5. For providing services to patients with respiratory symptoms, space in the building is organized by zoning it from general outpatients;
6. Among infected patients, separate areas are provided in specific areas and provide One Stop Service;

7. Arrangement of service areas at each service point to allow for social distancing while waiting for service, including cleaning measures in service areas, patient rooms, medical equipment, ambulances, wheelchairs, and various touch points in hospital, such as escalator handrails, elevator buttons, etc.

This is due to the epidemic situation of emerging infectious diseases such as monkeypox has spread from animals to people and is transmitted from person to person. The channels of infection spread are Droplet Precautions and Contact Precautions, and infections are increasing in the country. In December 2023, the Hospital Infectious Disease Control Committee Measures were taken according to the clinical practice guidelines for caring for monkeypox patients, Ministry of Public Health, second revised edition, November 9, 2023, to control and prevent the spread of infection in hospitals as follows:

1. Prepare an area for separating patients when receiving services. Specifying the use of emergency department isolation rooms
2. Provide One Stop Service
3. Create a guidelines to follow when suspecting a patient with monkeypox infection.
4. On January 19, 2024, there was the practise of 1st guidelines rehearsal and Root Cause Analysis to identify the reasons for non-compliance with the guidelines and to improve the guideline for more efficiency work.
5. On February 28, 2024, there was a second practise of guidelines rehearsal to provide more efficient services.
6. Prepare equipment for examinations and procedures ready for use.
7. Specimen has been sent for testing to the Ministry of Public Health and follow up on examination results within 24 hours after submitting the examination during business hours and report the results to the treating doctor who will inform the results to the patient.
8. There is surveillance to follow treatment in patients for 20 days (Home Isolation) until the spread of infection has passed.
9. Coordinate with public health service centers in patient areas to find closed contact who may be at risk of infection.

9. Innovation and Diffusion of Innovation obtained from CSR Operations for Society, Environment, and Stakeholders

- None -

10. Community and Social Development

CSR Activities

10.1 Thainakarin Hospital Received a plaque of honor for supporting the mission to help victims of the Singapore Airlines Flight SQ321 experienced some turbulence.

On May 30, 2024, Clinical Prof. Thipachart Punyaratabandhu, M.D, Hospital Director and Medical Director of Thainakarin Hospital being a representative of the hospital participated in the ceremony of presenting a plaque of honor from Mr. Kittipong Kittikachorn, Director of Suvarnabhumi Airport, Airports of Thailand Public Company Limited (AOT) to thank the agencies that supported the rescue mission for victims of the Singapore Airlines flight SQ321 which experienced some turbulence on May 21, 2024.

Clinical Prof. Thipachart Punyaratabandhu, M.D, As stated “Thaikarin Hospital is honored and pleased to join in supporting this rescue mission and most importantly, thank you to all the doctors, nurses, and ambulance team who have assisted the mission for the nation in this time. It was very well accomplished in providing quick care and ready to deliver the injuries to the hospital in a timely and safe manner”.



10.2 Thainakarin Hospital has contributed a donation to support the Ramathibodi Foundation.

Charoen Meensook, M.D., The chairman of the Board of Thainakarin Hospital Public Company Limited, along with the executive teams, donated 1,000,000 baht to the Ramathibodi Foundation to support the construction of the Ramathibodi Hospital Building and the Yothi Innovation District. Prakasit Chirappapha, M.D. and Chairat Supsamutchai, M.D., Executive Directos of the Ramathibodi Foundation, represented the foundation in receiving the donation on Tuesday, February 27, 2024.



Blood Donation



Thainakarin Hospital joined the Blood Center and the Organ Donation Center of the Thai Red Cross Society in running the Give Blood, Give lives, Give forever for any strong and healthy person can donate blood every 3 months (March, June, September, December) total 4 times per year.

Kor Kai Nai Sai Mok Project

Thainakarin Hospital deliver the school supplies along with medicine and medical supplies to donate to the project Koh Kai Nai Sai Mork (A Chicken in the mist) to Mr. Phichet Suksawat, Chairman of Koh Kai Nai Sai Mok group. The aim is to be used as lunch funds for children in the Mae Fah Luang mountain Thai community, Ban Tala Kong, Mae Chan Subdistrict, Umphang District, Tak Province which Koh Kai Nai Sai Mork Project has always provided continuous support by Thainakarin Hospital.



School's Activities

Thainakarin Hospital joins with Jai Rak Kindergarten School to organize a project to promote hygiene in schools. The aim is for children to know how to care for their health. It enhances knowledge about eating the right foods according to nutritional principles by dieticians and teaches how to wash hands and brush teeth properly by a professional nurse. There are also recreational activities for children to participate in fun activities together and receive souvenirs from the hospital. There were a large number of children showing interest in participating in this activity.



Training course on “Disease Surveillance and Emergency Management in Children”

Thainakarin Hospital cooperated with Lasalle School organized training courses “Disease surveillance and emergency management in children” to promote knowledge and practice skills for kindergarten teachers within the event there was a lecture on the topic “Popular diseases in children that come with rain” Lecturer by Kamphon Veerakanchana, M.D., Head of the Pediatric Department. Including teaching basic first aid and management of emergencies in children aged 2-5 years by professional nurses, such as choking on food in children sudden cardiac arrest, etc. Cardiopulmonary resuscitation was taught and training in using the Automatic External Defibrillator (AED) was taught, with a large number of teachers participating in the practice.



Activities with Contract Companies

“Fat Attack Award Ceremony & Kick off SS3” Project: Mission to Conquer Fat

Thainakarin Hospital Together with Thai Honda Company Limited, organized the “Fat Attack Award Ceremony & Kick off SS3” project activity, a mission to conquer fat. Organized for the third year in a row, Thai Honda focuses on the health of employees who are an important force in driving the organization forward. Including encouraging employees to see the importance of taking care of their own health. Prevent the occurrence of non-chronic communicable diseases (NCDs). Currently, most Thai people pay attention and change their behavior to stay away from disease.

During the event, awards were given to employees who achieved outstanding achievements in the past year. Ready to open applications for those interested in joining the project in year 3 and to make employees aware of eating correctly according to nutritional principles. Thainakarin Hospital has arranged for dietitians to provide knowledge. About fat loss foods and eating “reduce sweet, fatty, and salty food”. There are also recreational activities such as hula hoops, fat-conquering dances, Jump rope for heart fitness. Ask and answer questions about health problems and receive souvenirs. There were a large number of employees interested in participating in the activity and applying to join the project in the 3rd year at Thai Honda Company Limited, Lat Krabang Industrial Estate. and Samrong Office.



Activity: “Happy body, happy mind before retirement”

Thaikarin Hospital cooperated with Thai Yamaha Motor Co., Ltd. organized the activity “Happy Body, Happy Mind Before Retirement” to promote the knowledge for Thai Yamaha Motor employees who are about to enter retirement age to prepare both physically and mentally. Including a new way to plan their life with stability and confidence. Within the event, there was a lecture on the topic “Happy Body and Mind Before Retirement” by Ornkamol Inkong-ngam M.D., Head of the Holistic Health Promotion Center, Thainakarin Hospital.

There was also the exercise activities for the elderly at the event to prepare the physical health which is an extremely important part in retirement by physical therapist. Moreover, there was also a lecture giving knowledge about “Nutrition for Health” and “Healthy Food” Workshop activities by dietitians which a large number of employees participating in this activity.



Thainakarin Hospital Providing health check-ups to residents of My Condo Sukhumvit 52 condominium under the project ‘Good health with Thainakarin’

Thainakarin Hospital organized the ‘Good Health with Thainakarin’ project, providing basic health check-up services to residents of My Condo condominium, Sukhumvit 52 and ‘Casa Ville’ Bangna-Suvarnabhumi village. At the event there was a basic health check-up service by professional nurses such as measuring blood pressure, blood sugar levels measure and body composition measure including giving advice on health care, etc. There were also public relations activities for the hospital and increase communication channels in every channel such as Facebook, Line, IG.



10.3 Luang Por Bhuddh – Jatu Charoen Foundation

Luang Por Bhuddh - Jatu Charoen Foundation was established by the remark of Phra Rajasangvarayana (Luang Por Bhuddh Thaniyo) of Wat Pa Salawan, Nakhon Ratchasima. In the beginning, Phra Rajasangvarayana wished to set up a fund to help out sick monks who lacked attendants or money to pay for medical fees. He then gave a sum of 151,400 baht, donated by his disciples and benefactors, to the Company for use as the initial fund. On 1 February 1998, the Company therefore carried out his wish and established “**Luang Por Bhuddh for Sick Monks Fund,**” with Phra Rajasangvarayana being the advisor to the Fund Committee until his decease in 1999. Subsequently, the establishment of “**Luang Por Bhuddh - Thainakarin Hospital Foundation**” was registered on 1 June 2011. Its name was later changed to “**Luang Por Bhuddh - Jatucharoen Foundation**”.

Our Key Activities with Luang Por Bhuddh - Jatu Charoen Foundation

- **Provided Medical Treatment Fee Funding to help out Sick Monks** There are around 150 - 200 sick monks under the medical treatment fee funding program in every single year. The Company has fully supported this funding program in term of medical treatment fees for sick monks.
- **Offered Robes to Buddhist Monks** Offering robes to Buddhist monks is the great merit-performing. This offering will not be doing to a specific monk but to any of the Buddhist monks at monastery. The Company and the Foundation have arranged this activity every year.
- **Receiving a donation for the foundation** Phrakru Suthiyansophon (Lek Sutthiyano), abbot of Wat Pa Phichai Wattanamongkol, Bang Pla Subdistrict, Bang Plee District, Samut Prakan Province, along with the monks, donated 300,000 baht to the Luang Pho Phut-Chatucharoen Foundation for take it to help sick monks with Charoen Meensook M.D., Chairman of the Company’s Board of Directors and president of the foundation be the recipient.



- **Public Affairs Activities** In order to support general public affairs, the Foundation has donated to the following organizations.

Thainakarin Hospital in collaboration with Luang Por Buddh - Jatu Charoen Foundation with Charoen Meensook, M.D., the Chairman of the Board of Directors and Charoen Chouriyagune, M.D., the physician donated gifts baskets and essential items to the Priest-Hospital, Ban Bang Khae Elderly Social Welfare Development Center and Sosa Children's Foundation of Thailand (Sosa Children's Village, Bang Pu, Samut Prakan). The activity has been organizing continuously for over the years in a row with the commitment to help sick monks as well as the elderly, groups of children and youth who are the future of the nation. Mrs. Sirisilp Chiasuwan, Director and Secretary of Luang Por Buddh - Jatu Charoen Foundation, along with the party, acting as representative of the Company.



Donation can be made to:

Saving account: **“Luang Por Buddh - Jatu Charoen Foundation”**

TMBThanachart Bank Public Company Limited, Bangna Branch (Ample tower Building), account number: 725-2-01189-0

In case donation receipt is required:

Tel. 0 2340 7777, 0 2361 2727 ext. 3397 or Fax. 0 2340 6431

11. Social Performance

The Company places importance on human resource management by considering human rights principles. It promotes personnel development and works with safes. It also pays attention to the surrounding community to create good relationships and be aware of social responsibility in developing the organization to grow sustainably.

11.1 Personnel training

The Company realizes that personnel are an essential resource in driving business growth. The challenge for the organization is to prepare and develop the potential of personnel in line with the strategic direction under conditions of constant global change in terms of economy, society, and the environment.

In the past year, the Company has organized personnel training and development, including combining personnel development training in the form of Hybrid Training (Online & Onsite). It considers and determines the need for training and personnel development from the strategic plan. There are 233 courses of personnel development according to Training Needs. The total number of personnel training hours is 11,889, an average of 17.44 hours/person/year. It emphasizes training and development of specialized professional personnel in both nursing and other professions, such as guideline for breast cancer, pain management, wound care nursing for cancer patients and nursing for terminally ill patients, prevention and control of infection in hospitals for nurses, safety standards and advances in radiology, endoscopic nursing of the gastrointestinal and biliary tract, specialized nursing in the field of nursing for critical patients (adults and the elderly), nursing for cancer patients receiving chemotherapy, etc.

11.2 Occupational Safety, Health and Environment

In the past year, the Company continuously adjusted the efficiency of safety operations in order to reduce the risk of illness and took care for the safety of the personnel's work environment appropriately. Significant operations had been carried out, such as, the Safety, Occupational Health and Work Environment (ENV) Committee was set up, and this committee was responsible for considering occupational safety policies and plans, reporting and suggesting measures or solutions to legal improvements regarding occupational safety, and organizing workplace safety courses for personnel in order to instill personnel awareness of the importance of such matters, and be capable to work effectively and in accordance with the standards prescribed by law.

In the past year, the Company had 12 cases of work-related injuries. In this regard, the Company had already implemented such accident prevention measures, namely, reviewing existing Standard Procedures, Work Instruction, and developing standards policy that are essential for safety with safety manuals for the work of the unit so that personnel can comply correctly in accordance with the safety standards of the Hospital and regularly provide training on safety in the workplace knowledge for personnel.

Training

- Basic Firefighting Training, 2 Sessions, 2023
- Fire Drill and Evacuation Exercise, 2023
- Unit Fire Drill Code 199, 2023
- Monkeypox Response Plan Drill
- Basic Life Support 2023
- Biological and Chemical Spill Management Drill, 2023
- Chemical Spill Kit Drill, 2023

11.3 Personnel Engagement

The Organizational Engagement Survey is considered a measure of well-being within an organization. It is an expression of personnel's confidence and unity with the organization. The engagement survey results will lead to guidelines for organizational development to drive happy work and affect organizational efficiency and successful and sustainable business operations. In the past year, the Company has surveyed the engagement of personnel in the organization through a survey on the well-being and engagement of hospital personnel with personnel at every level, from management to operational personnel equal to 1,016 person, the survey results on the well-being and engagement of hospital personnel were at a good level.

The Company had significant operational personnel as follows;

Type	Number of Personnel	
	Male	Female
Full-time personnel	207	966
Personnel with disabilities	8	5
Total	215	971

4 Management Discussion and Analysis: MD&A


Operating Results and Profitability

Revenue

Operating results for the 2024 financial year from 1st August 2023 to 31st July 2024 registered total revenue of Baht 2,717.51 million, Baht 2,706.22 million or 99.58% of which came from medical service fees. The total revenue improved by Baht 302.18 million or 12.57% when compared to that of 2023 which resulted from increased number of IPD by Baht 149.42 million or 14.98% and the income of OPD increased by Baht 152.76 million or 10.86%

In 2024, The Company has carried out more marketing activities to build a brand and image to be known among both Thai and foreign patients including patients who have paid on their own or by the insurance. The Company has received good feedback regarding to the quality of treatment, special expertise of doctors as well as good service quality and worth the price. Besides, the Company has expanded its patient base to more foreign customers, after an opening of the country the foreign tourists has more increased and they are coming to use more service as well.

Revenues from OPD and IPD medical fees for 2024, 2023 and 2022 are as follows:



Most of the Hospital's customers in 2024 were Thais, consisting 4 largely group of self-pay patients, insured patients, contractual parties and accounts receivable from government agencies.

Furthermore, the Company have other revenues included interest income from investment and rental income which aggregately accounted for 0.42% of total revenue.

Cost of Medical Services

In 2024, the Company's cost of medical services (including depreciation and amortization) amounted to Baht 1,935.31 million. 71.51% of medical expenses is decreasing from 2023 which was 73.28% and direct medical expenses in 2024 increased by 173.55 million baht. This increase can be attributed to rising income, 45.12% of the rise in medical treatment costs is attributed to physician fees, while 36.15% is due to the cost of medications, medical supplies and other materials.

Administrative Expense

In 2024, the Company had total administrative expense of Baht 263.76 million, growth from 2023 by Baht 29.99 million or 12.83%. Regarding personnel compensation, an amount of approximately 32.51 million baht was affected by the reduced workload due to a decrease in the number of patients receiving services. Additionally, an increase of approximately 4.20 million baht in the allowance for credit losses occurred in 2023. This increase from general debtors and debtors awaiting reimbursement from government agencies settlements. Regarding Covid-19 patients, there remains an outstanding balance of approximately 10 million baht from 2022, which is still being gradually repaid.

Income Tax

Tax income of the Company in 2024 totaled Baht 103.37 million, increasing from 2023 by Baht 20.27 million or 24.39% as a result of increase operating net profits. Corporate income taxes in 2024 and 2023 were imposed at the rate of 20%.

	2024	2023	2022
Total Revenue (Million Baht)	2,737.36	2,429.20	2,609.14
Net Profit (Million Baht)	434.92	350.57	425.35
Net Profit Margin (%)	15.89	14.43	16.30
Gross Profit Margin (%)	28.49	26.72	29.73
Return on Equity (%)	15.01	13.44	18.36

For reasons mentioned above, the Company has increase in revenue growth rate of 12.68% and a net profit increase rate of 24.06% when compared to that of 2023. It has firmly pursued the policy on delivering high standard and quality services at fair prices.

Financial Position

The Company's financial position as of 31st July 2024 is as follows:

	Assets			Liabilities and Shareholders' Equity	
	Amount (MB)	Ratio (%)		Amount (MB)	Ratio (%)
Current assets	1,993.47	55.93	Current liabilities	389.49	10.93
Non-current assets	1,570.72	44.07	Non-current liabilities	113.15	3.17
			Shareholders' equity	3,061.55	85.90
Total	3,564.19	100.00	Total	3,564.19	100.00

Details of assets can be summarized as follows:

(Unit: Million Baht)

Description	2024	2023	2022
Cash and cash equivalents	1,300.95	1,297.93	699.57
Current investments	422.69	140.00	472.55
Trade and other receivables	229.03	211.89	360.77
Other current financial assets	39.98	33.57	36.17
Long-term deposits at financial institutions	-	-	-
Land, buildings and equipment	986.38	894.27	779.00
Other assets	585.16	603.49	621.62
Total assets	3,564.19	3,181.15	2,969.68

As of 31st July 2024, the Company recorded cash and cash equivalents of Baht 1,300.95 million, comprising Baht 6.83 million cash and Baht 1,294.12 million bank deposits.

As of 31st July 2024, the Company recorded current investments of Baht 422.69 million, increase from 2023 of Baht 282.69 million.

As of 31st July 2024, the Company recorded trade and other receivables of Baht 229.03 million, a year-on-year increase from 2023 of Baht 17.14 million or 8.09% due mostly to increase in 2024 came form credit sales to contract companies, general debtors and insurance companies.

Details of trade receivables as of 31st July 2024, 2023 and 2022 are as follows:

Trade Receivables	2024		2023		2022	
	(MB)	(%)	(MB)	(%)	(MB)	(%)
Not yet due	121.03	50.44	88.73	40.77	88.95	24.17
Overdue						
Less than 3 months	85.11	35.47	72.54	33.33	97.13	26.40
3 – 6 months	10.89	4.54	18.33	8.42	52.82	14.36
6 – 12 months	4.62	1.93	5.97	2.73	124.78	33.91
More than 12 months	18.29	7.62	32.08	14.75	4.25	1.16
Total trade receivables	239.94	100.00	217.62	100.00	367.93	100.00
Less: Allowance for doubtful accounts	(17.38)		(13.15)		(15.36)	
Total trade receivables - net	222.56		204.47		352.57	
Average collection period	31 days		45 days		44 days	

Because of the stringent debt management policy, the Company's average collection period by 31 days change from the previous year, a decrease of 14 day. If we consider the proportion of trade accounts receivable, it is found that 1.93 percent of the debtors whose payment are overdue by more than 6 months but not exceeding 12 months. Most of them are debtors that have to wait for a drawdown from government agencies that need to wait for approval for payment from the government with taking a longer time. Other accounts receivable and had debtors overdue for more than 12 months at 7.62%. The Company has the policy to set aside allowance for doubtful accounts for debtors that are expected to be unable to collect. It considered from past collection experiences and debt aging, as of July 31, 2024, the Company has recorded an allowance for doubtful accounts of Baht 17.38 million.

As of 31st July 2024, the Company's inventories amounted to Baht 39.98 million, divided into medicines and medical supplies of Baht 37.33 million or 93.37% and other materials of Baht 2.65 million. The inventories are increase from medicines and medical supplies due in 2024, it aligned with the rise in revenue from the growth of medicines and medical supplies.

As of 31st July 2024, the Company's land, buildings and equipment totaled Baht 986.38 million. During the year 2024, The Company has construction projects that are currently under construction is one more parking building #3 of Thainakarin Hospital that has been increased and land purchasing in Chachoengsao Province to expand the service potential of the clinic and nearby areas, including continuous investment in medical equipment to increase service potential and support future growth opportunities, in the fiscal year 2024, there was an investment value in land, buildings, and additional equipment as of 191.04 million baht and there was depreciation during 2024 in the amount of 98.47 million baht.

Financial Ratios	2024	2023	2022
Return on assets (%)	15.96	14.10	19.09

Return on fixed assets and return on assets for 2024 were 1.86%, decreasing from the last year because of the Company has net asset value of fix assets increase.

Liabilities

Details of liabilities as of 31st July 2024, 2023 and 2022 could be summarized as follows:

(Unit: Million Baht)

รายละเอียด	2024	2023	2022
Trade and other payables	209.72	185.07	210.25
Doctor fee payables	111.81	94.80	106.57
Income tax payables	33.86	29.02	26.80
Provision for long-term employee benefits	110.60	98.93	102.96
Other liabilities	36.64	38.69	39.10
Total liabilities	502.63	446.51	485.68

As of 31st July 2024, the Company registered trade and other payables of Baht 209.72 million, increasing from 2023 by Baht 24.65 million or 13.32% and the Company's doctor fee payable amounted to Baht 111.81 million, increasing from 2023 by Baht 17.01 million or 17.94% in consonance with the increase of medical fee revenue.

As of 31st July 2024, the Company had income tax payables of Baht 33.86 million, increase from 2023 by Baht 4.84 million or 16.68%. Income tax rates for 2024 and 2023 were 20%.

As of 31st July 2024, the Company registered provision for long-term employee benefits of Baht 110.60 million, rise from 2023 by Baht 11.67 million or 11.80%. This is an increase in the long - term employee benefit provision. During 2024, The Company has calculated the long-term benefit obligations of new employees using the same assumptions as in 2023, using a discount rate of 2.82 percent.

Shareholders' Equity

Shareholders' equities of the Company as of 31st July 2024, 2023 and 2022 were Baht 3,061.55 million, 2,734.63 million and 2,484.00 million respectively, showing a steady growth driven by increasing comprehensive profits net of interim dividend payments.

Liquidity

(Unit: Million Baht)

Description	2024	2023	2022
Cash flow from operating activities	563.93	606.48	462.21
Cash flow used in investing activities	(452.92)	99.89	(39.39)
Cash flow used in financing activities	(108.00)	(108.00)	(90.00)
Net increase (decrease) in cash and cash equivalents	3,014.89	598.37	332.82
Cash and cash equivalents as of 1 August	1,297.93	699.56	366.74
Cash and cash equivalents as of 31 July	1,300.95	1,297.93	699.56

The Company recorded cash and cash equivalents as of 31st July 2023 and 2024 of Baht 1,300.95 million and Baht 1,297.93 million respectively. Details of cash inflows and outflows in 2024 are as follows: The company experienced a positive net cash inflow from its operating activities, totaling 563.93 million baht. This represents an decrease of 42.55 million baht which amount is derived from a pre-tax profit of 538.29 million baht. This was adjusted for depreciation and amortization costs of 122.55 million baht, expenses for long-term employee benefits amounting to 14.70 million baht, an allowance for expected credit losses of 8.65 million baht, losses from equipment sales of 0.50 million baht, and deductions from interest income totaling 19.85 million baht.

The company reported net cash generated from its investment activities, amounting to 452.92 million baht. This was accompanied by increasing of 282.67 million baht in other current financial assets. Notably, the company received cash inflows through interest income of 19.85 million baht and proceeds from equipment sales, totaling 1.07 million baht. On the expenditure side, the company disbursed 189.06 million baht for the acquisition of building improvements and equipment. Additionally, during the year, 2.13 million baht was spent on the purchase of intangible assets.

Net cash used in financing activities total Baht 108.00 million from annual dividend payment.

Financial Liquidity of the Company of each year is as follows:

Financial Ratio	2024	2023	2022
Liquidity ratio (time)	5.12	4.92	4.19
Average collection period (day)	31	45	44
Average inventory period (day)	6.94	7.22	7.29
Average payment period (day)	37.23	40.95	37.29

As of 31st July 2023 and 2024, the Company registered fairly high liquidity ratios of 5.12 and 4.92 times respectively, which well reflected its capacity to settle contractual obligations.

As of 31st July 2023 and 2024, the Company's average collection periods were exactly at 31 days and 45 days which is an decrease from 2023 due to payment received from debtors, including insurance companies, contract partners government agencies, which increased in 2024.

As of 31st July 2023 and 2024, the Company's average inventory periods were 6.94 days and 7.22 days respectively, which indicated efficient inventory management.

As of 31st July 2023 and 2024, the Company recorded average payment periods of 37.23 days and 40.95 days respectively, which demonstrated its debt settlement ability and boosted the confidence of contractual parties.

Capital Structure

The Company has a solid capital structure, with the debt to equity ratios as of 31st July 2024 and 2023 being 0.16 and 0.16 times. However, the Company has maintained a rigid policy on financial structure management and control, while keeping an appropriate level of its financial ratios and liquidity.

Contractual Obligations

As of 31st July 2024, the Company had obligations under service agreements as follows:

(Unit: Million Baht)

Description	Term of Payment		Total
	Within 1 year	1-3 years	
Service agreement obligations	9.40	0.50	9.90

Factors Affecting Future Operations

Increasing Demand for Medical Care

The Company is confident that private hospital business shall continue to expand due to the rise in demand for medical care among domestic and foreign customers as a result of higher income per capita, need for quality medical care and growing number of elderly population.

Advantageous Location

Located on Debaratna Road and in close proximity to communities and industrial estates which are continually expanding, the Hospital has gained more customers. With largely middle-market customers, the Hospital adheres to its policy to deliver best medical care services with kindred hospitality at a reasonable price.

Capacity Enhancement for Specialty Clinics

Nowadays, diseases have become more complex and meanwhile people can access more medical-related information. Striving to treat complex diseases and to meet higher demand for medical care, the Hospital has therefore boosted its capacity with teams of specialist doctors, state-of-the-art equipment along with experienced support staff. It has seen from the number of patient is increasing from the launched of new specialty clinic such as Brain and Neurology Center and Heart Center.

Competition

Competition tends to intensify because of expansion of private hospitals, both existing and new ones, in Bangkok and perimeter areas. In response to this, the Company has plan to make improvements on the premises and services to ensure service user satisfaction.

Economic Factors

Government Intervention

Changes of standards or regulations governing the Hospital are as follows:

- **Control on the prices of drugs, medical supplies and medical fees by the Department of Internal Trade**
Thainakarin Hospital has already complied with the notification of the Central Committee on Prices of Goods and Services relating to price control of drugs, medical supplies and medical fees. However, the Hospital is not impacted by such measure because it charges moderate prices of drugs, and sets the prices of drugs, medical supplies and medical fees at reasonable rates.
- **Advertisement control by the Ministry of Public Health**
As the Department of Health Service Support (DoHSS) mandates that publication of advertisements or announcements by private hospitals must obtain prior approval of DoHSS, it becomes more complicated for private hospitals to give information to service users. As a result, service users shall be less informed.
- **“Universal Coverage for Emergency Patients” Program (UCEP)**
Under the “Universal Coverage for Emergency Patients” program (UCEP), the Hospital gets compensation at the rate of approximately 30-50% of the charges, which affects its profits.



5 General Information and Other Important Information



Name of Company	: Thainakarin Hospital Public Company Limited
Name of Business	: Thainakarin Hospital, Large General Hospital
Type of Business	: Private hospital
Address	: 345 Debaratna Road Bangna Nuea, Bangna, Bangkok 10260
Registration Number	: 0107547000974
Registered Capital	: Baht 180,000,000. The capital is fully paid-up and comprised of 180 million ordinary shares of the par value of Baht 1 per share.
Website	: www.thainakarin.co.th
E-mail	: ir@thainakarin.co.th
Telephone	: 0 2340 7777, 0 2340 6499, 0 2340 6488, 0 2361 2727, 0 2361 2828
Facsimile	: 0 2340 6431

Reference Information

●● Securities Registrar

Name	: Thailand Securities Depository Co., Ltd.
Address	: 93 Ratchadaphisek Road, Dindaeng, Dindaeng, Bangkok 10400
Telephone	: 0 2009 9000
Fax	: 0 2009 9991
TSD Call Center	: 0 2009 9999
Website	: http://www.set.or.th/tsd

●● Auditor

Name	: EY Office Limited
Auditors	: Mrs. Sarinda Hirunprasurtwutti, Certified Public Accountant, License No.4799 or Ms. Patcharawan Koonarangsri, Certified Public Accountant, License No.6650 or Mr. Samran Taengcham, Certified Public Accountant, License No.8021
Address	: 193/136-137, Lake Rajada Building, 33rd Floor, Ratchadaphisek Road, Klongtoey, Klongtoey, Bangkok 10110
Telephone	: 0 2264 0777
Facsimile	: 0 2264 0789

In 2024, the Company's auditor is Mr. Samran Taengcham, Certified Public Accountant, License No.8021, from EY Office Limited. The audit fee is Baht 1,345,000 with the out-of-pocket expenses which includes, for example, travel and copying costs as actually incurred but not exceeding Baht 30,000.

●● Internal Auditor

Name : Dharmniti Internal Auditing Company Limited
Address : 178 Dharmniti Building 5th Floor, Soi Permsap (Prachachuen 20),
Prachachuen Road, Bangsue, Bangkok, 10800
Telephone : 0 2596 0500
Facsimile : 0 2596 0539

●● Information of Subsidiary

Name : Jatu Charoen Development Company Limited
Address : 345 Debaratna Road Bangna Nuea, Bangna, Bangkok 10260
Registration Number : 0105565031035
Registered Capital : 1,000,000 Baht, the capital is fully paid-up and comprised of 1 million, ordinary shares of the par value of Baht 100 per share.
Shareholding : 99.97%
Other important information : Established in February 2022, according to the resolution of the Board of Directors Meeting No.5/2021, held on 13 December 2021

Legal Dispute

Currently, disputes and lawsuits by patients against hospitals and doctors are increasing because more laws related to medical facility business have been enacted or amended with the aim of securing and protecting the rights of patients, who are regarded as consumers. This results in higher risk of legal disputes.

Secondary Stock Exchange

Market for Alternative Investment (MAI)



PART

2

Corporate Governance

- ① Corporate Governance Policy
- ② Corporate Governance Structure
- ③ Significant Performance on Corporate Governance



1 Corporate Governance Policy



1.1 Overview on Corporate Governance Policy and Guidelines

The Company places much importance on undertaking business under corporate governance principles. With respect to this, the Board of Directors complies with Code of Best Practice for Directors of Listed Companies.

Furthermore, the Company recognizes its roles, duties and responsibilities under the Good Corporate Governance Principles, with firm belief that good corporate governance enables the Company to develop business monitoring systems with transparency, efficiency and social responsibility, helps shape corporate structure and strengthens relationships between directors, executives, shareholders, investors and all stakeholders for productive, continual and steady growth of the business. The Company therefore adopts the Good Corporate Governance Principles as guidelines for operations in order to facilitate and foster business transparency toward higher management efficacy that shall build up the confidence of the shareholders, investors and all related parties.

The Good Corporate Governance Principles cover 5 areas of conduct, which include Section 1: Shareholders' Rights, Section 2: Equitable Treatment of Shareholders, Section 3: Corporate Roles Toward Stakeholders, Section 4: Information Disclosure and Transparency, and Section 5: Responsibilities of the Board. Details of each section are as follows:

Chapter 1 Best practice on Rights of Shareholders

1. Shareholder Meeting

The Company gives the most importance to equitable treatment of all shareholders. At each shareholders' meeting, the Company has submitted the meeting invitation along with supporting information of each agenda item to the shareholders for at least 7 days in advance. In addition, the shareholders have equal rights to examine the Company's operations and able to give comments and recommendations independently. The Company performs the following actions to facilitate the shareholder's right exercising in the shareholder meeting.

The Company defines to hold the Annual General Shareholder Meeting of Shareholders once a year within 4 months as from the date on which the accounting year of the Company ends. In the event of any urgent case, the special agenda shall be offered and the company shall call the Extra-ordinary Meeting of Shareholders on a case by case basis.

The Annual General Meeting of Shareholders for the year 2023, the company held the meeting exclusively in the form of an electronic meeting on Wednesday, November 22, 2023, at 2.00 P.M. The meeting venue was at the meeting room A, 4th floor, Thainakarin Hospital Building.

For advance notice of meeting invitation, after having the resolution to hold the Annual General Meeting of Shareholders and the Company has already disclosed resolutions, meeting date, agendas, in the website of the Stock Exchange of Thailand in order to inform shareholders in advance or before 09:00 a.m. of the next day. The Company will send invitation letter consisted of details on meeting date, time, and venue, some necessary information for making decision or giving the resolution, Board's Opinion, former minutes, 56-1 One Report, supporting documents, and Proxy for any shareholder who is unable to attend the meeting in person. The method of proxy is already specified clearly in the company's documents sent to shareholders and also disclosed on the company's website prior the meeting date as well as announced on the daily newspaper for 3 consecutive days prior the meeting. Shareholders will have adequate time to

consider on obtained information. The Company will not perform any action that may hinder or obstruct shareholders from communicate with one another.

The Company will facilitate all groups of shareholders to exercise their right of meeting attending and voting fully without any expense and difficult method. The Company will not perform any action that may limit any opportunity on meeting attending of any shareholder. The Company will check the name list and number of shares of shareholders classified by types of shareholders helping to facilitate registration on the meeting date.

The Company also has a policy to allow shareholders who are unable to attend the meeting to appoint an Audit Committee member of the Company as their proxy to attend the meeting and vote on their behalf by using any Proxy Form sent by the Company with meeting invitation. Moreover, shareholders are also able to download Proxy Form via the Company's website.

2. Procedures of Shareholder Meeting

The Company defines that shareholders have to register via computer system prior attending the meeting and ballots are prepared for each agenda for convenience and correctness.

The Company will introduce the Board, Audit Committee, Executives, and Auditor (mediator) for transparency prior the meeting and the company will keep all ballots / voting data as evidence for any subsequent dispute.

The Company will moderate the meeting based on the order of agendas unless it is voted by the meeting's resolution to change any agenda with the votes not less than two third of total attended shareholders or proxies (if any).

At each shareholders' meeting, the Company has improved meeting procedures and provided all shareholders an equal opportunity to examine the Company's operations, to make enquiries, comments and recommendations. After the meeting, significant enquiries and comments shall be completely and accurately recorded in the meeting minutes.

3. Disclosure on Resolutions of Shareholder Meeting

The Company will disclose the resolutions of shareholder meeting with votes of all attended shareholders and proxies clearly specified with proportion of agreement, disagreement and abstaining of each agenda as well as voting method and vote counting. The Company will clarify this information prior the meeting and disclose this information via the Company's website and news system of the Stock Exchange of Thailand within end of the day after finished the meeting or within 9.00 a.m. of a next day, as well as send the minute of meeting to the Stock Exchange of Thailand and the Office of Securities and Exchange Commission within 14 days from the meeting date. The subject matter of all questions and suggestions provided by shareholders in each agenda shall be summarized completely as well as clarification of the Company's Board and executives.

Chapter 2 Equitable Treatment of Shareholders

1. Protection of Rights of Shareholders

In the shareholder meeting, the Company will nominate each director in election of directors to be considered by shareholders in order to enable shareholders to exercise their rights to vote directors individually.

The Company will not add any agenda without informing shareholders in advance in all cases. In the event of any necessary agenda, it will be specified in the next meeting therefore shareholders will have adequate time for considering.

2. Provision of Dual Language Documents

The Company shall disclose significant information via the electronic system of the Stock Exchange of Thailand and on the corporate website in Thai and English so as to allow equal access to the Company's information for both Thai and foreign shareholders.

3. Insider Trading

Recognizing the significance of prevention against the use of inside information for personal gain, the Board has set forth a policy to maintain the confidentiality of non-public information and to allow only concerned persons to have access to such information.

The Company has already informed all the directors and executives of the duty to report holdings in the Company's securities, including changes thereof, by them, their spouses and minor children to the Office of the Securities and Exchange Commission in accordance with the Securities and Exchange Act B.E. 2535.

Additionally, the Company has implemented a regulation prohibiting directors, executives, personnel as well as their spouses and minor children from utilizing the Company's non-public inside information, especially financial information, for personal gain through the trading, transfer or acquisition of the Company's securities. Except for the aforementioned case, the directors, executives, their spouses and minor children that have traded, transferred or acquired the Company's securities must report every such transaction to the Office of the Securities and Exchange Commission within 3 days from the transaction date, as well as submit a copy of the report to the Company Secretary as evidence.

4. Policy for directors and senior executives to report trading in the Company's securities

The Company has determined various actions to prevent disclosure and prevent transactions that may cause conflicts of interest, including the wrongful use of inside information. This may affect the Company's business operations as well as the securities or stock prices of the Company and causing inequality in receiving company news and information. As a result, someone will get the benefit from the use of such inside information. The Company has laid down the following guidelines.

1. Set a period forbidding trading of the Company's securities and directors and executives are prohibited from giving news (Silent Period) for 30 days before the announcement of operating results or announce quarterly financial statements and annual financial statements. During the Silent Period, directors and executives must not express opinions about investment guidelines, profit and operating results of the Company except for disclosing facts that have already been disclosed to the public.
2. Disclose securities holdings of directors and executives, the directors and executives are responsible for preparing and reporting the trading of the Company's securities within 1 month from the date of first assuming the position and within 3 business days after there is a change in the holding of such securities to the Office of the Securities and Exchange Commission along with reporting such holdings or changes to the Company Secretary to compile reports on changes in the Company's securities holdings.
3. Reporting of conflicts of interest, the Company requires directors and executives Prepare a report on the interests of themselves and related persons and send it to the Company secretary and provide those report if any information changes next time. The Company Secretary is responsible for collecting and reporting such information to the Chairman of the Board and to the Board of Directors' meeting for information. To comply with the Securities and Exchange Act B.E. 2535 and the announcement of the Capital Market Supervisory Board, the Company will use such information to control and conduct transactions between the Company and directors, executives, or related persons of such persons in order to comply with the principles of the law and the principles of good corporate governance.

Chapter 3 Roles of the Company Stakeholders

1. Shareholders

The Company has emphasized on developing the organization to grow continuously enabling the company to earn more income, profit, and value. Consequently, the company's shareholders will be able to gain the highest reward.

The Company puts emphasis on operating business for the ultimate benefit of shareholders and continuous growth of the company with transparency and reliability. The Company has a policy to pay for dividend to shareholders in the rate of 60% of net profit after deducted with corporate income tax. However, the company may specify lower rate of dividend payment in the event that it is necessary for the company to spend such net profit to expand the company's business operation.

2. Customer

The Company pays attention and takes responsibilities towards all customers by providing quality and standard services as well as keeping their secrets under legal compliance. In addition, the company also provides a unit to accept complaining of customers for solving their problems as well as to assess their satisfaction by making the questionnaires on satisfaction and demands of customers for every month.

3. Personnel

Regarding personnel as valuable asset and key factor to success, the Company puts emphasis on human resources and thus implements the following practices:

- For reasonable remuneration, the Company has paid reasonable and fair compensation to personnel in the form of salaries or payment for work, appointments, transfers, and rewards to encourage high-efficiency performance.
- Appropriate welfare: The Company sets up the Welfare Committee and arranges appropriate welfare benefits that extend to employees' families in order to promote their positive performance, work morale and well-being. These benefits include social security fund, provident fund, medical expense, medical expense discount for families, uniform, death-in-service insurance, annual checkup, annual influenza vaccination, COVID - 19 vaccination, wedding gift payment, condolence payment upon the death of employees' parents, children and spouses, financial assistance on flood or fire incident, etc.
- Personnel Development: The Company regularly provides basic knowledge training and training of various specialized professions. In order to broaden knowledge, capabilities, operational and technical skills so that personnel could be able to perform their tasks more efficiently. The average personnel training hours is 17.44 hours per person per year.

4. Competitors

The Company has complied with good competitive rules and avoided any dishonest method to destroy any competitor.

5. Suppliers / Alliance / Creditors

The Company treats suppliers, alliance and creditors in an honest and fair manner, and complies with all trading conditions or terms of agreements in order to establish healthy business relationship and also to bolster their confidence which will be beneficial to all parties. Moreover, the Company shall not conceal any information or facts damaging to its suppliers, alliance and creditors.

6. Society Community and Environment

The Company has always emphasized on community and environment as a part of society with responsibility towards environment of nearby communities by supporting many activities for public benefits including providing general health check-up service for free in Bangna and Prawet, etc. Moreover, The Company also emphasizes and takes responsibilities on environment by controlling wastewater discharge, standard and efficiency general infectious and toxic waste disposal as defined by laws.

Attentive to personnel development regarding environmental concern, moreover, the Company has arranged environment-related courses for working personnel and interested persons in effort to inculcate in them awareness of the issue. During August 202 - July 2024, training courses were organized as follows:-

Environment Related Course (August 202 - July 2024)					
Training	Course	Institution	Place	D/M/Y	Attendance
Internal Training	Preventing and basic suppressing fires in workplaces for the year 2023	Thainakarin Hospital PCL.	Thainakarin Hospital PCL.	19 Oct. 2023 and 24 Oct. 2023	149
External Training	How to start an occupational health management ? (for hospitals)	Faculty of Medicine Ramathibodi Hospital	Atthasit Vejjiva meeting room, 5 th floor, Sirikit Building, Ramathibodi Hospital	7 Nov. 2023	1
External Training	General knowledge about safety in using LPG gas.	Perfect Safety Training & Consulting Co., Ltd.	Online	5 Dec. 2023	1
External Training	Psycholinguistics for safety in life and work	Perfect Safety Training & Consulting Co., Ltd.	Online	12 Dec. 2023	1
External Training	Summary of important points that must be followed according to ministerial regulations. Set standards regarding safety management systems 2022	Online Institute for people who want to advance, taught by experts from real experience (SkillLane)	Online	14 Dec. 2023	1
External Training	Ministerial Regulations Providing occupational safety officers, personnel, agencies, or groups of people to carry out safety operations in business establishments, B.E. 2022	Perfect Safety Training & Consulting Co., Ltd.	Online	17 Dec. 2023	1
External Training	Developing the potential of personnel in IPC and collecting infection data in hospitals	Bamrasnaradura Infectious Diseases Institute	Best Western PLUS Wanda Grand Hote	20-21 Dec. 2023	1

Environment Related Course (August 202 – July 2024)					
Training	Course	Institution	Place	D/M/Y	Attendance
External Training	Heat, light and sound measurement	Perfect Safety Training & Consulting Co., Ltd.	Online	9 Jan. 2024	1
External Training	Knowledge about Section 3 of the Safety Act 2011	Perfect Safety Training & Consulting Co., Ltd.	Online	14 Jan. 2024	1
External Training	Heat, light, noise, danger, prevention and measurement and evaluation techniques as required by law.	Safety and Health At Work Promotion Association Thailand	Online	15 Jan. 2024	1
External Training	Guidelines for preparing safety management system standards Occupational health and work environment according to Ministerial Regulations on management systems.	Perfect Safety Training & Consulting Co., Ltd.	Online	19 Jan. 2024	1
External Training	Organizational analysis for risk and opportunity management according to ISO 45001 guidelines.	Safety and Health At Work Promotion Association Thailand	Online	22 Jan. 2024	1
External Training	Hazard identification and assessment of hazardous conditions Assessment of area and work conditions and preparation for working in confined spaces	Safety and Health At Work Promotion Association Thailand	Online	5 Feb. 2024	1
Internal Training	Rehearsal for Mass Casualty Plan (Mass Casualty) for the year 2024	Thainakarin Hospital PCL.	Thainakarin Hospital PCL.	7 Jul. 2024	41

Chapter 4 Disclosure and Transparency

1. Disclosure

1. The Company will disclose some important information on the Company's website, www.thainakarin.co.th, in order to enable shareholders investor, analysts and general persons to search for public information rapidly.
2. In the Annual General Meeting of Shareholders, the Company will send meeting invitation and 56-1 One report (in QR code) to shareholders via mail and announce this meeting via newspaper and the company's website. In the Extra-ordinary Meeting of Shareholders, the Company will send meeting invitation to shareholders via mail and announce this meeting via newspaper as well as the Company's website.

3. The Company assigned the person taking the highest responsibility in finance and accounting to act as the Investor Relation whereas the Administrative Office shall be responsible to provide information of Company activities to shareholders, investors, analysts general person via the Company's Website. All providing information shall base on truth and reliable facts and with careful operation. Those without assigned or relevant responsibilities to share information on interviewing for mass media or any public entity on the Company in any matter which might affect the reputation or the Company business are not allowed to do so.

Accordingly, the investors contact Administrative Office and the Investor Relation at telephone number 0 2340 7777, 0 2340 6488, 0 2340 6499, 0 2361 2727, 0 2361 2828 or Email: ir@thainakarin.co.th

4. The Company shall disclose some important information of the company via the websites of the Stock Exchange of Thailand and the Company's website.
5. The Company will provide a contact channel to any person with any complaint on any illegal action against ethics or any behavior that may lead to any incorrect financial report preparation or presentation or defect internal control system whereas the company will keep such complaint as secret. In the event that any person finds any action as mentioned above, please inform the Company via Telephone: 0 2340 7777, 0 2340 6488, 0 2340 6499, 0 2361 2727, 0 2361 2828 Email: cg@thainakarin.co.th.
6. Process of actions upon receipt of complaints: The supervisory unit shall prudently consider the reported complaint as appropriate to the case, by gathering facts, then evaluating and scrutinizing information. In a serious or complex case, the matter may either be sent to related unit for examination and investigation of facts, or be considered by the Audit Committee. If it is deemed necessary and appropriate, the supervisory unit can propose the matter to the consideration and scrutiny of the Audit Committee.
7. For financial report preparation, the Company will prepare the financial report correctly, completely, and transparently and the Company will send such financial report, annual and quarterly financial statements to related organizations within the due date as stipulated by laws strictly and will publicize such information on the company's website. The Company has emphasized on preparing financial statements correctly according to Accounting Standard.
8. The Company prepares explanation and analysis of the management by giving analytical explanation on financial position, performance, some important changes, and factors that are causes or affect to the Company's financial position and performance and such explanation must be submitted to the Securities and Exchange Commission and the Stock Exchange of Thailand.

2. Information Disclosure on Company's Website

The Company discloses some financial information and non-financial information as required by the Stock Exchange of Thailand correctly, completely, timely, and transparently via the Company's website as well as publicizes some important documents that may be interested by investors and analysts on the Company's website. For example, objectives, vision, mission, nature of business, financial statement and financial information, annual report, 56-1 One Report, invitation letter of Shareholders Meeting with documents related to Shareholders Meeting etc. In addition, all of these information and documents are always updated and the Company also provides the Company's telephone number, facsimile and email for contacting on the Company's website

3. Report on the change in the Company's directors shareholding in 2023

Name	Position	Number of shares as of July 27, 2022	Number of shares as of August 2, 2023	Number of shares changed increased/ decreased.	Shareholding (%)
Charoen Meensook, M.D.	Chairman of the Board	2,500,000	2,500,000	-	1.39
Spouse and minor children		2,285,500	2,285,500	-	1.27
Mr. Thiti Sihanatkathakul	Director /	2,485,000	5,485,000	+ 3,000,000	3.05
Spouse and minor children	Chief Executive Office	-	-	-	-
Mr. Prapat Suthawate	Director	-	-	-	-
Spouse and minor children		-	-	-	-
Arkorn Cheirsilpa, M.D.	Director	-	-	-	-
Spouse and minor children		-	-	-	-
Mr. Pitipat Sihanatkathakul	Director	1,000,000	1,000,000	-	0.56
Spouse and minor children		-	-	-	-
Mr. Noratthep Sihanartkatakul	Director	-	-	-	-
Spouse and minor children		-	-	-	-
Mr. Tosaporn Sihanatkathakul	Director	1,000,000	1,000,000	-	0.56
Spouse and minor children		-	-	-	-
Col. Dan Tanphaichitra, M.D.	Director	-	3,000	-	0.0017
Spouse and minor children		-	-	-	-
Mr. Kraisak Kadkum	Director/Independent	-	-	-	-
Spouse and minor children	Director / Chairman of the Audit Committee	-	-	-	-
Assoc. Prof. Chertsak	Director/Independent	-	-	-	-
Dhiraputra, M.D.	Director / Member of	-	-	-	-
Spouse and minor children	the Audit Committee	-	-	-	-
Assoc. Prof. Panya	Director/Independent	-	-	-	-
Issarawornrawanich, Ph.D.	Director / Member of	-	-	-	-
Spouse and minor children	the Audit Committee	-	-	-	-
Mr. Chailerg	Director/Independent	-	-	-	-
Viriyarattanaporn	Director / Member of	-	-	-	-
Spouse and minor children	the Audit Committee	-	-	-	-

Chapter 5 Responsibilities of the Board

1. Board Structure

The Board is consisted of qualified persons with knowledge and experiences in various fields who have to supervise the management to perform the operations as planned efficiently and effectively in order to give the maximum value to the Company and the ultimate confidence to shareholders. The Board Meeting should be held at least once a quarter in order to consider on performance reports of the Company.

2. Leadership and Vision

Despite no Nomination Committee, the Company's Board consists of directors with expertise, competence and experience in medical, accounting, legal and management fields. The Board shall set policies, vision, strategies, business goals, business plans and corporate budget as well as supervise the Management to efficiently and effectively comply with the specified policies, goals and plans under the legal framework, the Company's Articles of Association and the resolution of the shareholders' meeting, for the maximum benefit of the Company and shareholders as a whole.

The Board has also established effective internal control, internal audit and risk management systems, together with regular monitoring. In this regard, it shall supervise to ensure that all committees and responsible executives comply with the set policies.

3. Review and Approval of Corporate Vision, Mission and Business Policy and Direction

The Board reviews, revises and approves vision, mission, corporate governance policy and business ethics on an annual basis; takes part in determination of strategies, targets, business directions, business plan, budget, internal control system, internal audit and risk management measures, by assigning relevant committees to undertake the review, revision along with monitoring of such matters regularly; and supervises that all working units implement the determined business plan and budget efficiently and effectively in order to maximize economic value for the Company and investment security for the shareholders, taking account of the best interest of all stakeholders. It adheres to the code of conduct in performing the duties with integrity, and shall not perform any act for personal or other persons' gain or any act in conflict or competition with the Company's interest. This includes overseeing that business operations are in accordance with the Company's objectives as well as the laws and regulations of the Stock Exchange of Thailand and the Office of the Securities and Exchange Commission.

The Company's vision, mission, business targets, including corporate governance policy have been published on its website and disclosed in the 56-1 One Report.

4. Conflict of Interest

The Company currently has measures against conflicts of interest that may arise from related-party transactions between the Company and potential conflict-of-interest persons, where the executives and persons with related interest are unable to take part in approval of the transactions. Such related-party transactions shall be carried out in accordance with the laws on securities and exchange, the Public Limited Companies Act B.E. 2535, and the regulations, notifications, orders and requirements of the Stock Exchange of Thailand.

Additionally, the Audit Committee and the auditors are assigned to review and give opinions on the appropriateness of prices and reasonableness of transactions. Details of the related-party transactions shall be disclosed in the notes to financial statements according to the accounting standards stipulated by Federation of Accounting Professions. The Company has set forth clear procedures for approval of future related-party transactions, details as shown under the Internal Control heading. It has also implemented a policy and measures to prohibit executives and related persons from using inside information for personal gain, which require the executives to report the change in their securities holding to the Office of the Securities and Exchange Commission.

5. Insider Information Usage

The Company has implemented measures to prevent unauthorized disclosure and transactions that could lead to conflicts of interest, including the misuse of insider information which could adversely affect the Company's operations. These measures are documented in the corporate governance policy, specifying a trading blackout period for directors and executives. This "Silent Period" lasts for 30 days prior to the announcement of financial result or quarterly and annual financial statements. Directors and executives are required to report their shareholdings and any changes therein to the Board of Directors, ensuring transparency and adherence to corporate governance standard.

6. Balance of Power for Non-executive Directors

As of 31st July 2024, the Company's Board of Directors is comprised of 12 directors, 1 of whom is executive directors and 11 non-executive ones. Of the total number, 4 were independent directors and also members of the Audit Committee, representing 33.33% of the total directors.

All such directors are qualified under the notification of the Stock Exchange of Thailand, Public Limited Companies Act B.E. 2535 and the other relevant laws regarding qualifications and scope of duties of the Audit Committee, and shall perform their check-and-balance duties to ensure accurate and fair business management of the Company for the maximum benefit of its shareholders, transparency, and efficiency.

7. Aggregation or Segregation of Positions

The Company has set a policy to segregate duties of Executive from day-to-day management and defined clear scopes of authority for each position. Executives of company shall have neither absolute power over any particular matters, including to approve or execute transactions in which they or their related persons have interest or may lead to conflict of interest against the Company.

8. Director and Executive Development and Succession Plan

The Board of Directors places emphasis on the development of directors and executives through a project on continual enhancement of knowledge and capacity proper to the assigned duties in order to endorse performance efficiency and efficacy of directors and executives. In this regard, directors are encouraged to take relevant courses of the Thai Institute of Directors.

To Development and Succession Plan for Director and Executive Development, the Board of Directors have plan to prepare as soon as the directors or executive retired or unable to perform their duties that the management of the Company can continuously and develop sustainably.

The Executive who assigned as a successor must be a person who is ready with qualifications and has experience in the appropriate field. Also, it should have knowledge and experience to transfer by working rotation in other relevant departments and attend the necessary additional training courses to prepare for the future career in higher positions in order to work smooth and management continuously.

9. Committees

The Executive Director shall be in charge of managing the Company according to the set policies. Moreover, the quality structure has been established in order to enhance the supervision and management of the Company.

There are 37 committees overseeing corporate governance and quality structure management, as follows:

1. Thainakarin Hospital Policy and Strategy Committee
2. Directing Cross-Functional Team Committee
3. Directing Clinical Team Committee
4. Medical Staff Organization
5. Nurses - Service Organization
6. Dentist Committee
7. Risk Management Committee
8. Information Management Committee (IMC)
9. Pharmacy and Therapeutics Committee
10. Human Resources Management and Development Committee
11. Infection - Control Committee
12. Occupational Health, Safety and Environment Committee
13. Multidisciplinary Surgery Committee
14. Multidisciplinary Pediatrics Committee
15. Multidisciplinary Medicine Committee
16. Multidisciplinary Obstetrics and Gynecology Committee
17. Multidisciplinary Cardiology Committee
18. Multidisciplinary Orthopedics Committee
19. Multidisciplinary Eye Ear Nose Throat Committee
20. Multidisciplinary Eye committee
21. Multidisciplinary Stroke Committee
22. Multidisciplinary Emergency Medicine Committee
23. Multidisciplinary Gastroenterology Committee
24. Multidisciplinary Breast Cancer Committee
25. Kidney Transplantation Thainakarin Hospital Committee
26. Health Promotion Committee
27. Resuscitation Committee
28. Opioids Management Committee
29. Ethics Committee
30. Drug Selection and set drug price Subcommittee
31. Medical Record Quality Inspection Committee
32. NURSE CPR Committee
33. Hospital Infection Control Committee (Supporting agency)
34. Antimicrobial Stewardship Program (ASP) Committee
35. Palliative Care Team Committee
36. Infection Control Ward Nurse Committee
37. Medical equipment Committee

These committees are responsible for overseeing the quality of medical care for patients. Data has been compiled and analyzed for approaches or measures to improve the quality of medical care and services, aiming to attain high quality of services that meet the hospital accreditation standards and relevant regulations.

Consisting of 15 members from various department, the Risk Management Committee is responsible for formulating risk management policies and systems pertinent to quality of services and safety of patients. The Committee shall analyze and identify contributory risk factors, develop risk-mitigating measures, as well as assign concerned units to constantly monitor the risks in accordance with the standards of The Healthcare Accreditation Institute (Public Organization) and American Accreditation Commission International (AACI).

10. Internal Control and Internal Audit

The Company puts great emphasis on the internal control systems both at management and operational levels, with control measures to optimize the use of resources. Responsibilities for approval, transaction recording and asset custody are segregated in order to promote proper checks and balances. The Company also carries out internal audits of financial-related and financial reporting systems, and periodically reports the results to the executives in charge.

At present, the Company has appointed Office of Dharmniti Internal Audit Company Limited as the internal auditor and established the Compliance Audit Department to control, audit and oversee the internal systems for more efficiency. The internal auditor must directly report to the Audit Committee for independence and transparency.

11. Subcommittees

The Board of Directors has appointed the Audit Committee to review financial reports, internal control system and disclose information on related-transactions etc. The Audit Committee shall minimally have qualification on independence as defined by the Stock Exchange of Thailand. Qualifications, scope of responsibilities and duties of the Audit Committee can be seen in Audit Committee section.

12. Investor Relations

The Company pays much importance to the disclosure of both financial and general information in an accurate, complete, transparent and extensive manner which is also available by telephone at 0 2340 7777, 0 2340 6488, 0 2340 6499, 0 2361 2727, 0 2361 2828 and via the Company's website at www.thainakarin.co.th. It also has a policy to develop channel of the information disclosure continually.

1.2 Business Ethics

The Company has adopted code of ethics or statement as guidelines for the Board, executives and all personnel in discharging their duties with honesty, integrity and fairness. The Company shall supervise and monitor to ensure strict compliance with said code of ethics or statement, as well as stipulate disciplinary measures.

1.3 Significant Changes and Development of Corporate Governance Policy and System in the Previous Year

1.3.1 Practices in accordance with good corporate governance principles to support CGR assessment

Regarding to result of the Company's Corporate Governance Survey of the Thai Institute of Directors (IOD), according to the 2023 Corporate Governance Survey project, the Company received the level of "Good" result in the Corporate Governance Assessment of Thai Listed Companies.


The survey result based on the disclosure of the Company's data Publicly, such as information in the 56-1 One Report, Management Structure and Good Corporate Governance Section, Invitation to Shareholders' Meeting, Minutes of the Shareholders' Meeting, the Company's shareholders' Meeting, and the Company's Website in the Investor Relations Section.

In the past year, the Company has taken steps to improve the corporate governance in many areas and encouraged the implementation in concrete work processes in order to operate the business transparently and efficiently for social responsibility and to ensure the stability and sustainability for the Company's operations.



2 Corporate Governance Structure

2.1 Corporate Governance Structure



2.2 Board of Directors

As of 31st July 2024, the Board is comprised of 12 members as detailed below:

1.	Charoen	Meensook, M.D.	Chairman of the Board
2.	Mr. Thiti	Sihanatkathakul	Director
3.	Mr. Prapat	Suthawate	Director
4.	Arkorn	Cheirsilpa, M.D.	Director
5.	Mr. Pitipat	Sihanatkathakul	Director
6.	Mr. Norathep	Sihanartkatakul	Director
7.	Mr. Tosaporn	Sihanatkathakul	Director
8.	Col. Dan	Tanphaichitra, M.D.	Director
9.	Mr. Kraidak	Kadkum	Director, Independent Director and Chairman of the Audit Committee
10.	Assoc. Prof. Chertsak	Dhiraputra, M.D.	Director, Independent Director and Member of the Audit Committee
11.	Assoc. Prof. Panya	Issarawornrawanich, Ph.D.	Director, Independent Director and Member of the Audit Committee
12.	Mr. Chailerg	Viriyarattanaporn	Director, Independent Director and Member of the Audit Committee

Authorized Director

Two of the four authorized directors, namely Mr. Thiti Sihanatkathakul, Mr. Prapat Suthawate, Mr. Tosaporn Sihanatkathakul, and Arkorn Cheirsilpa, M.D., shall co-sign and affix the Company's seal to legally bind the Company

Scope of Duty and Responsibility of Chairman of the Board

The Chairman of the Board has Duty and Responsibility as followings:

- Acting as the Chairman of the Board's Meeting to enhance efficiency as required by Articles of Association of the Company or relevant laws.
- In case of an equality vote, the Chairman of the Meeting shall have a casting vote.
- Supporting for the Board effective operation by management principles of good governance.
- Acting as the Chairman of the Shareholders' meeting to enhance effectiveness as required by Articles of Association of the Company or relevant laws.

Scope of Duty and Responsibility of the Board

The Board shall have the authority, duties and responsibilities to perform acts with care and integrity to ensure the Company's compliance with applicable laws, the corporate purpose, the articles of association, and the resolutions of legitimate shareholders' meetings. Key authority and responsibilities of the Board are as summarized below.

- The Board shall convene an annual general meeting of shareholders within 4 months from account period of the Company.
- The Board shall convene a Board meeting at least every 3 months.
- The Board shall propose the audited statements of financial positions and the statement of comprehensive income as of the end of the Company's accounting period to a shareholders' meeting for approval.
- The Board may delegate a director, directors or other persons to perform acts on its behalf and under its supervision; or delegate to such persons the authority within the scope as the Board deems appropriate. Such delegation may be annulled, amended, or re-assigned to other persons as the Board deems appropriate.

The Board may delegate to executive directors the authority and responsibility to perform acts or duties as detailed in the scope of power and responsibilities of executive directors. Such delegation shall not explicitly or implicitly vest executive directors with the power to consider and approve transactions involving conflict of interest between themselves or their related parties and Company or its subsidiaries (if any), unless otherwise permitted by applicable policies and criteria previously approved by the Board.

- (e) The Board shall determine the Company's policies, directions, business plans and budget plans as well as govern executive directors' operations to assure compliance with the policies and directions given by the Board. This clause excludes matters such as capital increase, capital decrease, sale or transfer of entire business or significant part of business, business acquisition, acceptance of business transfer, amendment of the Company's articles of association, etc., which the Board must obtain prior approval from the shareholders' meeting in accordance with regulatory requirements.

The Board also has the duty to oversee the Company's compliance with Public Limited Companies Act, the Securities and Exchange Act, rules and regulations of the Stock Exchange of Thailand governing, for example, related-party transactions and acquisition or disposal of material assets, and other relevant laws.

- (f) The Board shall approve management structure and the appointment of executive directors and members of committees as appropriate.
- (g) The Board shall monitor the Company's performance and assure that it is consistently in line with business plans and budget plans.
- (h) Directors shall refrain from operating businesses similar to or competing with the Company or being partners in ordinary partnerships, partners with unlimited liability in limited partnerships, or directors of private companies or companies operating businesses similar to and competing the Company, regardless of whether such tenure is for the interest of themselves or others, unless the shareholders' meeting has been notified of the tenure before approving their directorship.
- (i) Directors shall, without delay, notify the Company of their direct and indirect conflict of interest related to the Company's contractual transactions, and change in their possession of shares or debentures of the Company or its subsidiaries.

Director and Executive Development

The Company focuses on promoting constant knowledge and performance development of directors, executive, Company Secretary and all staff. For the Board, directors are encouraged to participate in courses relating to fulfilment of duties or seminars arranged by the Thai Institute of Directors (IOD), the Stock Exchange of Thailand, etc., in order to enhance the knowledge and capacity for efficient discharge of duties as the Company's directors.

In the past year, Assoc. Prof. Panya Issarawornrawanich, Ph.D. a director, an independent director and member of the Audit Committee, attended 6 seminars on the following topics:

1. Sustainability reporting with a certified public accountant.
2. ESG Trend and Technology
3. Great business with accounting and taxes.
4. Seminar to consider (draft) the revised financial reporting standards 2024 (BV 2024) with additional principles.
5. Using management accounting in business.
6. Are survey and quasi-experimental research methods possible? with accounting research

Contents of these seminars strengthened his knowledge in accounting and finance.

2.3 Audit Committee

As of 31st July 2024, the Audit Committee is comprised of 4 members as follows:

1. Mr. Kraisaak	Kadkum	Independent Director and Chairman of the Audit Committee
2. Assoc. Prof. Chertsak	Dhiraputra, M.D.	Independent Director and Member of the Audit Committee
3. Assoc. Prof. Panya	Issarawornrawanich, Ph.D.	Independent Director and Member of the Audit Committee
4. Mr. Chailerg	Viriyarattanaporn	Independent Director and Member of the Audit Committee

Assoc. Prof. Panya Issarawornrawanich, Ph.D. a lecturer of Accounting Department, Thammasat Business School, Thammasat University, and a certified public accountant, and Mr. Chailerg Viriyarattanaporn a former Accounting and Tax Consultant, I.G.S Co. Ltd., both are Audit Committee members who possesses extensive accounting and finance knowledge and experience.

Acting Secretary to the Audit Committee

The Audit Committee considers and selects Miss Thanyaporn Ekpornpadung to hold the position of the secretary for the Audit Committee in order to manage the operation of the Audit Committee on appointment, meeting, preparation of meeting agendas, delivering supporting documents, and record the minutes.

Scope of Duties and Responsibilities of the Audit Committee

Scope of duties and responsibilities of the Audit Committee is as follows:

- (a) Review the Company's financial reports to ensure accuracy and adequacy of the quarterly and annual financial reports.
- (b) Review the Company's internal control and internal audit to ensure their appropriateness and effectiveness as well as consider on independence of internal audit unit and approve appointment, removal, and termination of employment of the Head of Internal Control Audit Unit or Heads of other units with responsibility on internal audit.
- (c) Review the Company's compliance with the Securities and Exchange Act, rules and regulations of the Stock Exchange of Thailand or applicable laws.
- (d) Screen and nominate external auditors for the Company by taking into consideration on the audit fees based on the credibility, resources, and workload of auditing firms concerned as well as the independence and experience of designated auditors and offer remuneration of auditor plus with attending the meeting with the auditor without the management at least once a year.
- (e) Examine the Company's disclosure of related-party transactions or conflict of interest to be correct and complete according to laws and requirements of the Stock Exchange of Thailand in order to ensure that such transactions are reasonable with ultimate benefit for the company.
- (f) Perform any other duties as assigned by the Board and concurred by the Audit Committee which include, for example, reviewing financial and the executives' compliance with the code of ethics which must be publicly disclosed in important reports such as the management discussion and analysis in accordance with the laws.
- (g) Prepare the Audit Committee's Report which signed by Chairmen of the Audit Committee and disclose in annual report regarding:
 - The accuracy and reliability of the Company's financial reports and disclosure.
 - The adequacy of the Company's internal control.
 - The appropriateness of the company's auditor.

- Compliance with Securities and Exchange Act, requirements of the Stock Exchange of Thailand or laws related to the company's business.
 - Transactions with conflict of interest.
 - Number of audit committee's meeting and attendance of each audit committee.
 - Other reports that are considered to be acknowledged by shareholders and general investors under the scope of duties and responsibilities as assigned by the Board of Directors.
- (h) Regularly report the Audit Committee's performance to the Board at least quarterly.
- (i) Provide opinions on the performance evaluation, appointment, removal and remuneration of internal auditors.

An office term of the Audit Committee

An office term of the Audit Committee is defined as follows:

- Chairman of the Audit Committee 2 years
- Member of the Audit Committee 2 years

The Chairman and members of the Audit Committee who retire by rotation may be re-appointed.

Qualification of Audit Committee Member and Selection Process

The Board is vested with the authority to appoint 3 persons possessing qualifications in accordance with the Securities and Exchange Act, and notifications, rules and/or regulations stipulated by the Securities and Exchange Commission to serve on the Audit Committee. At least 1 member of the Audit Committee shall have finance and accounting knowledge. Each member of the Audit Committee shall hold an office term of 2 years at a maximum and must meet the following qualification criteria: The Audit Committee members must possess qualifications as an independent director under the definitions of independence of independent director.

- (a) Holds not more than 1 percent of total voting shares of the Company, its parent company, its subsidiaries, its associate companies major shareholder, a controlling person and whose shareholding shall include the shares held by connected person of independent director.
- (b) Is not engaged in the Company's management and is not staff, employee, salaried advisor or person with controlling power of the Company, its parent company, its subsidiaries, its associate companies, major shareholder, a controlling person and whose shareholding shall include the shares held by connected person of independent director, unless such engagement is over not less than 2 years. Such prohibition is excluded with the case of government officer or government consultant who is the major shareholder or controller of the company.
- (c) Is not related by blood, marriage or legal registration as father, mother, spouse, sibling, child, child's spouse or close relative of director, executive, major shareholder or a controlling person of securities issuing company or be nominated as director, executive or a controlling person of the Company or its subsidiaries.
- (d) Does not have business relationship with the Company, its parent company, its subsidiaries, its associate companies, major shareholder or a controlling person in a manner that may obstruct his/her independent judgment as well as does not possess any characteristic which may obstruct his/her independent opinion on the Company's business operations and not being shareholder with implication or controlling person of person has business relationship with the Company, its parent company, its subsidiaries, its associate companies, unless such relationship is over not less than 2 years.

Business relationship as defined in the first paragraph and normal trading transactions for business operation or real estate leasing or letting of leasing, transactions on assets or services or financial support providing through loans providing or receiving, guaranty, mortgage, and other behaviors in the same manner causing the company or the party to have some debts required to be paid to other party from the rate of 3% of net tangible assets of the company or from 20 million baht and over, whichever is lower. Such debts shall be calculated in accordance with the method for calculating value of connected transactions specified by the Notification of the Capital Market Supervisory Board regarding connected transaction, mutatis mutandis However, to consider on such debts, all debts occurred during one year prior the day of making such business relationship with the same person.

The term “shareholder with implication” under the first paragraph means a shareholder holding shares in any business at an amount exceeding 10% of the total voting shares, and whose shareholding shall include the shares held by his/her connected person.

- (e) Has not ever been the auditor of the company, its parent company, its subsidiaries, its associate companies, major shareholder or a controlling person and not being shareholder with implication, a controlling person, or shares of the audit office with the auditor of the company, its parent company, its subsidiaries, its associate companies, major shareholder or a controlling person, unless such position is over not less than 2 years.

The term “shares” under the first paragraph means a person assigned by an audit firm to place signature on the audit report on behalf of such juristic person.

The term “shareholder with implication” under the first paragraph means a shareholder holding shares in any business at an amount exceeding 10% of the total voting shares, and whose shareholding shall include the shares held by his/her connected person.

- (f) Has never been the service provider of any profession including legal consultant or financial consultant with service fee over than 2,000,000 baht per year from the company, its parent company, its subsidiaries, its associate companies, major shareholder or a controlling person and not being shareholder with implication, a controlling person, or partner of the service provider of such profession unless such service providing is over not less than 2 years.

The term “partner” under the first paragraph means a person assigned by a professional service provider to place signature on the professional service report on behalf of such juristic person.

The term “shareholder with implication” under the first paragraph means a shareholder holding shares in any business at an amount exceeding 10% of the total voting shares, and whose shareholding shall include the shares held by his/her connected person.

- (g) Has never been the director who is appointed as the representative of the director of the company, major shareholder or shareholder related to major shareholder.
- (h) Does not operate any business with the same condition with implicit competition against the company or its subsidiaries or is not a partner with implication in any partnership or directors involving with management, employees, workers, full-time consultant or consultant holding shares over than 1% of total votes of other companies operating similar business with implicit competition against the company or its subsidiaries.
- (i) Has no other manners that obstruct independent opinion on the Company’s business operations.

The Audit Committee member must possess additional qualifications other than those of an independent director, as follows:

- (a) Not being a director assigned by the Board to make decisions on the business operations of the Company, parent company, subsidiaries, associate companies, same-level subsidiaries, major shareholders or controlling persons of the Company, and not being a director of parent company, subsidiaries or same-level subsidiaries that are listed on the Stock Exchange of Thailand;
- (b) Having adequate knowledge and experiences to perform duties as an Audit Committee member, provided that at least 1 Audit Committee member has adequate knowledge and experiences to review the credibility of financial statements;
- (c) Being capable of giving opinions and recommendations on internal control system reports of the Internal Audit unit or an internal audit service provider of the Company.

2.4 Management Team

As of July 31st, 2024 the management team is comprised of 10 executives as follows:

1.	Mr. Thiti	Sihanatkathakul	Chief Executive Officer
2.	Prof. Pittayapoom	Pattaranutaporn, M.D.	Deputy Chief Executive Officer
3.	Clinical Prof. Thipachart	Punyaratabandhu, M.D.	Hospital Director and Medical Director
4.	Phichai	Rattanarojsakul, Ph.D.	Deputy Hospital Director
5.	Watson	Aphiwatanakoon, M.D.	Administrative Director
6.	Paitoon	Kachornvachara, M.D.	Operation Director
7.	Pattarapon	Kammuntree, M.D.	Acting as Quality Director and Assistant Administrative Director
8.	Miss Malee	Boonleechai	Acting as Administrative Office Director and Senior Deputy Administrative Director - Corporate Support
9.	Rungarun	Gaesawahong, Ph.D.	Nurse Director
10.	Miss Suranchana	Tanpleeratana	Assistant Operation Director – Customer Service Support

Scope of Duty and Responsibility of Chief Executive Officer

Chief Executive Officer shall have the following scope of duty and responsibility:

- (a) Review the annual budget allocation plan proposed by the management prior to submission thereof for the Board's approval.
- (b) To approve procurement transactions within the limit of Baht 10,000,000 per transaction.
- (c) Appoint, determine the scope of authorities, duties, and responsibilities of the Company's executive director according to the business management structure.
- (d) Amend, change, and determine the limit for approval of the procurement or revise, change, and determine the authorized person to approve the Company's procurement of not more than 10,000,000 baht per time.

Chief Executive Officer shall not have the power to approve transactions of the Company and its subsidiaries (if any) which involve conflict of interest with himself or his related parties in accordance with rules and regulations of the Stock Exchange of Thailand. Such transactions shall be proposed to the Board's meeting or the shareholders' meeting for approval as required by the Company's articles of association or applicable laws, unless they are in the ordinary course of the Company's business and meet the specific approval criteria previously established by the Board.

Directorship in Other Listed Companies

The Board of Directors sets a policy on directorship in other listed companies as follows:

Policy on the directors' holding of directorship in other listed companies:

- 1) The Board prescribes that each director is able to hold directorship in no more than 3 other listed companies so as to ensure director's efficiency and total dedication of time to perform duties as the Company's director.
- 2) Directors should not take up directorship in other listed companies that may cause a conflict of interest with the Company and the discharge of duties as the Company's director.

New Director Orientation

The Company arranges orientation session for newly appointed directors. In this regard, the Company Secretary is assigned to provide the new directors with all documents and information helpful to the discharging of their duties. This will acquaint the new directors with the Company's business policy including other relevant information such as capital structure, shareholders, operating performance, internal systems, and also regulatory laws and regulations. At the session, the new directors shall receive a Corporate Director Manual, which consists of:

1. Public Limited Companies Act B.E.2535;
2. Securities and Exchange Act B.E. 2535;
3. Certificate of Corporate Registration;
4. Company Affidavit;
5. Memorandum of Association;
6. Articles of Association;
7. Corporate Governance Handbook;
8. Director's Handbook;

In 2024, The Company has no new directors.

Director and Executive Remuneration

The Company's expenses on remuneration and fringe benefits for directors and executives for the year ended on 31st July 2024 are as shown below:

- a. Total directors' remuneration in relation to attendance fees and benefits is as listed below:

Name	Board of Directors		Audit Committee		Total
	No. of Attendance / No. of Meeting	Attendance Total Fee (Baht)	No. of Attendance / No. of Meeting	Attendance Total Fee (Baht)	
Charoen Meensook, M.D.	4/4	120,000	-	-	120,000
Mr. Thiti Sihanatkathakul	4/4	80,000	-	-	80,000
Mr. Prapat Suthawate	4/4	80,000	-	-	80,000
Arkorn Cheirsilpa, M.D.	4/4	80,000	-	-	80,000
Mr. Pitipat Sihanatkathakul	3/4	60,000	-	-	60,000
Mr. Norathep Sihanatkathakul	4/4	80,000	-	-	80,000
Mr. Tosaporn Sihanatkathakul	4/4	80,000	-	-	80,000
Col. Dan Tanphaichitra, M.D.	3/4	60,000	-	-	60,000
Mr. Kraisa Kadkum	4/4	80,000	5/5	150,000	230,000
Assoc. Prof. Chertsak Dhiraputra, M.D.	4/4	80,000	5/5	100,000	180,000
Assoc. Prof. Panya Issarawornrawanich, Ph.D.	4/4	80,000	5/5	100,000	180,000
Mr. Chailerg Viriyarattanaporn	4/4	80,000	5/5	100,000	180,000
Total		960,000		450,000	1,410,000

Directors' remuneration refers to remuneration paid to the Company's directors, excluding their of monthly salary and fringe benefits offered to executives. The directors' remuneration has been approved by the shareholders' meeting.

Medical benefit for directors and their families are limited at Baht 800,000 per year and the Company's expenses on the said benefit in 2024 amounted to Baht 4,095,263 as detailed in the note 6 to the financial statements. All medical expenses which exceed the limit are charged and collected in accordance with the Company's procedures.

b. Executive Director and Executive Remuneration

Total remuneration of executive directors and executives of the Company in 2024 amounted to Baht 58.89 million, inclusive of monthly salary, medical benefits and fringe benefits offered to executives.

2.5 Personnel

The Company determines remuneration to personnel in commensurate to individual responsibilities and performance. It also has a policy to review and adjust, on an annual basis, the payment of remuneration and special rewards appropriately and fairly to be in line with such factors as economic conditions, cost of living, remuneration benchmark of companies in the same industry, as well as the Company's operating results in tandem with work performance.

As of 31st July 2024, the Company has 1,173 permanent employees and 144 contractual employees, now a total of 1,317 employees. Expenses on salary, wages and fringe benefits of employees in 2024 are as shown below.

Category	Amount (Million Baht)
Salary, overtime, bonus, retiring allowance and others	584.48
Benefits	40.61
Contribution to Social Security Fund	10.75
Contribution to provident fund	3.59
Contribution to Fund for Empowerment of Persons with Disabilities	-
Others	0.50
Total	639.93

2.5.1 Provident Fund

The Company has established a provident fund by the Provident Fund Act B.E. 2530. The Company contributes 2 percent of personnel salary to the provident fund, which personnel can choose to pay savings into the fund at 2 - 15 percent of each personnel salary.

In 2024, 596 personnel entered the fund, accounting for 45.25 percent of the total personnel.

2.5.2 Personnel Capability Development

The Company has a policy to support personnel to work efficiently according to the standards of the hospital and the Company by promoting the development of knowledge, abilities and professional skills in medical treatment and various related areas. To provide personnel with skills and readiness in services. Create an impression on service recipients and be the Hospital of Choices for the people in Eastern Bangkok and the Eastern region. According to the strategic plan and vision of the Company, supporting the rapidly changing situation of the country including studying the needs of executives. To develop and improve the curriculum provided to executives and personnel to meet their needs and use them to be most efficient and effective for both executives, personnel and the Company.

Personnel Orientation Day training courses for newly employed composing of;

Day 1	Day 2
1. History of Thainakarin Hospital	1. Hospital Culture and Quality Development
2. Regulations, Work Practices and Welfare	2. Awareness in the Prevention and Control of Infectious Diseases in Hospital
3. The key essence of healthcare service business	3. Knowledge of Occupational Health and Work Environment, Preliminary of Fire Prevention and Suppression in the Workplace
4. The general service facilitation standards for service recipients	4. International Marketing, Product development and sales
5. Standard for service and telephone handling (practice and testing)	5. Cybersecurity and the Personal Data Protection Act B.E. 2562 (PDPA)
6. Introduction to Key Departments in the Hospital	
7. Introduction of New Personnel to the Assigned Department	
8. Team-Building Activity, Welcome new friends	

2.5.3 Safety Occupational, Health of Personnel

The Company provides safety and occupational health knowledge to hospital personnel, including quality management systems, quality promotion, and a safety management system. It also includes courses according to safety laws that have been established so that personnel can perform their duties correctly according to hospital standards.

2.5.4 Major Labor Disputes over the past 1 year

- None -

2.6 Other Important Information

Company Secretary

The Board of Directors appointed Mr. Prapat Suthawate, director, and Mr. Attapong Tipaksorn, Legal Manager, to perform the duties of the company secretary in order to supervise and hold the meeting of the Board of Directors and Shareholders' Meeting as well as to prepare a register of directors, a notice calling a director meeting and the minutes of the Meeting of the Board of Directors and to prepare a notice calling a Shareholders' Meeting, annual report, and documents storage as defined by law i.e. report on interest field by a director or an executive etc. Moreover, They are also assigned to provide some suggestions to the Board of Directors and executives on criteria related to the listed companies of the Stock Exchange of Thailand and good corporate governance.

Scope of Duty and Responsibility of Company Secretary

1. To provide primary suggestions to the Board of Directors on laws, regulations and rules of the company as well as to monitor compliance and report all significant changes to the directors.
2. To prepare notices of the Meeting of Shareholders and the Meeting of the Board of Directors, as well as to make arrangements for said Meetings in compliance with laws.
3. To record the minutes of the Shareholders' Meeting and the Meeting of Board of Directors as well as to follow-up the compliance with the meeting's resolution.
4. To prepare and keep documents specified by laws, such as director registration, reporting of conflict of interest as reported by the Company's directors or executives, etc.

5. To supervise information disclosure and disclosure of information report of the company unit with responsibility on corporate governance.
6. To contact and communicate with shareholders.
7. To supervise activities of Board of Directors

Person taking the highest responsibility in accounting and finance

The company has assigned the person holding the position of Finance and Accounting Manager (Senior), Miss Perapa Teerajareonsup as the person taking the highest responsibility in finance and accounting as of December 1, 2021. The background of the person responsible for the accounting and finance is listed in Attachment 1.

Audit Fees

In 2024, the Company paid the auditors fees separately as follows;

(Unit: Baht)

Auditors' Remuneration	2023
Quarterly review fees, 3 quarters (Consolidated Financial Statements)	495,000
Annual audit fees (Consolidated Financial Statements)	900,000
Total	1,395,000

Non-audit fee

Inspection expenses such as travel expenses and photocopying costs, etc., were of actual disbursement but not exceeding 30,000 baht.

Subsidiary auditor's fee

Jatu Charoen Development Co., Ltd. Paid 150,000 Baht per year and non-audit fee to the auditors of EY Office Company Limited.



3 Significant Performance on Corporate Governance

Nomination, Development and Evaluation of the Board of Directors

The Company emphasis on the development of directors and executives through a project on continual enhancement of knowledge and capacity proper to the assigned duties in order to endorse performance efficiency and efficacy of directors and executives. In this regard, directors are encouraged to take relevant courses of the Thai Institute of Directors (IOD).

Director and Executive Nomination

The nomination of directors is proposed to the shareholders' meeting and subject to the majority vote of shareholders. Though the Nomination Committee is not involved in the nomination process, the Company has taken steps to ensure that director candidates meet the qualification criteria as set out in the Public Limited Companies Act B.E. 2535 and possesses professional knowledge and expertise which are beneficial to the Company's business, visionary leadership, integrity, morality, proven record of transparency, and independence.

The Company has established a committee consisting of senior medical, nursing and other professional to be responsible for screening and interviewing candidates for executive positions. The remuneration packages of executives is based on their scope of duties and responsibilities and benchmarked with other companies of comparable size in the same industry.

Director and Executive Development

The Company focuses on promoting constant knowledge and performance development of directors, executive, Company Secretary and all staff. For the Board, directors are encouraged to participate in courses relating to fulfilment of duties or seminars arranged by the Thai Institute of Directors (IOD), the Stock Exchange of Thailand, etc., in order to enhance the knowledge and capacity for efficient discharge of duties as the Company's directors.

Director and Executive Development and Succession Plan

To Development and Succession Plan for Director and Executive Development, the Board of Directors have plan to prepare as soon as the directors or executive retired or unable to perform their duties that the management of the Company can continuously and develop sustainably.

The Executive who assigned as a successor must be a person who is ready with qualifications and has experience in the appropriate field. Also, it should have knowledge and experience to transfer by working rotation in other relevant departments and attend the necessary additional training courses to prepare for the future career in higher positions in order to work smooth and management continuously.

Board of Director's Meeting

Directors must attend the Board of Directors' Meeting regularly to acknowledge and jointly make decisions on the Company's business. In 2024, the Company has formally set the dates of the Board meetings for the entire year and notified all directors in advance so that they could allocate time for attendance. Special Board meetings may be convened as necessary. In 2024, the Board meetings, exclusive of special ones, for the year 2025 have been scheduled in advance (subject to change) as follows:

No.	Audit Committee's meeting	Board of Directors' meeting
1	11 December 2024	12 December 2024
2	11 March 2025	13 March 2025
3	10 June 2025	12 June 2025
4	23 September 2025	24 September 2025

According to the Articles of Association, the quorum of a Board meeting must not be less than one-half. To encourage the Company's good corporate governance implementation, however, the Board of Directors has jointly laid down guidelines that the quorum must not be less than two-third of the total number of directors.

In 2024, the Company held the Board meetings at least once every 3 months. From 1 August 2023 to 31 July 2024, the Board of Directors convened 4 times, each of which was attended by more than 70% of the total number of directors. The rate of meeting attendance over the 4 meetings accounted for 95% of the total number of directors. At each meeting, agenda items were clearly specified and meeting invitation was submitted at least 7 days in advance in order that the directors had sufficient time to study the information. Minutes of the meetings were recorded in writing and, after being adopted by the Board of Directors, kept ready for inspection by the Board of Directors and concerned parties.

Furthermore, if a director has any interest or benefit in an agenda item to be considered, he/she shall leave the meeting room before the consideration of such agenda so that the meeting can consider the matter independently.

Remuneration of Directors and Executives

The shareholders' meeting has clearly fixed remuneration for directors. Remuneration of directors and executives shall be determined commensurate with their assigned roles, duties and responsibilities, and be at an appropriately attractive level to retain competent personnel with the Company. Determination of the remuneration shall be in accordance with the Board-specified principles and policy and in line with business performance and operating results alongside performance of each executive.

Individual Meeting Attendance and Remuneration of the Board of Directors

The Board of Directors has monitored and supervised the operations, cover various departments within the organization and having appropriate responsibility for shareholders. There are a number of committee attended the Board of Directors' meeting in the past year as the following meetings were held:

Name	Board of Directors	Audit Committee	Annual General Meeting of Shareholders 2023
Charoen Meensook, M.D.	4/4	-	1/1
Mr. Thiti Sihanatkathakul	4/4	-	1/1
Mr. Prapat Suthawate	4/4	-	1/1
Arkorn Cheersilpa, M.D.	4/4	-	1/1
Mr. Pitipat Sihanatkathakul	3/4	-	1/1
Mr. Noratthep Sihanartkatakul	4/4	-	0/1

Name	Board of Directors	Audit Committee	Annual General Meeting of Shareholders 2023
Mr. Tosaporn Sihanatkathakul	4/4	-	1/1
Col. Dan Tanphaichitra, M.D.	3/4	-	1/1
Mr. Kraisak Kadkum	4/4	5/5	1/1
Assoc. Prof. Chertsak Dhiraputra, M.D.	4/4	5/5	0/1
Assoc. Prof. Panya Issarawornrawanich, Ph.D.	4/4	5/5	1/1
Mr. Chailerg Viriyarattanaporn	4/4	5/5	1/1

Reports of the Board of Directors

The Board of Directors is responsible for the Company's financial statements and financial information in the annual report. The financial statements are prepared according to the accounting standards generally accepted in Thailand, using appropriate accounting policies that are applied on a consistent basis based on prudent consideration and best estimates. All significant information is adequately disclosed in the notes to the financial statements.

The Board of Directors establish internal control in order to ensure that accounting data record is correct, complete and adequate for maintaining the Company's assets and perceiving some weaknesses in order to significantly prevent any abnormal operation. The Board also gives the opinion that, in overall, the Company's internal control is reliable.

The Audit Committee comprised of Independent Directors and non-executive Directors with accounting expertise, is assigned to review the financial reports and the disclosure of information in the Company's financial statements.

Supervision over Operations of Subsidiaries and Associated Companies

The Company performs and operates business with 1 subsidiary: Jatu Charoen Development Company Limited. The Company has mechanisms to supervise the subsidiary as follows:

1. The Company's 3 representatives serving as directors in the subsidiary company, namely Charoen Meensook, M.D., Mr. Thiti Sihanatkathakul and Mr. Tosaporn Sihanatkathakul, with percentage of the Company's shareholding, Thainakarin Hospital Public Company Limited, amounting to 99.97%, which was approved by the Board of Directors Meeting No. 5/2021 on December 13, 2021.
2. The Company has a regulatory mechanism in related to the disclosure of financial position and operating results, the transaction between the said company and the connected person, the acquisition or disposition of assets or any other important transactions of the said company to be complete and correct. The rules related to disclosure of information and transactions in the manner mentioned above are used in the same way as the Company's rules with the consolidated financial statements were prepared and used by the same auditor as the Company.

Internal Control and Risk Management

In effort to prevent potential damages to the business, the Company focuses on establishing internal control systems that cover financial activities, operating activities, risk management and supervision at both management and operational levels, thus enabling it to accomplish goals in resource optimization, asset protection, and error, leakage and loss reduction. The control responsibilities for approval, transaction recording and asset custody are segregated in order to secure proper checks and balances. Besides, the Company has put in place internal financial audits, accompanied by periodic monitoring by executives in charge, to ensure that its financial reporting system is accurate and reliable in compliance with relevant regulations and laws.

In 2024, the Board and the Audit Committee has jointly assessed the adequacy of the Company's internal control system in 6 interrelated aspects as follows:

1. Organization and Control Environment

The Company has an appropriate organizational structure, with a clear scope of authorities, duties and responsibilities. It has adopted a policy to inculcate a positive corporate culture where employees at all levels perform their duties with accountability, utmost ability and conformity to internal control system. All employees are well aware of their roles, authorities, duties and responsibilities, and also strictly comply with corporate policies and procedures. The adequacy of internal control including actual operations are reviewed and reported regularly to ensure policy compliance.

2. Risk Management

The Company has established the Risk Management Committee, with the Quality Director being the Chairman by position. The Committee is in charge of setting policies in relation to risks and safety, laying strategic plan in enterprise risk management, putting in place the risk management system that incorporates risk detection, risk reporting, enterprise risk analysis, continual improvement, preventive measures and contingency plan against potential risks and undesirable incidents in healthcare services. The system shall also promote well-organized risk information management system, safety culture, consistent and efficient risk management practices at enterprise, the Committee and working unit levels, together with constant monitoring and assessment of risks in accordance with the standards of The Healthcare Accreditation Institute (Public Organization) and American Accreditation Commission International (AACI).

3. Management Control

The Company has clearly set out scopes of authorities and duties, approval authority limits of the Management, and regulations and procedures on conflict of interest of directors and senior executives. Pertinent actions by the Management shall be reported to the Board and included as a regular agenda item of the Board meeting every 3 months.

The Company has rationally laid down its internal control system that ensure that payments and receipts of money are properly approved by the executives and the Board. The internal control system is developed in consistent with the anti-corruption measures and appropriate to corruption risks of the Company.

The internal control encompasses policy and procedures to ensure that the guidelines laid by the Board and the executives are implemented into practice and in accordance with the corporate governance policy of the Company. Widely popular, internal control is a process executed by the Board, executives or other personnel in order to provide reasonable confidence regarding business efficiency, reliability of financial reports and compliance with the laws and regulations. Meanwhile, auditing is a process to review the reliability of internal control system, documents and performance in order to assure the executives, investors and other stakeholders of said matters. The auditing is carried out jointly by the internal auditors and the external auditors.

4. Information and Communication Systems

The Company has improved the server hardware to increase the processing efficiency and support the storage of higher volumes which could serve the long-term usage for no less than 5 years. Security controls on data access and the usage of information systems have been developed as well as a roadmap for information security processes. The information especially of patients, service recipients and information of the Company's personnel are treated with appropriateness and compliance with standards such as information in the electronic medical record (E - Medical Record), human resources management system, network system in the organization (Network), including data backup of various work systems. The purpose is to provide stability in the management of risks to various forms of information systems, etc.

The Company has continuously improved its IT service system, for example, improving the internet speed signal to be able to respond to the successively increasing number of users and to support the usage volume effectively. In addition, the Company's printing system has also been improved with the aim of promoting service efficiency, and at the same time, it's costs saving with the effective improvement of the printing system.

Overall, the information and communication systems are in continuous development direction, so that the utilization of information by executives and working groups can be carried out in the most efficient manner.

5. Monitoring System

The Company holds meetings to follow up operating performance, risks and key performance indicators on a regular basis. In addition, the Company has implemented risk managing process and analyzed for causes of performance gaps in order to take corrective actions, as per the opinion of the Audit Committee disclosed in the Audit Committee's Report for 2024.

In addition, the Company has established a system of monitoring and reviewing operational manuals to be in line with all risks across-the-board.

6. Internal Audit

The Audit Committee appointed Miss Thanyaporn Ekpornpadung to hold the position of Head of Compliance Audit for supervise and control the company's operation whereas Miss Thanyaporn Ekpornpadung graduated Bachelor of Accountancy, Faculty of Business Administration, Ramkhamhaeng University. She has had some experiences on internal audit for a period of 8 years. Since she has understanding on the company's business and operation, the Audit Committee agrees that the Audit Manager is appropriate to perform such duty. Consideration and approval on appointment and transfer of the Audit Manager must be approved by the Audit Committee.

Related-party Transactions

In 2024 and as of 31 July 2024, the Company had related-party transactions and outstanding balances with persons of possible conflict of interest as shown in the financial statements and note No. 6 to the financial statements.

Necessity and Reasonableness

Related-party transactions are executed based on necessity and reasonableness for the best interest of the Company in line with its normal business practice and fair price basis. The Audit Committee has already given opinions on these related-party transactions in the preceding section.

Measures and Procedures for Related-party Transaction

The Company has strictly complied with the Securities and Exchange Act B.E. 2535, the Stock Exchange of Thailand's regulations, notifications and requirements, and the Public Limited Companies Act B.E. 2535. Directors or persons who have interest in a transaction or may have conflict of interest with the Company shall have no right to approve such transaction, unless otherwise allowed the Securities and Exchange Act B.E. 2535, notifications or requirements of Stock Exchange of Thailand, or the Public Limited Companies Act B.E. 2535. Principles regarding execution of related-party transactions as well as acquisition and disposal of the Company's assets have clearly been stipulated in its Articles of Association.

Policy or Trend of Future Related-party Transactions

The Company has laid a policy on future related-party transactions, where the Board shall take into consideration the necessity and reasonableness of transactions along with the Company's best interest in terms of prices and normal business conditions. The Audit Committee is responsible for giving opinions on the necessity and reasonableness of the related-party transactions and compliance with normal business practice, based on comparison with prices on an arm's length basis. As a policy, such related-party transactions as borrowings from persons with possible conflict of interest shall be executed only when the Company is in financial need yet there are no other sources of fund that offer better terms or interest rates closer to market rates than its related persons.

Measures on Investor Protection

In relation to related-party transactions and acquisition/disposal of assets, the Company has set in its Articles of Association clear regulations prohibiting directors or persons who have interest or may have any conflict of interest in a transaction from voting and approval of such transaction, which is in compliance with the Stock Exchange of Thailand's regulations, notifications or requirements and governing laws. Additionally, the Audit Committee is assigned to give opinions on the necessity and reasonableness of the related-party transactions. Pertinent information shall be disclosed in accordance with the Stock Exchange of Thailand's regulations, and also be included in the Company's financial statements and annual reports.

In the event that the Audit Committee has no expertise in reviewing a future related-party transaction, the Company shall seek opinions thereon from independent experts or the Company's auditors to support decision-making of the Board of Directors or the shareholders, as the case may be.

Related-party transaction report for 31 July 2023 and 2024

Related party and relationship	Transaction	Transaction Value (MB)		Necessity and Reasonableness
		2023	2024	
1. Doctors being directors and executives	Doctor's fees are paid to directors and executives of the Company	0.48	0.33	The transactions are necessary and reasonable because the directors and executives being doctors are entitled to receive doctor's fees at the rates comparable to other doctors working for the hospital.
	Accrued doctor's fee expenses as of 31 July	0.00	0.00	
2. Siam Property Development Company Limited	Medical fee income The transactions are in the normal course of the Company's business and charged at the rates applicable to general customers.	0.00	0.02	The transactions are necessary and reasonable. They are considered normal trade transactions and charged the rates applicable to general customers.
	Medical fee receivables as of 31 July	0.009	0.00	
3. Boontuang Company Limited	Lump Sum service income The transactions are in the normal course of the Company's business and charged at the rates applicable to general customer	0.07	0.03	The transactions are reasonable. They are considered normal trade transactions and charged the rates applicable to general customers.
	Medical fee receivable as of 31 July	0.014	0.002	
4. Jatu Charoen Development Company Limited	Product Income The represents normal business operations using standard prices and returns as typically provided by the company to its customers	-	0.00	
	Trade receivable as of 31 July			
5. Directors	Welfare expenses According to the Company's The transactions are necessary regulations, medical benefits for directors and their spouse, children and parents are limited at Baht 800,000 per year per person and do not cover doctor's fees, lab tests and examination by other hospitals and special equipment.	3.43	4.09	The transactions are necessary and reasonable. They are considered normal trade transactions.
6. Fixed assets	Fixed assets The Company has been approval from the Board of Directors Meeting No. 1/2023 (March 13, 2023) to purchase land and a total of 3 plots of buildings from the Company's directors with the main objective of the project being expanding the service recipient base in Chachoengsao province and nearby provinces in the Eastern region.	16.10	-	

PART

3

Financial Statement



Scope of the Board of Directors' Responsibilities for Financial Reports

The Board of Directors gives priority to discharging its supervisory duties and responsibilities in accordance with the Company's Good Corporate Governance Policy. Financial reports and information disclosed in the 56-1 One Report 2024 contain accurate, complete, adequate details, and are prepared in compliance with the generally-accepted accounting standards using appropriate accounting policies that are consistently applied based on prudent consideration. The Board has assigned the Audit Committee to review the Company's latest financial statements. Said financial reports have been reported to be carefully prepared in accordance with the generally-accepted accounting principles using appropriate accounting policies, and been assessed for the appropriateness of overall items presented in the statements, with adequate information disclosed in the notes to the financial statements. The Audit Committee's opinions regarding such matters are stated in the Company's 56-1 One Report 2024.

Additionally, the Board has set up an efficient and effective internal control system to ensure complete and accurate recording of accounting transactions, as well as an asset control system to prevent frauds or material damages.

In summary, the Board is of an opinion that the Company's overall internal control system is at a satisfactory level to establish reasonable confidence in the reliability of the Company's financial statements as of 31st July 2024. The external auditor has audited the aforementioned statements according to the generally-accepted auditing standards and viewed that the financial statements present fairly, in all material respects, the financial position and financial performance in accordance with generally-accepted accounting principles.



(Charoen Meensook, M.D.)

Chairman of the Board

Thainakarin Hospital Public Company Limited




Financial Highlights

Financial Performance (Million Baht)	2024	2023	2022
Total current assets	1,993.47	1,683.66	1,570.59
Total assets	3,564.19	3,181.15	2,969.68
Total current liabilities	389.49	342.14	374.77
Total liabilities	502.64	446.51	485.68
Total shareholder's equity	3,061.55	2,734.64	2,484.00
Total revenues	2,737.36	2,429.20	2,609.14
Profit for the year	434.92	350.57	425.35
Basic earning per share (Baht)	2.42	1.95	2.36
Financial Ratios			
1. Liquidity Ratio (time)			
1.1 Current ratio	5.12	4.92	4.19
2. Efficiency Ratio (Day)			
2.1 Average Collection Period	31	45	44
2.2 Average Inventory Period	6.94	7.22	7.29
2.3 Average Payment Period	37.23	40.95	29.73
3. Profitability Ratio (%)			
3.1 Gross Profit Margin	28.49	26.72	29.73
3.2 EBITDA Margin	24.14	22.65	23.55
3.3 Net Profit Margin	15.89	14.49	16.33
3.4 Return on Assets	15.96	14.10	19.09
3.5 Return on Equity	15.01	13.44	18.36
4. Financial Policy Ratio (time)			
4.1 Total Liabilities to Equity	0.16	0.16	0.20
4.2 Interest Coverage	-	-	-
5. Other Financial Ratio			
5.1 Growth on Revenues from Hospiatal Operations (%)	12.57	-7.53	26.57
5.2 Growth on Net Profit for the Year (%)	24.06	-17.58	44.97
5.3 Book Value per Share (Baht)	17.01	15.19	13.80


Financial Highlights

(Unit: Million Baht)


Total Assets




Total Shareholder's Equity



Total Revenues



Profit



Independent Auditor's Report



To the Shareholders of Thai Nakarin Hospital Public Company Limited

Opinion

I have audited the accompanying consolidated financial statements of Thai Nakarin Hospital Public Company Limited and its subsidiary ("the Group"), which comprise the consolidated statement of financial position as at 31 July 2024, and the related consolidated statements of comprehensive income, changes in shareholders' equity and cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies, and have also audited the separate financial statements of Thai Nakarin Hospital Public Company Limited for the same period.

In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Thai Nakarin Hospital Public Company Limited and its subsidiary and of Thai Nakarin Hospital Public Company Limited as at 31 July 2024, their financial performance and cash flows for the year then ended in accordance with Thai Financial Reporting Standards.

Basis for Opinion

I conducted my audit in accordance with Thai Standards on Auditing. My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Group in accordance with the Code of Ethics for Professional Accountants including Independence Standards issued by the Federation of Accounting Professions (Code of Ethics for Professional Accountants) that are relevant to my audit of the financial statements, and I have fulfilled my other ethical responsibilities in accordance with the Code of Ethics for Professional Accountants. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Key Audit Matters

Key audit matters are those matters that, in my professional judgement, were of most significance in my audit of the financial statements of the current period. These matters were addressed in the context of my audit of the financial statements as a whole, and in forming my opinion thereon, and I do not provide a separate opinion on these matters.

I have fulfilled the responsibilities described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report, including in relation to these matters. Accordingly, my audit included the performance of procedures designed to respond to my assessment of the risks of material misstatement of the financial statements. The results of my audit procedures, including the procedures performed to address the matters below, provide the basis for my audit opinion on the accompanying financial statements as a whole.

Key audit matter and how audit procedures respond to the matter are described below.

Revenue recognition

Revenues from hospital operations are considered significant in the financial statements especially revenue with contract companies, insurance companies and government agencies, as the amounts recorded are material, representing 99% of the total revenues and they directly affect the operating results of the Company. In addition, there are various types in revenues from hospital operations which include revenue from sales of medicines and medical supplies, revenue from medical services, revenue from patient rooms, including discounts for counterparties, whereas the agreements contain various conditions for each party. I therefore gave significant attention to the revenue recognition of the Company.

I examined the revenue recognition of the Company by assessing and testing the Company's internal controls with respect to the revenue cycle by making enquires of responsible executives, gaining an understanding of the controls and selecting representative samples to the operation of the designed controls. In addition, I have performed substantive procedure. I applied a sampling method to select revenue from hospital operation transactions occurring during the year to examine the supporting documents. I requested a balance confirmation from accounts receivable. In addition, I also performed analytical procedures of disaggregated data and performed analytical procedures for significant revenue ratios with the past information and industry to detect possible irregularities in revenues from sales and services throughout the period. In addition, I have performed the test of journal entries related to revenue recognition throughout the period.

Other Information

Management is responsible for the other information. The other information comprise the information included in annual report of the Group, but does not include the financial statements and my auditor's report thereon. The annual report of the Group is expected to be made available to me after the date of this auditor's report.

My opinion on the financial statements does not cover the other information and I do not express any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit or otherwise appears to be materially misstated.

When I read the annual report of the Group, if I conclude that there is a material misstatement therein, I am required to communicate the matter to those charged with governance for correction of the misstatement.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Thai Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Thai Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Thai Standards on Auditing, I exercise professional judgement and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. I am responsible for the direction, supervision and performance of the group audit. I remain solely responsible for my audit opinion.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide those charged with governance with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, I determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, I determine that a matter should not be communicated in my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

I am responsible for the audit resulting in this independent auditor's report.



Samran Taengcham

Certified Public Accountant (Thailand) No. 8021

EY Office Limited

Bangkok: 26 September 2024



Thai Nakin Hospital Public Company Limited and its subsidiary
Statement of financial position
As at 31 July 2024

(Unit: Baht)

	Note	Consolidated financial statements		Separate financial statements	
		31 July 2024	31 July 2023	31 July 2024	31 July 2023
Assets					
Current assets					
Cash and cash equivalents	7	1,300,948,857	1,297,933,964	1,299,683,436	1,296,170,525
Trade and other receivables	6, 8	229,026,982	211,889,462	228,834,367	211,709,274
Inventories	9	39,976,738	33,574,535	39,925,682	33,574,535
Other current financial assets	10	422,686,833	140,000,000	422,686,833	140,000,000
Other current assets		828,431	262,907	828,431	262,907
Total current assets		1,993,467,841	1,683,660,868	1,991,958,749	1,681,717,241
Non-current assets					
Investment in subsidiary	11	-	-	999,700	999,700
Property, plant and equipment	12	986,379,658	894,272,091	986,274,139	894,272,091
Intangible assets	13	11,026,469	10,402,457	10,996,173	10,402,457
Right-of-use assets	14	547,073,500	569,657,405	547,073,500	569,657,405
Deferred tax assets	19	26,130,992	23,020,388	26,130,992	23,020,388
Other non-current assets		109,335	133,127	109,335	133,127
Total non-current assets		1,570,719,954	1,497,485,468	1,571,583,839	1,498,485,168
Total assets		3,564,187,795	3,181,146,336	3,563,542,588	3,180,202,409

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary
Statement of financial position (continued)
As at 31 July 2024

(Unit: Baht)

		Consolidated financial statements		Separate financial statements	
	Note	31 July 2024	31 July 2023	31 July 2024	31 July 2023
Liabilities and shareholders' equity					
Current liabilities					
Trade and other payables	15	209,717,611	185,074,426	209,573,722	184,924,426
Doctor fee payable	6	111,811,754	94,800,412	111,811,754	94,800,412
Income tax payable		33,863,723	29,022,904	33,863,723	29,022,904
Other current liabilities		34,094,667	33,241,688	34,090,110	33,241,688
Total current liabilities		389,487,755	342,139,430	389,339,309	341,989,430
Non-current liabilities					
Provision for long-term employee benefits	16	110,604,505	98,933,912	110,604,505	98,933,912
Other non-current liabilities		2,543,222	5,440,230	2,543,222	5,440,230
Total non-current liabilities		113,147,727	104,374,142	113,147,727	104,374,142
Total liabilities		502,635,482	446,513,572	502,487,036	446,363,572
Shareholders' equity					
Share capital					
Registered					
180,000,000 ordinary shares of Baht					
1 each		180,000,000	180,000,000	180,000,000	180,000,000
Issued and fully paid-up					
180,000,000 ordinary shares of Baht					
1 each		180,000,000	180,000,000	180,000,000	180,000,000
Share premium		20,537,768	20,537,768	20,537,768	20,537,768
Retained earnings					
Retained earnings					
Appropriated - statutory reserve	17	18,000,000	18,000,000	18,000,000	18,000,000
Unappropriated		2,843,014,245	2,516,094,696	2,842,517,784	2,515,301,069
Equity attributable to owners of the					
Company		3,061,552,013	2,734,632,464	3,061,055,552	2,733,838,837
Non-controlling interests of the subsidiary		300	300	-	-
Total shareholders' equity		3,061,552,313	2,734,632,764	3,061,055,552	2,733,838,837
Total liabilities and shareholders'					
equity		3,564,187,795	3,181,146,336	3,563,542,588	3,180,202,409

The accompanying notes are an integral part of the financial statements.

Thai Nakin Hospital Public Company Limited and its subsidiary
Statement of comprehensive income
For the year ended 31 July 2024

(Unit: Baht)

	Note	Consolidated financial statements		Separate financial statements	
		2024	2023	2024	2023
Profit and loss:					
Revenues					
Revenues from hospital operations		2,706,219,409	2,404,040,084	2,706,219,409	2,404,040,084
Other income		11,287,862	15,515,464	11,221,880	14,752,345
Total revenues		<u>2,717,507,271</u>	<u>2,419,555,548</u>	<u>2,717,441,289</u>	<u>2,418,792,429</u>
Expenses	18				
Cost of hospital operations		1,935,306,211	1,761,760,320	1,935,306,211	1,761,424,754
Administrative expenses		263,763,005	233,772,662	263,390,407	233,619,704
Total expenses		<u>2,199,069,216</u>	<u>1,995,532,982</u>	<u>2,198,696,618</u>	<u>1,995,044,458</u>
Operating profit		<u>518,438,055</u>	<u>424,022,566</u>	<u>518,744,671</u>	<u>423,747,971</u>
Finance income		19,851,480	9,646,694	19,842,030	9,640,361
Profit before income tax expenses		<u>538,289,535</u>	<u>433,669,260</u>	<u>538,586,701</u>	<u>433,388,332</u>
Income tax expenses	19	(103,369,986)	(83,103,167)	(103,369,986)	(83,094,701)
Profit for the year		<u>434,919,549</u>	<u>350,566,093</u>	<u>435,216,715</u>	<u>350,293,631</u>
Other comprehensive income:					
<i>Other comprehensive income not to be reclassified to profit or loss in subsequent periods</i>					
Actuarial gain	16	-	10,083,880	-	10,083,880
Less: Income tax effect	19	-	(2,016,776)	-	(2,016,776)
Actuarial gain - net of income tax					
Other comprehensive income for the year		<u>-</u>	<u>8,067,104</u>	<u>-</u>	<u>8,067,104</u>
Total comprehensive income for the year		<u>-</u>	<u>8,067,104</u>	<u>-</u>	<u>8,067,104</u>
Basic earnings per share		<u>434,919,549</u>	<u>358,633,197</u>	<u>435,216,715</u>	<u>358,360,735</u>
Profit	20				
Weighted average number of ordinary shares (shares)		2.42	1.95	2.42	1.95
		<u>180,000,000</u>	<u>180,000,000</u>	<u>180,000,000</u>	<u>180,000,000</u>

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of changes in shareholders' equity

For the year ended 31 July 2024

(Unit: Baht)

	Note	Consolidated financial statements					
		Issued and paid-up share capital	Share premium	Retained earnings	Total equity attributable to owners of the Company	Equity attributable to non-controlling interests of the subsidiaries	Total shareholders' equity
				Appropriated - statutory reserve	Unappropriated		
Balance as at 1 August 2022		180,000,000	20,537,768	18,000,000	2,265,461,499	2,483,999,267	2,483,999,567
Profit for the year		-	-	-	350,566,093	350,566,093	350,566,093
Other comprehensive income for the year		-	-	-	8,067,104	8,067,104	8,067,104
Total comprehensive income for the year	21	-	-	-	358,633,197	358,633,197	358,633,197
Dividend paid		-	-	-	(108,000,000)	(108,000,000)	(108,000,000)
Balance as at 31 July 2023		180,000,000	20,537,768	18,000,000	2,516,094,696	2,734,632,464	2,734,632,764
Balance as at 1 August 2023		180,000,000	20,537,768	18,000,000	2,516,094,696	2,734,632,464	2,734,632,764
Profit for the year		-	-	-	434,919,549	434,919,549	434,919,549
Other comprehensive income for the year		-	-	-	-	-	-
Total comprehensive income for the year	21	-	-	-	434,919,549	434,919,549	434,919,549
Dividend paid		-	-	-	(108,000,000)	(108,000,000)	(108,000,000)
Balance as at 31 July 2024		180,000,000	20,537,768	18,000,000	2,843,014,245	3,061,552,013	3,061,552,313

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of changes in shareholders' equity (continued)

For the year ended 31 July 2024

(Unit: Baht)

	Note	Separate financial statements				
		Issued and paid-up share capital	Share premium	Retained earnings		Total shareholders' equity
				Appropriated - statutory reserve	Unappropriated	
Balance as at 1 August 2022		180,000,000	20,537,768	18,000,000	2,264,940,334	2,483,478,102
Profit for the year		-	-	-	350,293,631	350,293,631
Other comprehensive income for the year		-	-	-	8,067,104	8,067,104
Total comprehensive income for the year		-	-	-	358,360,735	358,360,735
Dividend paid	21	-	-	-	(108,000,000)	(108,000,000)
Balance as at 31 July 2023		180,000,000	20,537,768	18,000,000	2,515,301,069	2,733,838,837
Balance as at 1 August 2023		180,000,000	20,537,768	18,000,000	2,515,301,069	2,733,838,837
Profit for the year		-	-	-	435,216,715	435,216,715
Other comprehensive income for the year		-	-	-	-	-
Total comprehensive income for the year	21	-	-	-	435,216,715	435,216,715
Dividend paid		-	-	-	(108,000,000)	(108,000,000)
Balance as at 31 July 2024		180,000,000	20,537,768	18,000,000	2,842,517,784	3,061,055,552

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary
Statement of cash flows
For the year ended 31 July 2024

(Unit: Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Cash flows from operating activities				
Profit before tax	538,289,535	433,669,260	538,586,701	433,388,332
Adjustments to reconcile profit before tax to net cash provided by (paid from) operating activities:				
Depreciation and amortisation expenses	122,546,671	116,463,319	122,541,921	116,463,319
Allowance for expected credit losses (reversal)	4,227,391	(2,207,878)	4,227,391	(2,207,878)
Write off bad debts	4,432,175	3,922,682	4,432,175	3,922,682
Long-term employee benefit expenses	14,699,733	13,856,923	14,699,733	13,856,923
Gain on disposals of equipment	(500,967)	(1,867,487)	(500,967)	(1,867,487)
Loss on disposals of intangible assets	8,079	-	8,079	-
Interest income	(19,851,480)	(9,646,694)	(19,842,030)	(9,640,361)
Profit from operating activities before changes in operating assets and liabilities	663,851,137	554,190,125	664,153,003	553,915,530
Decrease (increase) in operating assets				
Trade and other receivables	(25,833,076)	147,810,971	(25,820,649)	147,811,464
Inventories	(6,402,203)	2,596,976	(6,351,147)	2,596,976
Other current assets	(565,524)	1,269,684	(565,524)	1,269,684
Other non-current assets	23,792	(33,792)	23,792	(33,792)
Increase (decrease) in operating liabilities				
Trade and other payables	22,561,782	2,109,811	22,567,893	3,075,476
Doctor fee payable	17,011,342	(11,771,356)	17,011,342	(11,771,356)
Other current liabilities	852,979	2,087,171	848,422	2,087,171
Provision for long-term employee benefits	(3,029,140)	(7,795,317)	(3,029,140)	(7,795,317)
Other non-current liabilities	(2,897,008)	(2,513,879)	(2,897,008)	(2,513,879)
Cash from operating activities	665,574,081	687,950,394	665,940,984	688,641,957
Cash paid for income tax	(101,639,771)	(81,472,652)	(101,639,771)	(81,372,229)
Net cash from operating activities	563,934,310	606,477,742	564,301,213	607,269,728

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of cash flows (continued)

For the year ended 31 July 2024

(Unit: Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Cash flows from investing activities				
Interest received	19,887,470	8,999,191	19,878,020	8,992,858
Net (increase) decrease in other current financial assets	(282,686,833)	332,547,148	(282,686,833)	332,547,148
Cash paid for purchases of building improvement and equipment	(189,063,875)	(237,131,796)	(188,954,310)	(237,131,796)
Cash paid for purchase of intangible assets	(2,127,684)	(7,773,100)	(2,096,684)	(7,773,100)
Cash received from disposals of equipment	1,068,350	3,246,980	1,068,350	3,246,980
Cash received from disposals of intangible assets	3,155	-	3,155	-
Net cash from (used in) investing activities	(452,919,417)	99,888,423	(452,788,302)	99,882,090
Cash flows from financing activities				
Dividend paid	(108,000,000)	(108,000,000)	(108,000,000)	(108,000,000)
Net cash used in financing activities	(108,000,000)	(108,000,000)	(108,000,000)	(108,000,000)
Net increase in cash and cash equivalents	3,014,893	598,366,165	3,512,911	599,151,818
Cash and cash equivalents at beginning of year	1,297,933,964	699,567,799	1,296,170,525	697,018,707
Cash and cash equivalents at end of year (Note 7)	1,300,948,857	1,297,933,964	1,299,683,436	1,296,170,525
Supplemental cash flows information				
Non-cash items				
Write-off trade receivables as bad debts	4,432,175	3,922,682	4,432,175	3,922,682
Accounts payable - construction and equipment purchase	29,292,063	27,210,661	29,292,063	27,210,661

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary

Notes to financial statements

For the year ended 31 July 2024

1 General information

Thai Nakarin Hospital Public Company Limited (“the Company”) is a public company incorporated and domiciled in Thailand. The Company is principally engaged in hospital business. The registered office of the Company is at No. 345 Thepparat Road, Kwaeng Bangna Nuea, Khet Bangna, Bangkok and its branch is located at No. 107/1 Moo 7, Sirisothon Road, Bang Phra, Mueang Chachoengsao, Chachoengsao.

2 Basis of preparation

- 2.1 The financial statements have been prepared in accordance with Thai Financial Reporting Standards enunciated under the Accounting Profession Act B.E. 2547 and their presentation has been made in compliance with the stipulations of the Notification of the Department of Business Development issued under the Accounting Act B.E. 2543.

The financial statements in Thai language are the official statutory financial statements of the Company. The financial statements in English language have been translated from the Thai language financial statements.

The financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.

2.2 Basis of consolidation

- a) The consolidated financial statements include the financial statements of Thai Nakarin Hospital Public Company Limited (“the Company”) and the following subsidiary company (“the subsidiary”) (collectively as “the Group”):

Company's name	Nature of business	Percentage of shareholding
Jatu Charoen Development Company Limited	Health establishment and hotel business, providing elderly and dependency care	99.97

- b) The Company is deemed to have control over an investee or subsidiary if it has rights, or is exposed, to variable returns from its involvement with the investee, and it has the ability to direct the activities that affect the amount of its returns.
- c) Subsidiary is fully consolidated, being the date on which the Company obtains control, and continue to be consolidated until the date when such control ceases.
- d) The financial statements of the subsidiary are prepared using the same significant accounting policies as the Company.
- e) Material balances and transactions between the Group have been eliminated from the consolidated financial statements.
- f) Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately in the consolidated profit or loss and within equity in the consolidated statement of financial position.

The separate financial statements present investments in subsidiary under the cost method.

3 New financial reporting standards

(a) Financial reporting standards that became effective in the current period

During the period, the Group has adopted the revised financial reporting standards and interpretations which are effective for fiscal years beginning on or after 1 January 2023. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards.

The adoption of these financial reporting standards does not have any significant impact on the Group's financial statements.

(b) Financial reporting standards that became effective for fiscal years beginning on or after 1 January 2024

The Federation of Accounting Professions issued a number of revised financial reporting standards, which are effective for fiscal years beginning on or after 1 January 2024. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and, for some standards, providing temporary reliefs or temporary exemptions for users.

The management of the Group is currently evaluating the impact of these standards on the financial statements in the year when they are adopted.

4 Significant accounting policies

4.1 Revenue and expense recognition

Revenue from hospital operations

Revenues from hospital operations, mainly consisting of medical fees, hospital room sales and medicine sales, are recognised as income when services have been rendered or medicines have been delivered.

Revenue from sales of goods

Sales of goods are recognised at the point in time when control of the goods is transferred to the customer, generally on delivery of the goods. Sales are the invoiced value, excluding value added tax, of goods supplied after deducting discounts.

Revenue from rental

Revenue from rental is recognised over the term of the rental agreements.

Finance income

Interest income is calculated using the effective interest method and recognised on an accrual basis. The effective interest rate is applied to the gross carrying amount of a financial asset, unless the financial assets subsequently become credit-impaired when it is applied to the net carrying amount of the financial asset (net of the expected credit loss allowance).

Finance cost

Interest expense from financial liabilities at amortised cost is calculated using the effective interest method and recognised on an accrual basis.

Other income

Other income is recognised on an accrual basis.

4.2 Cash and cash equivalents

Cash and cash equivalents consist of cash in hand and at banks, and all highly liquid investments with an original maturity of 3 months or less and not subject to withdrawal restrictions.

4.3 Inventories

Inventories are valued at the lower of cost (first-in first out) and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale.

4.4 Investment in subsidiary

Investment in subsidiary is accounted for in the separate financial statements using the cost method less allowance for impairment loss (if any).

4.5 Property, plant and equipment and depreciation

Land is stated at cost. Buildings and equipment are stated at cost less accumulated depreciation and allowance for loss on impairment of assets (if any).

Depreciation of buildings and equipment is calculated by reference to their costs on the straight-line basis over the following estimated useful lives:

Particulars	Useful lives (years)	
	Assets acquired before 1 August 2004	Assets acquired as from 1 August 2004
Land improvement	30	30
Buildings	25	Over the lease term
Building improvement	10	10
Facility systems	15, 20	3 - 10
Medical accessory equipment	5 - 20	5 - 15
Furniture, fixtures and equipment	8 - 15	5 - 10
Vehicles	10	10

Depreciation is included in determining income. No depreciation is provided on land and assets under construction and installation.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on disposal of an asset is included in profit or loss when the asset is derecognised.

4.6 Intangible assets

Intangible assets are measured at cost on the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses (if any).

Intangible assets with finite lives are amortised on a systematic basis over the economic useful life and tested for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method of such intangible assets are reviewed at least at each financial year end. The amortisation expense is charged to profit or loss.

A summary of the intangible assets with finite useful lives is as follows:

	Useful lives
Computer software	10 Years

4.7 Leases

Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised through initial measurement, initial direct costs incurred, and lease payments made at or before the commencement date, less any lease incentives received.

Unless the Company is reasonably certain that it will obtain ownership of the leased asset at the end of the lease term, the recognised right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

Lease liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of the lease payments to be made over the lease term, discounted by the interest rate implicit in the lease or the Company's incremental borrowing rate. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification or reassessment.

Short-term leases and Leases of low-value assets

Payments under leases that, have a lease term of 12 months or less at the commencement date, or are leases of low-value assets, are recognised as expenses on a straight-line basis over the lease term.

4.8 Related party transactions

Related parties comprise individuals or enterprises that control, or are controlled by, the Company, whether directly or indirectly, or which are under common control with the Company.

They also include individuals or enterprises which directly or indirectly own a voting interest in the Company that gives them significant influence over the Company, key management personnel, directors, and officers with authority in the planning and direction of the Company's operations.

4.9 Impairment of non-financial assets

At the end of each reporting period, the Company performs impairment reviews in respect of the property, plant and equipment right-of-use asset and other intangible assets whenever events or changes in circumstances indicate that an asset may be impaired. An impairment loss is recognised when the recoverable amount of an asset, which is the higher of the asset's fair value less costs to sell and its value in use, is less than the carrying amount.

An impairment loss is recognised in profit or loss.

In the assessment of asset impairment, if there is any indication that previously recognised impairment losses may no longer exist or may have decreased, the Company estimates the asset's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The increased carrying amount of the asset attributable to a reversal of an impairment loss shall not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in profit or loss.

4.10 Foreign currencies

The financial statements are presented in Baht, which is also the Company's functional currency.

Transactions in foreign currencies are translated into Baht at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into Baht at the exchange rate ruling at the end of reporting period.

Gains and losses on exchange are included in determining income.

4.11 Employee benefits

Short-term employee benefits

Salaries, wages, bonuses and contributions to the social security fund are recognised as expenses when incurred.

Post-employment benefits and other long-term employee benefits

Defined contribution plans

The Company and its employees have jointly established a provident fund. The fund is monthly contributed by employees and by the Company. The fund's assets are held in a separate trust fund and the Company's contributions are recognised as expenses when incurred.

Defined benefit plans and other long-term employee benefits

The Company has obligations in respect of the severance payments it must make to employees upon retirement under labor law. The Company treats these severance payment obligations as a defined benefit plan. In addition, the Company provides other long-term employee benefit plan, namely long service awards.

The obligation under the defined benefit plan and other long-term employee benefit plan is determined by a professionally qualified independent actuary based on actuarial techniques, using the projected unit credit method.

Actuarial gains and losses arising from post-employment benefits are recognised immediately in other comprehensive income.

Actuarial gains and losses arising from other long-term employee benefits are recognised immediately in profit or loss.

4.12 Provisions

Provisions are recognised when the Group has a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

4.13 Income tax

Income tax expense represents the sum of corporate income tax currently payable and deferred tax.

Current tax

Current income tax is provided in the accounts at the amount expected to be paid to the taxation authorities, based on taxable profits determined in accordance with tax legislation.

Deferred tax

Deferred income tax is provided on temporary differences between the tax bases of assets and liabilities and their carrying amounts at the end of each reporting period, using the tax rates enacted at the end of the reporting period.

The Group recognises deferred tax liabilities for all taxable temporary differences while it recognises deferred tax assets for all deductible temporary differences and tax losses carried forward to the extent that it is probable that future taxable profit will be available against which such deductible temporary differences and tax losses carried forward can be utilised.

At each reporting date, the Group reviews and reduces the carrying amount of deferred tax assets to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax assets to be utilised.

The Group records deferred tax directly to shareholders' equity if the tax relates to items that are recorded directly to shareholders' equity.

4.14 Financial instruments

The Company initially measures financial assets at its fair value plus, in the case of financial assets that are not measured at fair value through profit or loss, transaction costs. However, trade receivables, that do not contain a significant financing component, are measured at the transaction price as disclosed in the accounting policy relating to revenue recognition.

Classification and measurement of financial assets

Financial assets are classified, at initial recognition, as to be subsequently measured at amortised cost, fair value through other comprehensive income ("FVOCI"), or fair value through profit or loss ("FVTPL"). The classification of financial assets at initial recognition is driven by the Company's business model for managing the financial assets and the contractual cash flows characteristics of the financial assets.

Financial assets at amortised cost

The Company measures financial assets at amortised cost if the financial asset is held in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets at amortised cost are subsequently measured using the effective interest rate ("EIR") method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired.

Financial assets at FVTPL

Financial assets measured at FVTPL are carried in the statement of financial position at fair value with net changes in fair value recognised in profit or loss.

These financial assets include derivatives, security investments held for trading, equity investments which the Group has not irrevocably elected to classify at FVOCI and financial assets with cash flows that are not solely payments of principal and interest.

Dividends on listed equity investments are recognised as other income in profit or loss.

Classification and measurement of financial liabilities

Except for derivative liabilities, at initial recognition the Company's financial liabilities are recognised at fair value net of transaction costs and classified as liabilities to be subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process. In determining amortised cost, the Company takes into account any fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance costs in profit or loss.

Derecognition of financial instruments

A financial asset is primarily derecognised when the rights to receive cash flows from the asset have expired or have been transferred and either the Company has transferred substantially all the risks and rewards of the asset, or the Company has neither transferred nor retained substantially all the risks and rewards of the asset but has transferred control of the asset.

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in profit or loss.

Impairment of financial assets

The Company recognises an allowance for expected credit losses ("ECLs") for all debt instruments not held at FVTPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate.

For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure (a lifetime ECL).

The Company considers a significant increase in credit risk to have occurred when contractual payments are more than 30 days past due and considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to have a significant increase in credit risk and to be in default using other internal or external information, such as credit rating of issuers.

For trade receivables, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. It is based on its historical credit loss experience and adjusted for forward-looking factors specific to the debtors and the economic environment.

A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Offsetting of financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Trade accounts receivable

Trade accounts receivable are stated at the net realisable value. Allowance for doubtful accounts is provided for the estimated losses that may be incurred in collection of receivables. The allowance is generally based on collection experience and analysis of debt aging.

4.15 Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between buyer and seller (market participants) at the measurement date. The Company applies a quoted market price in an active market to measure its assets and liabilities that are required to be measured at fair value by relevant financial reporting standards. Except in case of no active market of an identical asset or liability or when a quoted market price is not available, the Company measures fair value using valuation techniques that are appropriate in the circumstances and maximises the use of relevant observable inputs related to assets and liabilities that are required to be measured at fair value.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy into three levels based on categories of input to be used in fair value measurement as follows:

Level 1 - Use of quoted market prices in an observable active market for such assets or liabilities

Level 2 - Use of other observable inputs for such assets or liabilities, whether directly or indirectly

Level 3 - Use of unobservable inputs such as estimates of future cash flows

At the end of each reporting period, the Company determines whether transfers have occurred between levels within the fair value hierarchy for assets and liabilities held at the end of the reporting period that are measured at fair value on a recurring basis.

5 Significant accounting judgements and estimates

The preparation of financial statements in conformity with financial reporting standards at times requires management to make subjective judgements and estimates regarding matters that are inherently uncertain. These judgements and estimates affect reported amounts and disclosures and actual results could differ from these estimates. Significant judgements and estimates are as follows:

Allowance for expected credit losses of trade receivables

In determining an allowance for expected credit losses of trade receivables, the management needs to make judgement and estimates based upon, among other things, past collection history, aging profile of outstanding debts and the forecast economic condition for groupings of various customer segments with similar credit risks. The Group's historical credit loss experience and forecast economic conditions may also not be representative of whether a customer will actually default in the future.

Fair value of financial instruments

In determining the fair value of financial instruments recognised in the statement of financial position that are not actively traded and for which quoted market prices are not readily available, the management exercises judgement, using a variety of valuation techniques and models. The input to these models is taken from observable markets, and includes consideration of credit risk (bank and counterparty, both), liquidity, correlation and longer-term volatility of financial instruments. Change in assumptions about these factors could affect the fair value recognised in the statement of financial position and disclosures of fair value hierarchy.

Property, plant and equipment and depreciation

In determining depreciation of buildings and equipment, the management is required to make estimates of the useful lives and residual values of the Company's buildings and equipment and to review estimate useful lives and residual values when there are any changes.

In addition, the management is required to review property, plant and equipment for impairment on a periodical basis and records impairment losses in the period when it is determined that their recoverable amount is lower than the carrying amount. This requires judgements regarding forecast of future revenues and expenses relating to the assets subject to the review.

Deferred tax assets

Deferred tax assets are recognised for deductible temporary differences to the extent that it is probable that taxable profit will be available against which the temporary differences can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and level of estimate future taxable profits.

Post-employment benefits and other long-term employee benefits under defined benefit plans

The obligations under the post-employment benefit plan and other long-term employee benefit plan are determined based on actuarial techniques. Such determination is made based on various assumptions, including discount rate, future salary increase rate, mortality rate and staff turnover rate.

Litigation

The Company has contingent liabilities as a result of litigation. The Company's management has used judgement to assess of the results of the litigation and believes that no loss will result. Therefore, no contingent liabilities are recorded as at the end of reporting period.

6 Related party transactions

During the years, the Company had significant business transactions with related parties. Such transactions, which are summarised below, were concluded on commercial terms and bases agreed upon between the Company and those related parties.

	Transfer pricing policy
Revenues from hospital operations	Based on the price charged to normal customers
Rental income	Rates as stipulated in the agreements
Purchase fixed assets	Rates as stipulated in the agreements
Doctor fee expenses (directors and management)	The same rate as other doctors in the hospital
Medical welfare expenses	Under the Company's regulations, medical welfare benefits are granted to directors, their spouses, children and parents, up to a specified amount per annum. These benefits exclude doctor fees, examinations conducted on other premises and special equipment charges

(Unit: Thousand Baht)

	Consolidated and separate financial statements	
	For the years ended 31 July	
	2024	2023
Transactions with related companies and persons		
Revenues from hospital operations	47	69
Purchase fixed assets	-	16,100
Doctor fee expenses (directors and management)	5,047	9,226
Medical welfare expenses	4,095	3,432

The balances of accounts as at 31 July 2024 and 2023 between the Company and its related parties are as follows:

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Trade receivables - related parties (Note 8)				
Related companies				
(related by common shareholders and directors)	2	23	2	23
Total trade receivables - related parties	2	23	2	23
Other payable - related parties (Note 15)				
Subsidiary	-	-	5	-
Total other payable - related parties	-	-	5	-
Doctor fee payable - related persons				
Related persons (directors and management)	334	475	334	475
Total doctor fee payable - related persons	334	475	334	475

Directors and management's benefits

During the years ended 31 July 2024 and 2023, the Company had employee benefit expenses payable to its directors and management as below.

(Unit: Thousand Baht)

	Consolidated and Separate financial statements	
	2024	2023
Short-term employee benefits	40,409	45,898
Post-employment benefits	3,744	2,511
Total	44,153	48,409

7 Cash and cash equivalents

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Cash	6,833	5,301	6,833	5,301
Bank deposits	1,294,116	1,292,633	1,292,850	1,290,870
Total cash and cash equivalents	1,300,949	1,297,934	1,299,683	1,296,171

As at 31 July 2024, bank deposits in savings accounts carried interests between 0.15 and 1.40 percent per annum (2023: between 0.15 and 1.25 percent per annum).

8 Trade and other receivables

(Unit: Thousand Baht)

Trade receivables - related parties

Aged on the basis of due dates

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Not yet due	-	10	-	10
Past due				
Up to 3 months	2	4	2	4
3 - 6 months	-	-	-	-
6 - 12 months	-	9	-	9
Total trade receivables - related parties	2	23	2	23

Trade receivables - unrelated parties

Aged on the basis of due dates

Not yet due	121,031	88,718	121,031	88,718
Past due				
Up to 3 months	85,111	72,533	85,111	72,533
3 - 6 months	10,883	18,332	10,883	18,332
6 - 12 months	4,622	5,934	4,622	5,934
Over 12 months	18,291	32,084	18,291	32,084
Total trade receivables - unrelated parties	239,938	217,601	239,938	217,601
Less: Allowance for expected credit loss	(17,380)	(13,152)	(17,380)	(13,152)
Total trade receivables - unrelated parties - net	222,558	204,449	222,558	204,449
Total trade receivables - net	222,560	204,472	222,560	204,472

Other receivables

Other receivables - unrelated parties	4,739	5,653	4,546	5,473
Accrued interest income	1,728	1,764	1,728	1,764
Total other receivables	6,467	7,417	6,274	7,237
Total trade and other receivables - net	229,027	211,889	228,834	211,709

9 Inventories

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Medicines and medical supplies	37,334	30,976	37,283	30,976
Supplies and others	2,643	2,599	2,643	2,599
Total	39,977	33,575	39,926	33,575

10 Other current financial assets

As at 31 July 2024 and 2023, other current financial assets consisted of the following:

(Unit: Thousand Baht)

	Consolidated and separate financial statements			
	Other current financial assets		Interest rate (percent per annum)	
	2024	2023	2024	2023
Fixed deposits at financial institutions (5 - 12 months)	422,687	140,000	1.00 - 2.15	1.00 - 2.00
Total other current financial assets	422,687	140,000		

11 Investment in subsidiary

Details of investments in subsidiary as presented in the separate financial statements are as follows:

(Unit: Thousand Baht)

Company's name	Type of relation	Shareholding percentage		Cost	
		31 July 2024	31 July 2023	31 July 2024	31 July 2023
		(%)	(%)		
Local subsidiary					
Jatu Charoen Development Company Limited	Direct holding	99.97	99.97	1,000	1,000

On 13 December 2021, the Board of Directors' meeting No. 5/2021 resolved to approve the establishment of a new subsidiary, Jatu Charoen Development Company Limited, which is engaged in health establishment and hotel business, providing elderly and dependency care both onsite and offsite as well as distributions of medicines, supplement products, medical supplies and equipments. The subsidiary has a registered capital of 10,000 shares with a par value of Baht 100 per share, totaling Baht 1 million. The subsidiary registered the establishment with the Department of Business Development, the Ministry of Commerce on 18 February 2022.

12 Property, plant and equipment

(Unit: Thousand Baht)

	Consolidated financial statements						
	Land and land improvements	Buildings and building improvements	Facility systems	Medical accessory equipment	Furniture, fixtures and equipment	Vehicles	Assets under construction and installation
Cost							Total
1 August 2022	227,760	250,839	316,052	557,609	174,145	15,425	1,719,290
Additions	-	127	1,682	83,295	6,844	953	215,108
Transfer in (transfer out)	258	69,252	21,644	110,103	5,728	-	(78)
Disposals and write-off	-	(5,350)	(509)	(23,699)	(9,365)	-	(38,923)
31 July 2023	228,018	314,868	338,869	727,308	177,352	16,378	1,895,397
Additions	667	-	2,435	48,427	7,598	3,141	191,146
Transfer in (transfer out)	8,005	57,985	12,723	417	5,493	-	-
Disposals and write-off	-	(96)	(1,556)	(21,458)	(4,130)	(1,351)	(28,591)
31 July 2024	236,690	372,757	352,471	754,694	186,313	18,168	2,057,952

(Unit: Thousand Baht)

	Consolidated financial statements						
	Land and land improvements	Buildings and building improvements	Facility systems	Medical accessory equipment	Furniture, fixtures and equipment	Vehicles	Assets under construction and installation
Accumulated depreciation							Total
1 August 2022	2,126	126,543	263,982	393,450	142,734	11,456	-
Depreciation for the year	46	9,923	10,710	59,519	12,219	780	-
Depreciation on disposals and write-off	-	(108)	(509)	(22,474)	(9,272)	-	-
31 July 2023	2,172	136,358	274,183	430,495	145,681	12,236	-
Depreciation for the year	49	14,442	11,359	60,580	11,162	879	-
Depreciation on disposals and write-off	-	(97)	(1,466)	(20,987)	(4,124)	(1,350)	-
31 July 2024	2,221	150,703	284,076	470,088	152,719	11,765	-
Net book value							
31 July 2023	225,846	178,510	64,686	296,813	31,671	4,142	92,604
31 July 2024	234,469	222,054	68,395	284,606	33,594	6,403	136,859
Depreciation for the year							
2023 (Baht 88.24 million included in cost of hospital operations, and the balance in administrative expenses)							93,197
2024 (Baht 92.90 million included in cost of hospital operations, and the balance in administrative expenses)							98,471

(Unit: Thousand Baht)

Separate financial statements								
	Land and land improvements	Buildings and building improvements	Facility systems	Medical accessory equipment	Furniture, fixtures and equipment	Vehicles	Assets under construction and installation	Total
Cost								
1 August 2022	227,760	250,839	316,052	557,609	174,145	15,425	177,460	1,719,290
Additions	-	127	1,682	83,295	6,844	953	122,207	215,108
Transfer in (transfer out)	258	69,252	21,644	110,103	5,728	-	(207,063)	(78)
Disposals and write-off	-	(5,350)	(509)	(23,699)	(9,365)	-	-	(38,923)
31 July 2023	228,018	314,868	338,869	727,308	177,352	16,378	92,604	1,895,397
Additions	667	-	2,435	48,427	7,488	3,141	128,878	191,036
Transfer in (transfer out)	8,005	57,985	12,723	417	5,493	-	(84,623)	-
Disposals and write-off	-	(96)	(1,556)	(21,458)	(4,130)	(1,351)	-	(28,591)
31 July 2024	236,690	372,757	352,471	754,694	186,203	18,168	136,859	2,057,842

(Unit: Thousand Baht)

	Separate financial statements						
	Land and land improvements	Buildings and building improvements	Facility systems	Medical accessory equipment	Furniture, fixtures and equipment	Vehicles	Assets under construction and installation
Accumulated depreciation							Total
1 August 2022	2,126	126,543	263,982	393,450	142,734	11,456	940,291
Depreciation for the year	46	9,923	10,710	59,519	12,219	780	93,197
Depreciation on disposals and write-off	-	(108)	(509)	(22,474)	(9,272)	-	(32,363)
31 July 2023	2,172	136,358	274,183	430,495	145,681	12,236	1,001,125
Depreciation for the year	49	14,442	11,359	60,580	11,158	879	98,467
Depreciation on disposals and write-off	-	(97)	(1,466)	(20,987)	(4,124)	(1,350)	(28,024)
31 July 2024	2,221	150,703	284,076	470,088	152,715	11,765	1,071,568
Net book value							
31 July 2023	225,846	178,510	64,686	296,813	31,671	4,142	894,272
31 July 2024	234,469	222,054	68,395	284,606	33,488	6,403	986,274
Depreciation for the year							
2023 (Baht 88.24 million included in cost of hospital operations, and the balance in administrative expenses)							93,197
2024 (Baht 92.90 million included in cost of hospital operations, and the balance in administrative expenses)							98,467

As at 31 July 2024, certain building improvements and equipment items have been fully depreciated but are still in use. The gross carrying amount before deducting accumulated depreciation of those assets amounted to Baht 742.85 million (2023: Baht 690.49 million).

13 Intangible assets

The net book value of intangible assets, which are computer software, as at 31 July 2024 and 2023 is presented below.

(Unit: Thousand Baht)

	Consolidated financial statements	Separate financial statements
Cost		
1 August 2022	24,151	24,151
Additions	7,694	7,694
Transfer in	78	78
31 July 2023	31,923	31,923
Additions	2,128	2,097
Disposals	(123)	(123)
31 July 2024	33,928	33,897
Accumulated amortisation		
1 August 2022	20,777	20,777
Amortisation for the year	744	744
31 July 2023	21,521	21,521
Amortisation for the year	1,493	1,492
Disposals	(112)	(112)
31 July 2024	22,902	22,901
Net book value		
31 July 2023	10,402	10,402
31 July 2024	11,026	10,996

14 Right-of-use assets

(Unit: Thousand Baht)

	Consolidated and separate financial statements	
	2024	2023
Cost	675,348	675,348
Less: Accumulated amortisation	(128,274)	(105,691)
Book value - net	547,074	569,657

(Unit: Thousand Baht)

	Consolidated and separate financial statements	
	2024	2023
Net book value as at beginning of the year	569,657	592,180
Amortisation for the year	(22,583)	(22,523)
Net book value as at end of the year	547,074	569,657

The Company entered into a long-term lease agreement for lease of land and building on which are the current operation hospital building with Thai Red Cross Society. The agreement is for a period of 30 years, from 9 November 2018 to 8 November 2048 with the lease payment of Baht 668 million, being payable in full upon signing the new lease agreement. The Company paid the lease payment of Baht 668 million to the Thai Red Cross Society on 22 February 2019.

15 Trade and other payables

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Trade payables - unrelated parties	118,902	101,985	118,794	101,985
Other payables - related parties	-	-	5	-
Other payables - unrelated parties	18,506	18,505	18,506	18,505
Accounts payable - construction and equipment purchase	29,292	27,210	29,292	27,210
Accrued expenses	43,018	37,374	42,977	37,224
Total trade and other payables	209,718	185,074	209,574	184,924

16 Provision for long-term employee benefits

Provision for long-term employee benefits, which are compensations on employees' retirement and long service awards, was as follows:

(Unit: Thousand Baht)

	Consolidated and separate financial statements		
	Retirement benefit plan	Long service award plan	Total
As at 1 August 2022	95,667	7,289	102,956
Current service cost	11,732	829	12,561
Interest cost	1,961	145	2,106
Actuarial gain arising from			
Financial assumptions changes	(10,084)	(810)	(10,894)
Benefits paid during the year	(6,391)	(1,404)	(7,795)
As at 31 July 2023	92,885	6,049	98,934
Current service cost	11,350	600	11,950
Interest cost	2,589	161	2,750
Benefits paid during the year	(2,236)	(793)	(3,029)
As at 31 July 2024	104,588	6,017	110,605

Long-term employee benefit expenses included in the profit or loss were as follows:

(Unit: Thousand Baht)

	Consolidated and separate financial statements	
	2024	2023
Current service cost	11,950	12,561
Interest cost	2,750	2,106
Actuarial losses	-	(810)
Total expenses recognised in profit or loss	14,700	13,857
Line items in profit or loss under which such expenses are included		
Cost of hospital operations	10,790	10,642
Administrative expenses	3,910	3,215

The Company expects to pay Baht 9.08 million of long-term employee benefits during the next year (2023: Baht 3.50 million).

As at 31 July 2024, the weighted average duration of the liabilities for long-term employee benefits is 13 years (2023: 13 years).

Key actuarial assumptions used for the valuation are as follows:

	Consolidated and separate financial statements	
	2024	2023
	(% per annum)	(% per annum)
Discount rate	2.82	2.82
Future salary increase rate	3.9	3.9
Staff turnover rate (depending on age of employees)	0.00 - 25.00	0.00 - 25.00

The results of sensitivity analysis for significant assumptions that affect the present value of the long-term employee benefit obligations as at 31 July 2024 and 2023 are summarised below.

(Unit: Million Baht)

	Consolidated and separate financial statements			
	2024		2023	
	Increase 0.5%	Decrease 0.5%	Increase 0.5%	Decrease 0.5%
Discount rate	(4.7)	5.0	(4.3)	4.7
	Increase 1.0%	Decrease 1.0%	Increase 1.0%	Decrease 1.0%
Future salary increase rate	9.3	(8.1)	7.7	(6.8)
	Increase 10%	Decrease 10%	Increase 10%	Decrease 10%
Staff turnover rate	(3.1)	3.4	(2.9)	3.1

17 Statutory reserve

Pursuant to Section 116 of the Public Limited Companies Act B.E. 2535, the Company is required to set aside to a statutory reserve at least 5 percent of its net profit after deducting accumulated deficit brought forward (if any), until the reserve reaches 10 percent of the registered capital. The statutory reserve is not available for dividend distribution. At present, the statutory reserve has fully been set aside.

18 Expenses by nature

Significant expenses classified by nature are as follows:

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Salaries and wages and other employee benefits	639,930	607,417	639,776	607,417
Cost of doctors' fee	690,847	612,551	690,847	612,551
Cost of medicines and medical supplies, supplies and others	483,564	421,131	483,564	420,819
Depreciation and amortisation	122,547	116,463	122,542	116,463
Service fees for outside treatments	24,693	21,611	24,693	21,611
General supplies	43,740	36,568	43,725	36,568
Other expenses	193,748	179,792	193,550	179,615

19 Income tax

Income tax expenses for the years ended 31 July 2024 and 2023 are made up as follows:

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Current income tax:				
Current income tax charge	106,481	83,694	106,481	83,686
Deferred tax:				
Relating to origination and reversal of temporary differences	(3,111)	(591)	(3,111)	(591)
Income tax expenses reported in the income statements	103,370	83,103	103,370	83,095

The amount of income tax relating to each component of other comprehensive income for the year ended 31 July 2024 and 2023 are as follows:

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Deferred tax on actuarial gain	-	2,017	-	2,017

The reconciliation between accounting profit and income tax expenses is presented below.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2024	2023	2024	2023
Accounting profit before tax	538,290	433,669	538,587	433,388
Applicable tax rate	0%, 20%	0%, 20%	20%	20%
Accounting profit before tax multiplied by income tax rate	107,717	86,678	107,717	86,678
Adjustment in respect of income tax previous year	-	8	-	-
Effects of:				
Non-deductible expenses	69	447	69	447
Additional expenses deductions allowed	(4,416)	(4,030)	(4,416)	(4,030)
Total	(4,347)	(3,583)	(4,347)	(3,583)
Income tax expenses reported in the statements of comprehensive income	103,370	83,103	103,370	83,095

The components of deferred tax assets are as follows:

(Unit: Thousand Baht)

	Consolidated and separate financial statements	
	2024	2023
Deferred tax assets		
Allowance for excepted credit loss	3,476	2,630
Provision for long-term employee benefits	22,121	19,787
Accumulated depreciation - equipment	391	490
Other	143	113
Total	26,131	23,020

20 Earnings per share

Basic earnings per share is calculated by dividing profit for the year (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the year.

21 Dividends

Dividends	Approved by	Total dividends (Million Baht)	Dividend per share (Baht)
Final dividends for 2022	Annual General Meeting of the shareholders on 17 November 2022	108.0	0.60
Total dividends for 2023		108.0	0.60
Final dividends for 2023	Annual General Meeting of the shareholders on 22 November 2023	108.0	0.60
Total dividends for 2024		108.0	0.60

22 Operating segment information

Operating segment information is reported in a manner consistent with the internal reports that are regularly reviewed by the chief operating decision maker in order to make decisions about the allocation of resources to the segment and assess its performance. The chief operating decision maker has been identified as executive committee.

The one main reportable operating segment of the Company is the hospital business and the single geographical area of its operation is Thailand. Segment performance is evaluated based on operating profit or loss and is measured consistently with operating profit or loss in the financial statements. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain to the aforementioned reportable operating segment and geographical area.

For the years ended 31 July 2024 and 2023, the Company has no major customer with revenue of 10 percent or more of its revenues.

23 Provident fund

The Company and its employees have jointly established a provident fund scheme in accordance with the Provident Fund Act B.E. 2530 whereby both the employees and the Company are to contribute to the fund monthly at the rate of 2 percent of basic salary. The fund is managed by TISCO Asset Management Company Limited and will be paid to the employees upon employment termination in accordance with the fund rules. During the year ended 31 July 2024, the contributions of Baht 3.6 million were recognised as expenses in profit or loss (2023: Baht 3.3 million).

24 Commitments and contingent liabilities

24.1 Commitments under service agreements

The Company had total minimum payments to be paid in the future under the service agreements as follows:

(Unit: Million Baht)		
As at 31 July		
	2024	2023
Payable:		
In up to 1 year	9.4	11.0
In over 1 year and up to 3 years	0.5	1.2

24.2 Capital Commitments

As at 31 July 2024, the Company had capital commitments of Baht 121.4 million (2023: Baht 24.9 million) in respect of the acquisitions of medical equipment, facility systems and construction project.

24.3 Guarantees

- (a) As at 31 July 2024, the Company had credit facilities with a commercial bank for overdrafts of Baht 20.0 million and short-term loans of Baht 10.0 million (2023: Credit facilities with a commercial bank for overdrafts of Baht 20.0 million and short-term loans of Baht 10.0 million).
- (b) As at 31 July 2024, the Company had outstanding bank guarantees of approximately Baht 6.4 million issued by the bank on behalf of the Company in respect of electricity use as required in the normal course of business. (2023: Baht 6.4 million).

25 Financial instruments

25.1 Financial risk management objectives and policies

The Group's financial instruments principally comprise cash and cash equivalents, other current financial assets, trade and other accounts receivable and trade, other accounts payable. The financial risks associated with these financial instruments and how they are managed is described below.

Credit risk

The Group is exposed to credit risk primarily with respect to trade accounts receivable, deposits with banks and financial institutions. The Group's maximum exposure relating to derivatives is noted in the liquidity risk topic.

Trade receivables

The Group manages the risk by adopting appropriate credit control policies and procedures and therefore does not expect to incur material financial losses. Outstanding trade receivables are regularly monitored and the Group does not have high concentrations of credit risk since it has a large customer base in various industries.

An impairment analysis is performed at each reporting date to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar credit risks. The Group classifies customer segments by customer type and rating. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written-off if past due for more than one year and not subject to enforcement activity.

Financial instruments and cash deposits

The Group manages the credit risk from balances with banks and financial institutions by making investments only with approved counterparties and within credit limits assigned to each counterparty. Counterparty credit limits are reviewed by the Group's Board of Directors on an annual basis, and may be updated throughout the year subject to approval of the Company's Executive Committee. The limits are set to minimise the concentration of risks and therefore mitigate financial loss through a counterparty's potential failure to make payments.

Interest rate risk

The Group's exposure to interest rate risk relates primarily to its deposits at financial institutions. However, most of the Group's financial assets and liabilities bear floating interest rates or fixed interest rates which are close to the market rate. The interest rate risk is therefore minimal.

Significant financial assets and liabilities classified by type of interest rates are summarised in the table below.

(Unit: Million Baht)

	Consolidated financial statements				
	As at 31 July 2024				
	Fixed interest rates within 1 year	Floating interest rate	Non-interest bearing	Total	Interest rate (% p.a.)
Financial assets					
Cash and cash equivalents	-	1,294.12	6.83	1,300.95	0.15 - 1.40
Trade and other receivables	-	-	229.03	229.03	-
Other current financial assets	422.69	-	-	422.69	1.00 - 2.15
	422.69	1,294.12	235.86	1,952.67	
Financial liabilities					
Trade and other payables	-	-	209.72	209.72	-
	-	-	209.72	209.72	

(Unit: Million Baht)

Financial assets

Cash and cash equivalents	-	1,292.63	5.30	1,297.93	0.15 - 1.25
Trade and other receivables	-	-	211.89	211.89	-
Other current financial assets	140.00	-	-	140.00	1.00 - 2.00
	140.00	1,292.63	217.19	1,649.82	

Financial liabilities

Trade and other payables	-	-	185.07	185.07	-
	-	-	185.07	185.07	

(Unit: Million Baht)

Financial assets

Cash and cash equivalents	-	1,292.85	6.83	1,299.68	0.15 - 1.40
Trade and other receivables	-	-	228.83	228.83	-
Other current financial assets	422.69	-	-	422.69	1.00 - 2.15
	422.69	1,292.85	235.66	1,951.20	

Financial liabilities

Trade and other payables	-	-	209.57	209.57	-
	-	-	209.57	209.57	

Consolidated financial statements				
As at 31 July 2023				
Fixed interest rates within 1 year	Floating interest rate	Non-interest bearing	Total	Interest rate (% p.a.)

Separate financial statements				
As at 31 July 2024				
Fixed interest rates within 1 year	Floating interest rate	Non-interest bearing	Total	Interest rate (% p.a.)

(Unit: Million Baht)

	Separate financial statements				
	As at 31 July 2023				
	Fixed interest rates within 1 year	Floating interest rate	Non-interest bearing	Total	Interest rate (% p.a.)
Financial assets					
Cash and cash equivalents	-	1,290.87	5.30	1,296.17	0.15 - 1.25
Trade and other receivables	-	-	211.71	211.71	1.00 - 2.00
Other current financial assets	140.00	-	-	140.00	-
	140.00	1,290.87	217.01	1,647.88	
Financial liabilities					
Trade and other payables	-	-	184.92	184.92	
	-	-	184.92	184.92	

Foreign currency risk

The Group's exposure to foreign currency risk is minimal since the majority of business operations are denominated in Thai Baht.

Liquidity risk

The Group monitors its liquidity requirements to ensure it has sufficient cash to meet operational needs. The Group assesses the concentration of risk with respect to refinancing its debt (if any) and concludes it to be low. The Group has access to a sufficient variety of funding sources.

25.2 Fair value of financial instruments

Since the majority of the Group's financial instruments are short-term in nature or carrying interest at rates close to the market rate, their fair value is not expected to be materially different from the amounts presented in the statement of financial position.

26 Capital management

The primary objective of the Group's capital management is to ensure that it has appropriate capital structure in order to support its business and maximise shareholders value. As at 31 July 2024, the Group's debt-to-equity ratio was 0.16:1 (2023: 0.16:1) and the Company's debt-to-equity ratio was 0.16:1 (2023: 0.16:1).

27 Event after the reporting period

On 26 September 2024, the Meeting of the Board of Directors of the Company passed a resolution approving the dividend payment for the year 2024 to the Company's shareholders at Baht 0.60 per share or a total of Baht 108 million. The payment of dividend will later be proposed for approval in the Annual General Meeting of the Company's shareholders.

28 Approval of financial statements

These financial statements were authorised for issue by the Company's Board of Directors on 26 September 2024.

PART

4



Certification of Accuracy



Certification of Accuracy

The Company has reviewed the information in this report with caution. The Company certifies that such information is correct, complete, not false and does not mislead others or lack of information that should be notified in material aspects. In addition. The Company certified that

- (1) Financial Statement and financial information as part of this One Report have presented accurate and complete information on material aspects relating to the financial position, operating performance, and cash flows of the Company and its subsidiaries.
- (2) The Company has established an excellent information disclosure system to ensure that it has disclosed the material information of both the Company and its subsidiaries correctly and completely, as well as supervising compliance according to the system.
- (3) The Company has established an excellent internal control system and supervised to ensure compliance with such a system. The Company has informed the internal control system assessment information as of July 31st, 2024, to the auditor. It covers deficiencies and significant changes in the internal control system, including malpractices that may affect the preparation of the Company's financial reports and subsidiaries.

The Company has assigned Mr. Prapat Suthawate to sign this document on every page. Suppose any document does not have the signature of Mr. Prapat Suthawate on it. In that case, the Company will assume that it is not the information that the Company has certified the accuracy of above information. In this regard, as evidence that all documents are the same set of certified documents by the Company.

Authorized Director

Name	Position	Signature
1. Mr. Thiti Sihanatkathakul	Director and Chief Executive Officer	
2. Mr. Prapat Suthawate	Director and Company Secretary	

Attorney

Name	Position	Signature
Mr. Prapat Suthawate	Director and Company Secretary	

Attachment

Attachment ① - ⑥



Attachment 1

Board of Directors



Charoen Meensook, M.D.

Chairman of the Board

Age 82 Years

Appointment of Board of Directors 11th October 2004

Education

- M.D. 1967
- Diplomate American Board of Internal Medicine & Subspecialty Board of Gastroenterology 1968 - 1973
- New York State Board 1974
- DTM & H (Liverpool) 1974
- FACG 1975
- FACP 1986

Training

- Director Accreditation Program (DAP) 2005, Thai Institute of Directors (IOD)

Work Experience

2020 - Present	Chairman of the Board, Thainakarin Hospital Public Company Limited
Feb. 2022 - Present	Director, Jatu Charoen Development Company Limited
1993 - Present	Specialist doctor and consultant specialized in internal medicine and gastroenterology, Thainakarin Hospital Public Company Limited
2011 - 2020	Chief Medical Officer, Thainakarin Hospital Public Company Limited
2004 - 2020	Director, Thainakarin Hospital Public Company Limited
1989 - 2010	Medical Director, Thainakarin Hospital Public Company Limited
1989 - 2004	Director, Thainakarin Hospital Company Limited

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

Feb. 2022 - Present Director,
Jatu Charoen Development Company Limited

Shareholding in the Company

Shareholding in the Company: 2,500,000 Shares

(Spouse: 2,285,500 Shares)

Shareholding in the Company (%): 1.39 (Spouse: 1.27)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

4/4



Mr. Thiti Sihanatkathakul

Director and Chief Executive Officer

Age 49 Years

Appointment of Board of Directors 20th November 2008

Education

- BBA, Banking and Finance, Chulalongkorn Business School, Chulalongkorn University
- M.Sc. Analysis, Design and Management of Information Systems, The London School of Economics and Political Science, United Kingdom
- MBA, Huron University, United Kingdom

Training

- N/A

Work Experience

2008 - Present	Director, Thainakarin Hospital Public Company Limited
2022 - Present	Director, Jatu Charoen Development Company Limited
2020 - Present	Chief Executive Officer, Thainakarin Hospital Public Company Limited
2010 - Present	Director, Komars Management Company Limited
2003 - Present	Executive and Director, The Landmark Lancaster Hotel Group
2001 - 2002	Acting Director of Human Resources Department, The Landmark Bangkok
1999 - 2000	Associate Judge, The Central Labour Court
1998	Marketing Department, Dhana Siam Finance Public Company Limited
1997	Management Trainee, Royal Lancaster London, United Kingdom

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

Feb. 2022 - Present	Director, Jatu Charoen Development Company Limited
2010 - Present	Director, Komars Management Company Limited
2003 - Present	Executive and Director, The Landmark Lancaster Hotel Group

Shareholding in the Company

Shareholding in the Company: 5,485,000 Shares (Spouse: N/A)

Shareholding in the Company (%): 3.05 (Spouse: N/A)

Family Relationship among Directors and Executives

- Elder brother of Mr. Pitipat Sihanatkathakul and Mr. Tosaporn Sihanatkathakul
- Cousin of Mr. Norathep Sihanartkatakul

Attendance at the Board of Directors' Meeting

4/4



Mr. Prapat Suthawate

Director and Company Secretary

Age 80 Years

Appointment of Board of Directors 11th October 2004

Education

- Bachelor of Political Science (Public Administration), Ramkhamhaeng University
- Master of Political Science (Government), Chulalongkorn University
- Diploma in Tourism Management and Development, University of Haifa, Israel

Training

- Director Accreditation Program (DAP) 2004, Thai Institute of Directors (IOD)

Work Experience

- 2004 - Present Director, Thainakarin Hospital Public Company Limited
- 2021 - Present Company Secretary, Thainakarin Hospital Public Company Limited
- 2016 - Present Senior Administrative Advisor, Thainakarin Hospital Public Company Limited
- 2016 - Present Member of Bangna Commercial College Council
- 2018 (Jun. - Sep.) Acting on behalf of the Company Secretary, Thainakarin Hospital Public Company Limited
- 2011 - 2016 Acting Administrative Director, Thainakarin Hospital Public Company Limited
- 2010 - 2017 Guest Lecturer, Faculty of Business Administration, Ramkhamhaeng University
- 2007 - 2013 Guest Lecturer, Faculty of Business Administration, Kasetsart University
- 2005 - 2011 Director of International Hotel Management Course, (Joint – venture project between CHN University (Netherlands) and Rangsit University)

- 2005 - 2011 Chairman of Working Group, RSU Horizon Travel, Rangsit University
- 2005 - 2011 Senior Advisor, Thainakarin Hospital Public Company Limited
- 1999 - 2005 Administrative Director, Thainakarin Hospital Public Company Limited
- 1999 - 2004 Director, Thainakarin Hospital Company Limited
- 1992 - 2005 Guest Lecturer, Faculty of Liberal Art, Siam University
- 1992 - 2005 Manager and Advisor, Human Resources Department, Siam Property Development Company Limited

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

- 2016 - Present Member of Bangna Commercial College Council

Shareholding in the Company

Shareholding in the Company: N/A (Spouse: N/A)

Shareholding in the Company (%): N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

4/4



Arkom Cheirsilpa, M.D.

Director

Age 77 Years

Appointment of Board of Directors 20th November 2008

Education

- B.Sc., Mahidol University
- M.D., Cebu Institute of Medicine, Philippines
- Board of Internal Medicine, The Medical Council of Thailand
- Sub - Speciality Board Certified in Medical Oncology
- Fellowship in Oncology (RPMI, USA and RMH, UK)
- Mini MBA, Chulalongkorn University
- MBA in Health, Chulalongkorn University
- Cert. in Hospital Management, Harvard School of Public Health, USA

Training

- Director Accreditation Program (DAP) 2017, Thai Institute of Directors (IOD)

Work Experience

- 2008 - Present Director and Director of Holistic Oncology Center,
Thainakarin Hospital Public Company Limited
- 2007 - Present Honorary Advisor, Thai Society of Clinical Oncology
- 2007 - Present Medical Consultant, Chulabhorn Hospital, Chulabhorn Research Institute
- 1980 - Present Cancer Specialist, Food and Drug Administration Department, Ministry of Public Health
- 2007 Received the World Scientists Forum International Awards in Cancer Research and Clinical Oncology "Eminent Scientist of the Year 2007: Asia" International Research Promotion Council (IRPC), UK
- 2002 - 2007 Deputy Director, National Cancer Institute

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

- 2007 - Present Honorary Advisor,
Thai Society of Clinical Oncology
- 2007 - Present Medical Consultant, Chulabhorn Hospital,
Chulabhorn Research Institute
- 1980 - Present Cancer Specialist, Food and Drug
Administration Department, Ministry of
Public Health

Shareholding in the Company

Shareholding in the Company: N/A (Spouse: N/A)

Shareholding in the Company (%): N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

4/4



Mr. Pitipat Sihanatkathakul

Director

Age 48 Years

Appointment of Board of Directors 20th November 2013

Education

- B.Acc., Assumption University
- Mini MBA, Chulalongkorn University
- M.M. (Organization Development and Management), Assumption University
- Essentials of Leadership Training Course, London Business School, United Kingdom

Training

- Director Accreditation Program (DAP) 2019, Thai Institute of Directors (IOD)

Work Experience

2013 - Present	Director, Thainakarin Hospital Public Company Limited
2016 - Present	Policy, Marketing & Information Technology Advisor, Thainakarin Hospital Public Company Limited
2006 - 2016	Assistant Administrative Director, Thainakarin Hospital Public Company Limited
2005 - 2006	Acting Assistant Administrative Director, Thainakarin Hospital Public Company Limited
2004 - 2005	Information Center and PR Advisor, Thainakarin Hospital Public Company Limited
2002 - 2004	Assistant Manager, Board of Directors Office, Siam Property Development Company Limited

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

- N/A

Shareholding in the Company

Shareholding in the Company: 1,000,000 Shares (Spouse: N/A)

Shareholding in the Company (%): 0.56 Shares (Spouse: N/A)

Family Relationship among Directors and Executives

- Younger brother of Mr. Thiti Sihanatkathakul
- Elder brother of Mr. Tosaporn Sihanatkathakul
- Cousin of Mr. Norathep Sihanartkatakul

Attendance at the Board of Directors' Meeting

3/4



Mr. Noratthep Sihanartkatakul

Director

Age 64 Years

Appointment of Board of Directors 19th November 2015

Education

- Bachelor of Commerce (Marketing), Faculty of Commerce and Accountancy, Chulalongkorn University

Training

- Director Accreditation Program (DAP) 2019, Thai Institute of Directors (IOD)

Work Experience

2015 - Present	Director, Thainakarin Hospital Public Company Limited
2017 - Present	Director, Landmark Overseas Development Company Limited
2011 - Present	Director, Boontuang Company Limited
1998 - Present	Director of Legal Affairs, Siam Property Development Company Limited
1999 - 2001	Associate Judge, The Central Labour Court
1993 - 1998	Assistant Manager of Internal Audit Department, Siam Property Development Company Limited

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

2017 - Present	Director, Landmark Overseas Development Company Limited
2011 - Present	Director, Boontuang Company Limited
1998 - Present	Director of Legal Affairs, Siam Property Development Company Limited

Shareholding in the Company

Shareholding in the Company: N/A (Spouse: N/A)

Shareholding in the Company (%): N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- Cousin of Mr. Thiti Sihanatkathakul, Mr. Pitipat Sihanatkathakul and Mr. Tosaporn Sihanatkathakul

Attendance at the Board of Directors' Meeting

4/4



Mr. Tosaporn Sihanatkathakul

Director

Age 41 Years

Appointment of Board of Directors 13th March 2020

Education

- Tonbridge School, United Kingdom
- BSc. Management, The London School of Economics and Political Science, United Kingdom
- MSc. Organizational and Social Psychology, The London School of Economics and Political Science, United Kingdom

Training

- Successful Formulation & Execution of Strategy (SFE44/2024), Thai Institute of Directors (IOD)

Work Experience

- | | |
|---------------------|--|
| 2020 - Present | Director,
Thainakarin Hospital Public Company Limited |
| Feb. 2022 - Present | Director,
Jatu Charoen Development Company Limited |
| 2007 - Present | Executive and Director,
The Landmark Lancaster Hotel Group |
| 2006 - 2007 | Analyst, Deloitte Management Consultant Service Ltd., United Kingdom |
| 2005 - 2006 | Volunteer, Donations for the Human Development Foundation (HDF) Mercy Centre |

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

- | | |
|---------------------|---|
| Feb. 2022 - Present | Director,
Jatu Charoen Development Company Limited |
| 2007 - Present | Executive and Director,
The Landmark Lancaster Hotel Group |

Shareholding in the Company

Shareholding in the Company: 1,000,000 Shares (Spouse: N/A)

Shareholding in the Company (%): 0.56 (Spouse: N/A)

Family Relationship among Directors and Executives

- Younger brother of Mr. Thiti Sihanatkathakul and Mr. Pitipat Sihanatkathakul
- Cousin of Mr. Norathep Sihanartkatakul

Attendance at the Board of Directors' Meeting

4/4



Col. Dan Tanphaichitra, M.D.

Director

Age 49 Years

Appointment of Board of Directors 18th November 2021

Education

- Doctor of Medicine, Faculty of Medicine, Chulalongkorn University
- Thai Board of internal medicine, Phramongkutklao College of Medicine
- Thai Subspecialty Board of Nephrology, Phramongkutklao College of Medicine

Training

- Director Accreditation Program (DAP) 2022, Thai Institute of Directors (IOD)

Work Experience

2021 - Present	Director, Thainakarin Hospital Public Company Limited
2007 - Present	Nephrologist, Internal medicine division and Medical Secretary Organization, Ananda Mahidol Hospital
2004 - 2006	Nephrology Fellowship, Phramongkutklao College of Medicine
2000 - 2003	Internal medicine residency, Phramongkutklao College of Medicine

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

2007- Present Nephrologist, Internal medicine division and Medical Secretary Organization, Ananda Mahidol Hospital

Shareholding in the Company

Shareholding in the Company: 3,000 Shares (Spouse: N/A)

Shareholding in the Company (%): 0.0017 (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

3/4



Mr. Kraisaak Kadmum

Director, Independent Director and Chairman of the Audit Committee

Age 61 Years

Appointment of Board of Directors 11th October 2004

Education

- LL.B., Faculty of Law, Ramkhamhaeng University
- Barrister-at-law, Thai Bar Institute
- Diploma in Business Laws, Thammasat University

Training

- Director Accreditation Program (DAP) 2004, Thai Institute of Directors (IOD)

Work Experience

- 2005 - Present Director, Independent Director and Chairman of the Audit Committee,
Thainakarin Hospital Public Company Limited
- 2021 - Present Director, Juthai Group Company Limited
- 1994 - Present Lawyer and Executive Director,
Sahakarn Law Office Company Limited
- 2004 - 2005 Director, Independent Director and Member of the Audit Committee,
Thainakarin Hospital Public Company Limited

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

- 2021 - Present Director, Juthai Group Company Limited
- 1994 - Present Lawyer and Executive Director,
Sahakarn Law Office Company Limited

Shareholding in the Company

Shareholding in the Company: N/A (Spouse: N/A)

Shareholding in the Company (%): N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

4/4

Attendance at the Audit Committee Meeting

5/5



Assoc. Prof. Chertsak Dhiraputra, M.D.

Director, Independent Director and Member of the Audit Committee

Age 81 Years

Appointment of Board of Directors 8th June 2006

Education

- Doctor of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
- M.S.C. Microbiology University of New South Wales, Australia

Training

- N/A

Work Experience

2006 - Present	Director, Independent Director and Member of the Audit Committee, Thainakarin Hospital Public Company Limited
2014 - Present	Advisor, Faculty of Medicine Siriraj Hospital, Mahidol University
2005 - Present	Honorary Advisor, Siriraj Foundation
1968 - Present	Lecturer, Faculty of Medicine Siriraj Hospital, Mahidol University
1998 - 2000	Advisor to Hospital Director, Siriraj Hospital
1997 - 2004	Executive Director, Faculty of Medicine Siriraj Hospital, Mahidol University

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

2014 - Present	Advisor, Faculty of Medicine Siriraj Hospital, Mahidol University
2005 - Present	Honorary Advisor, Siriraj Foundation
1968 - Present	Lecturer, Faculty of Medicine Siriraj Hospital, Mahidol University

Shareholding in the Company

Shareholding in the Company: N/A (Spouse: N/A)

Shareholding in the Company (%): N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

4/4

Attendance at the Audit Committee Meeting

5/5



Assoc. Prof. Panya Issarawornrawanich, Ph.D.

Director, Independent Director and Member of the Audit Committee

Age 52 Years

Appointment of Board of Directors 27th September 2006

Education

- B.Acc. Chulalongkorn Business School, Chulalongkorn University
- Diploma (Auditing), Thammasat Business School, Thammasat University
- M.S Accounting, Thammasat Business School, Thammasat University
- Ph.D. in Accounting, Chulalongkorn Business School, Chulalongkorn University

Training

- Director Accreditation Program (DAP) 2006, Thai Institute of Directors (IOD)

Work Experience

- 2006 - Present Director, Independent Director and Member of the Audit Committee, Thainakarin Hospital Public Company Limited
- 2020 - Present Lecturer, Associate Professor of Accounting Department, Thammasat Business School, Thammasat University
- 1997 - Present Certified Public Accountant, Federation of Accounting Professions
- 2004 - 2020 Lecturer, Assistant Professor of Accounting Department, Thammasat Business School, Thammasat University
- 2015 - 2016 Associate Dean for Student Affairs, Thammasat Business School, Thammasat University
- 2013 - 2015 Assistant Dean for Finance and Planning, Thammasat Business School, Thammasat University
- 2000 - 2004 Head of Accounting Department, Faculty of Business Administration, Mahanakorn University of Technology
- 1995 - 2000 Senior Audit Assistant, Ernst and Young Office Limited

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

- 2020 - Present Lecturer, Associate Professor of Accounting Department, Thammasat Business School, Thammasat University
- 1997 - Present Certified Public Accountant, Federation of Accounting Professions

Shareholding in the Company

Shareholding in the Company: N/A (Spouse: N/A)

Shareholding in the Company (%): N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

4/4

Attendance at the Audit Committee Meeting

5/5



Mr. Chailerg Viriyarattanaporn

Director, Independent Director and Member of the Audit Committee

Age 73 Years

Appointment of Board of Directors 10th August 2017

Education

- Bachelor of Business Administration (Accounting), Faculty of Business Administration, Ramkhamhaeng University

Training

- Director Accreditation Program (DAP) 2018, Thai Institute of Directors (IOD)

Work Experience

- 2018 - Present Director, Independent Director and Member of the Audit Committee,
Thainakarin Hospital Public Company Limited
- 2021 - Present Director,
Siamsport Syndicate Public Company Limited
- 2013 - 2017 Accounting & Tax Consultant,
I.G.S Public Company Limited

Current Position in other business

Listed Companies

- N/A

Non-Listed Companies

- 2021 - Present Director,
Siamsport Syndicate Public Company Limited

Shareholding in the Company

Shareholding in the Company: N/A (Spouse: N/A)

Shareholding in the Company (%): N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Attendance at the Board of Directors' Meeting

4/4

Attendance at the Audit Committee Meeting

5/5

Executive



Mr. Thiti Sihanatkathakul

Chief Executive Officer

Age 49 Years

Education

- BBA, Banking and Finance, Chulalongkorn Business School, Chulalongkorn University
- M.Sc. Analysis, Design and Management of Information Systems, The London School of Economics and Political Science, United Kingdom
- MBA, Huron University, United Kingdom

Work Experience

- Oct. 2020 - Present Chief Executive Officer, Thainakarin Hospital Public Company Limited.
- Feb. 2022 - Present Director, Jatu Charoen Development Company Limited
- 2008 - Present Director, Thainakarin Hospital Public Company Limited.
- 2010 - Present Director, Komars Management Company Limited.
- 2003 - Present Executive and Director, The Landmark Lancaster Hotel Group
- 2001 - 2002 Acting Director of Human Resources Department, The Landmark Bangkok Associate Judge, The Central
- 1999 - 2000 Labor Court Marketing Department, Dhana
- 1998 Siam Finance Public Company Limited. Management Trainee, Royal
- 1997 Lancaster Hotel, United Kingdom

Shareholding in the Company (%)

3.05 (Spouse: N/A)

Family Relationship among Directors and Executives

- Elder brother of Mr. Pitipat Sihanatkathakul and Mr. Tosaporn Sihanatkathakul
- Cousin of Mr. Norathep Sihanartkatakul



Prof. Pittayapoom Pattaranutaporn, M.D.

Deputy Chief Executive Officer

Age 68 Years

Education

- Doctor of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

Work Experience

- 2020 - Present Deputy Chief Executive Officer, Thainakarin Hospital Public Company Limited

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A



Clinical Prof. Thipachart Punyaratabandhu, M.D.

ผู้อำนวยการโรงพยาบาลและผู้อำนวยการแพทย์

Age 62 Years

Education

- M.D., Faculty of Medicine, Faculty of Medicine Phramongkutklao, Mahidol University
- Thai board of Orthopaedic Surgery

Work Experience

Nov. 2022 - Present The Hospital Director and Medical Director, Thainakarin Hospital Public Company Limited

1996 - 2022 Orthopedic department, Phramongkutklao Hospital

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A



Phichai Rattanarojsakul, Ph.D.

Deputy Hospital Director

Age 57 Years

Education

- Bachelor of Medicine, Chiang Mai University
- Graduate Diploma Program in Clinical Sciences: Obstetrics and Gynecology, Mahidol University
- Board Certification: Thai Board of Obstetrics and Gynaecology
- Master of Business Administration (M.B.A.), National Institute of Development Administration
- Doctor of Philosophy (Ph.D.), Chulalongkorn University

Work Experience

2023 - Present Deputy Hospital Director, Thainakarin Hospital Public Company Limited

2018 - 2024 Deputy Chief Executive Officer, BPK Hospital Group

2017 - 2020 Managing Director of Innovation, BPK Hospital Group

2017 Director, Bangkok 9 international hospital

2014 - 2017 Director of Medical Technology Innovation and Business Division, Samitivej Hospital Group and BNH Hospitals

2013 - 2014 Director, Kasemrad Prachachuen Hospital

2006 - 2013 Medical Director, Kasemrad Rattana Tibeth Hospital

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A



Dr. Watson Aphiwatanakoon, M.D.

Administrative Director

Age 64 Years

Education

- Bachelor of Medicine, Chiangmai University
- Board Certification: Thai Board of Ophthalmology
- Bachelor of Laws, Sukhothai Thammathirat University
- Mini MBA in Health Care for Senior Executives BDMS & ABAC
- Business and Economics Analyst
Academic Service and Continuing Education Centre,
Faculty of Economics, Chulalongkorn University

Work Experience

- 2022 - Present Administrative Director, Thainakarin Hospital Public Company Limited
- 2022 Executive Vice President of International Affairs, Ratchaphruek Hospital (Khon Kaen)
- 2019 - 2021 Chief Operation Officer, Thonburi Bumrungruang Hospital
- 2019 - 2020 Executive Chairman, Welly Hospital, Weihai, Shandong, China (THG)
- 2017 - 2019 Chief Executive Officer, Ar Yu International Hospital Yangon, Myanmar
- 2015 - 2017 Deputy Hospital Director, Royal Phnom Penh Hospital, Phnom Penh, Cambodia
- 2015 Assistant Hospital Director, Royal Phnom Penh Hospital, Phnom Penh, Cambodia
- 2014 - 2015 Director of Network Operation, Bumrungrad Hospital

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A



Paitoon Kachornvachara, M.D.

Operation Director

Age 61 Years

Education

- Doctor of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
- Diploma of the Thai Board of Internal Medicine, Bhumibol Adulyadej Hospital
- Diploma, Thai Subspecialty Board of Nephrology

Work Experience

- 2020 - Present Operation Director, Thainakarin Hospital Public Company Limited
- 2017 - Present Internal Medicine Physician Thainakarin Hospital Public Company Limited
- 2017 - 2019 Head physician of internal medicine department, Thainakarin Hospital Public Company Limited
- 2015 - 2017 Head of kidney Department, Thainakarin Hospital Public Company Limited

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A



Rungarun Gaesawahong, Ph.D.

Nurse Director

Age 60 Years

Education

- Bachelor of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University
- Master of Nursing Sciences, Nursing Administration from faculty of Nursing, Chulalongkorn University
- Philosophy of Human Resource Development, Faculty of Human Resource Development, Ramkamkaeng University

Work Experience

- 2023 - Present Nurse Director,
Thainakarin Hospital Public Company Limited
- 2022 - 2023 Deputy Medical Director - Nursing,
Thainakarin Hospital Public Company Limited
- 2020 - 2022 Assistant Dean of health Promotion and
Deputy Nursing Director, Ramathibodi hospital,
Faculty of Medicine Ramathibodi Hospital
- 2012 - 2017 Clinical Nurse Development Department
Manager, Samitivej Sukhumvit and Samitivej
Srinakarin
- 2010 - 2011 Nursing Lecturer, Faculty of Nursing Science,
Assumption University
- 2009 - 2010 Nursing Research Director, Bumrungrad
Hospital
- 2007 - 2009 Nursing Director, Nonthavej Hospital,
Nonthaburi
- 2004 - 2006 IPD, Special Unit Nurse Manager, Samitivej
Sukhumvit Hospital
- 2001 - 2004 ICU Nurse Manager and Heart Coordinator at
SBU Heart Institute, Samitivej Sukhumvit
Hospital
- 1989 - 2000 ICU Head Nurse, Samitivej Sukhumvit Hospital

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

*End of tenure as Director of Nursing,
effective from September 1, 2024 onwards.*



Pattarapon Kammuntree, M.D.

Acting as Quality Director and Assistant

Administrative Director

Age 39 Years

Education

- Doctor of medicine, Naresaun University
- Diploma Thai board of Preventive medicine (Public health)
- Master of Business Administration (MBA.), Kasetsart University

Work Experience

- July. 2024 - Present Acting as Quality Director, Thainakarin
Hospital Public Company Limited
- April. 2024 - Present Assistant Administrative Director,
Thainakarin Hospital Public Company
Limited
- 2023 - 2024 Hospital Director,
Panacee Rama II Hospital
- 2022 - 2023 Deputy Hospital Director,
Panacee Rama II Hospital
- 2020 - 2022 Quality Management Representative,
Aek Udon International Hospital

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A



Miss Malee Boonleechai

Acting as Administrative Office Director and Senior
Deputy Administrative Director - Corporate Support

Age 60 Years

Education

- Bachelor of Economics, The Faculty of Economics, Chiang Mai University
- Mini MBA, Thammasat University
- Mini MBA, Chulalongkorn University
- Private Hospital Administration, Private Hospital Association

Work Experience

- | | |
|----------------|--|
| 2020 - Present | Acting as Administrative Office Director, Thainakarin Hospital Public Company Limited |
| 2016 - Present | Senior Deputy Administrative Director - Corporate Support, Thainakarin Hospital Public Company Limited |
| 2018 - 2020 | Deputy Administrative Director - Business Development Thainakarin Hospital Public Company Limited |
| 2006 - 2016 | Deputy Administrative Director, Thainakarin Hospital Public Company Limited |
| 2005 - 2006 | Acting Deputy Administrative Director, Thainakarin Hospital Public Company Limited |
| 2002 - 2005 | Assistant Administrative Director, Thainakarin Hospital Public Company Limited |
| 1994 - 2002 | Manager, Office of Administrative Directors, Thainakarin Hospital Company Limited |
| 1992 - 1994 | Manager, Procurement Department, Thainakarin Hospital Company Limited |

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A



Miss Surunchana Tanpleeratana

Assistant Operation Director -
Customer Service Support

Age 50 Years

Education

- Bachelor of Science (Physiotherapy), Mahidol University
- Mini MBA, Chulalongkorn University
- Master of Business Administration, Faculty of Commerce and Business Administration, Burapha University

Work Experience

- | | |
|----------------|--|
| 2020 - Present | Assistant Operation Director - Customer Service Support, Thainakarin Hospital Public Company Limited |
| 2017 - 2020 | Assistant Administrative Director - Front Service, Thainakarin Hospital Public Company Limited |
| 2016 | Allied Medical Manager, Thainakarin Hospital Public Company Limited |
| 2013 - 2016 | Human Resource Development Manager, Thainakarin Hospital Public Company Limited |
| 1999 - 2013 | Physical therapy Department Manager, Thainakarin Hospital Public Company Limited |

Shareholding in the Company (%)

- N/A (Spouse: N/A)

Family Relationship among Directors and Executives

- N/A

Company Secretary

Mr. Prapat Suthawate

Director and Company Secretary

Education and training

- Bachelor of Political Science (Public Administration), Ramkhamhaeng University
- Master of Political Science (Government), Chulalongkorn University
- Diploma in Tourism Management and Development, University of Haifa, Israel
- Director Accreditation Program (DAP) 2004, Thai Institute of Directors (IOD)

Work Experience

- | | |
|--------------------|--|
| 2004 - Present | Director, Thainakarin Hospital Public Company Limited |
| 2016 - Present | Senior Administrative Advisor, Thainakarin Hospital Public Company Limited |
| 2016 - Present | Member of Bangna Commercial College Council |
| 2018 (Jun. - Sep.) | Acting on behalf of the Company Secretary, Thainakarin Hospital Public Company Limited |
| 2011 - 2016 | Acting Administrative Director, Thainakarin Hospital Public Company Limited |

Current Position in other business

- | | |
|----------------|---|
| 2016 - Present | Member of Bangna Commercial College Council |
|----------------|---|

Mr. Attapong Tipaksorn

Legal Manager and Company Secretary

Education and training

- Bachelor of Law, Bangkok University
- Master of Law, National Institute of Development Administration
- Thai Barrister at Law, The Thai Bar Under Royal Patronage
- Certificate in Advanced Corporate Law, Lawyer Council of Thailand
- Certificate in Advanced Intellectual Property Law, Lawyer Council of Thailand
- Certificate in Medical Law, Medical Law Office, Department of Medical Services, Ministry of Public Health
- Certificate in Fact of Medical Case: Evidence Law, Medical Law Office, Department of Medical Services, Ministry of Public Health
- Company Secretary Program (CSP 117/2021), Thai Institute of Directors (IOD)

Work Experience

- | | |
|----------------|--|
| 2015 - Present | Legal Manager, Thainakarin Hospital Public Company Limited |
| 2015 - 2022 | Audit Committee Secretary, Thainakarin Hospital Public Company Limited |
| 2012 - 2015 | Senior Legal Officer, Ini3 Digital Public Company Limited |
| 2011 - 2012 | Lawyer, Nitichat Accounting and Law Office Company Limited |
| 2007 - 2011 | Lawyer, Arunamrin Law Company Limited |

Current Position in other business

- N/A

The person taking the highest responsibility in finance and accounting and the person supervising accounting

Miss Perapa Teerajareonsup

Age 54 Years

Acting as the person taking the highest responsibility in finance and accounting

Appoint Position 1 November 2021

The person supervising accounting

Appoint Position 1 October 2020

Financial Accounting Manager (Senior)

Appoint Position 1 June 2024

Education

- Bachelor of Business Administration Faculty of Business Administration (Accounting) Ramkhamhaeng University
- Master of Business Administration Management branch For Executives (X-MBA) Class 1 Srinakharinwirot University

Training

- Computer Assisted Analysis Techniques and Solutions (CAATs) by Federation of Accounting Professions Under the Royal Patronage of His Majesty The King
- CFO Orientation Course for New IPOs (Thai Version) by The Stock Exchange of Thailand
- CFO Forum: Shaping the Future of Finance, EY Company Limited (Thailand)
- Corruption Issues that need to be addressed, Federation of Accounting Professions under the Royal Patronage of His Majesty The King

Work Experience

2021 - Present	The person taking the highest responsibility in finance and accounting, Thainakarin Hospital Public Company Limited
June. 2024 - Present	Financial Accounting Manager (Senior), Thainakarin Hospital Public Company Limited
2020 - May 2024	Accounting Manager and The person supervising accounting, Thainakarin Hospital Public Company Limited
2017 - 2019	Accounting and Finance Director, Bangpakok Hospital Group Company Limited (Bangpakok 9 International Hospital)
2016 - 2017	Accounting and Finance Manager, Bangpakok Hospital Group Company Limited (Bangpakok 9 International Hospital)
2015 - 2016	Director of Central Administration Department, Bangkok Chain Hospital Public Company Limited (Kasemrad Hospital Bang Khae)
2005 - 2014	Accounting and Finance Manager, Bangkok Chain Hospital Public Company Limited (Kasemrad Hospital Bang Khae)
2004 - 2005	Head of Accounts Receivable Department, Hospital Network Company Limited (Bangpakok 1 Hospital)
1997 - 2003	Accountant, Cost Accounting Department, Yum Restaurants International (Thailand) Company Limited
1995 - 1997	Auditor's Office Officer, Empire Accounting and Attorney Company Limited

Finance Manager

Miss Thanthanut Choumok

Age 54 Years

Appoint Position: 1 February 2024

Education

- Bachelor Faculty of Business Administration, Faculty of Business Administration, (Accounting), Krirk University

Training

- N/A

Work Experience

Feb. 2024 - Present	Financial Manager, Thainakarin Hospital Public Company Limited
2023 - Jan. 2024	Financial and Accounting Manager, Kluaynamthai Hospital Company Limited
2020 - 2022	Financial and Accounting Manager, Intrarat Hospital Company Limited
2018 - 2020	Financial and Accounting Manager, Vimut Hospital Company Limited
2015 - 2018	Assistant Director of Accounting and Finance, Bangkok Chain Hospital Public Company Limited (World Medical Hospital)
2011 - 2014	Accountant, Phetchaburi Medical Company Limited (Petcharavej Hospital)
2006 - 2011	Accountant, Bangkok Chain Hospital Public Company Limited (Kasemrad Hospital Sukhapibal 3)



Attachment 2



Details of Directors of Subsidiaries

Details of directors of Subsidiaries is Jatu Charoen Development Company Limited as of July 31st, 2024. The Board of Directors consist of 3 Directors as follows;

1. Charoen Meensook, M.D.
2. Mr. Thiti Sihanatkathakul
3. Mr. Tosaporn Sihanatkathakul

Shareholding Structure consist of 4 Shareholders as follows;

List of Shareholders	Number of Shares (Shares)	Shareholding Proportion (%)
Thainakarin Hospital Public Company Limited	9,997	99.97
Charoen Meensook, M.D.	1	0.01
Mr. Thiti Sihanatkathakul	1	0.01
Mr. Tosaporn Sihanatkathakul	1	0.01
Total	10,000	100.00



Attachment 3



Details of the Head of Internal Audit and the Head of Compliance

Miss Thanyaporn Ekpornpadung

Head of Compliance Audit

Age 29 Years

Appoint Position: 12 March 2024

Education and training

- Bachelor of Accountancy, Faculty of Business Administration, Ramkhamhaeng University
- Certified Professional Internal Auditors of Thailand (CPIAT)

Training

- Self-assessment on anti-corruption measures, Thai Institute of Directors (IOD)
- Training of Internal Auditors of Thailand No 70, Institute of Internal Auditors Thailand
- Audit Working Paper and Audit Evidence, Institute of Internal Auditors Thailand
- Strategic Audit Plan and Annual Audit Plan [End-to-End Process], Institute of Internal Auditors Thailand
- Control Measures for Preventing and Detecting Potential Fraud, Federation of Accounting Professions under the Royal Patronage of His Majesty The King
- Analytical Thinking for Internal Audit, Federation of Accounting Professions under the Royal Patronage of His Majesty The King
- COSO 2013, Federation of Accounting Professions under the Royal Patronage of His Majesty The King

Work Experience

Mar. 2024 - Present	Head of Compliance Audit, Thainakarin Hospital Public Company Limited
2023 - Feb. 2024	Internal Audit Assistant Manager, Power Solution Technology Public Company Limited
2021 - 2023	Internal Audit Supervisor, Zhulian (Thailand) Company Limited
2018 - 2020	Senior Internal Audit, Thonburi Healthcare Group Public Company Limited
2016 - 2018	Internal Audit Officer, Berli Jucker Public Company Limited



Attachment 4



Business Assets and Details on asset Valuation

The company discloses information in the Operating Asset section, page 17.



Attachment 5



Policy and Guidelines for Corporate Governance and Code of Conduct

- In progress -



Attachment 6

Report of the Audit Committee

Dear The Company's Board

Thainakarin Hospital Public Company Limited

The Audit Committee is appointed by the Board of Directors and consists of 4 independent directors, namely Mr. Kraisak Kadkum, the Chairman of the Audit Committee, with Assoc. Prof. Chertsak Dhiraputra, M.D., Assoc. Prof. Panya Issarawornrawanich, Ph.D. and Mr. Chailerk Wiriyaratanaporn serves as the Audit Committees whereas Miss Thanyaporn Ekpormpadung acting secretary to the Audit Committee.

The Audit Committee has carefully and independently performed duties in accordance with the scope of roles and responsibilities approved by the Board of Directors and in accordance with applicable laws, rules of the Stock Exchange of Thailand and relevant instructions. The Audit Committee members have effectively harnessed knowledge and competencies in such duty performance and received full access to relevant information and good cooperation from executives, internal auditors and auditors. During the 2024 accounting period from 1 August 2023 to 31 July 2024, the Audit Committee held 5 meetings and executives, internal auditors and external auditors were invited to the meetings to provide relevant information as summarized below:

1. Review of quarterly financial statements and 2024 financial statements - The Audit Committee made inquiries and received clarification from executives and auditors regarding the accuracy and adequacy of financial statements and disclosure. The Audit Committee concurs with the auditor that the financial reports are materially accurate, reliable and in accordance with generally accepted accounting standards.

2. Review of internal audit - The Audit Committee has reviewed the scope of work, roles, responsibilities and independence of internal auditors based on the internal audit guidelines stipulated by the Stock Exchange of Thailand. The Audit Committee is of the opinion that the Company's internal controls are adequate, appropriate and effective, and meet good standards.

3. Review of performance and internal controls - The aim of the review is to assess the adequacy and effectiveness of internal controls which are necessary for the Company's goal achievement. The review is based on the reports on internal audits which have been carried out in accordance to approved audit plans and covered key systems of the Company.

No material issues are found. The Company has appropriately managed the properties and assets and complied with the Securities and Exchange Act, requirements stipulated by the Stock Exchange of Thailand and applicable laws and regulations. Authority delegation and approval have conformed to applicable procedures and effective internal control principles. The Company has also adhered to and updated the principles of good corporate governance to promote transparency and adapt to changes.

4. Review and opinion on related-party transactions and conflicts of interest - Transactions of the Company are reasonable, transparent and beneficial to the Company. Relevant disclosure has been accurately and adequately made.

5. Screening and nomination of auditors - The Audit Committee has reviewed and rendered opinions on the nomination of auditors to the Board of Directors which will be proposed to the shareholders' meeting for approval. The nominated auditors for 2024 are Mrs. Sarinda Hirunprasurtwutti, CPA license number 4799 or Mr. Samran Taengcham, CPA license number 8021 or Mr. Somsak Chiratdhitiampiyong, CPA license number 8874 of EY Office Company Limited. The audit expense budget for the year ended 31 July 2025 includes the audit fee of Baht 1,395,000 and the out-of-pocket expenses within the limit of Baht 30,000 and the company must recruit other auditors for proposing to the General Meeting of Shareholders for considering and approving.

The Audit Committee has dutifully undertaken its responsibilities as assigned by the Board of Directors and is of the opinion that the Company's financial report and operations are correct. The Company has implemented internal controls and internal audits, complied with legal and regulatory requirements and correctly disclosed related-party transactions. In addition, the Company has adhered to the principles of good corporate governance to promote transparency and reliability as well as continuously developed its systems and operations to meet the quality standards and match the business environment.



(Mr. Kraisak Kadkum)

The Chairman of the Audit Committee
Thainakarin Hospital Public Company Limited





345 Debaratna Rd. (Bangna - Trad Rd.), Bong Na Nuea, Bang Na, Bangkok 10260



THE HOSPITAL
—YOU CAN TRUST—
อบอุ่น มั่นใจ ที่ไทรนครินทร์



THAINAKARIN HOSPITAL PUBLIC COMPANY LIMITED
บริษัท โรงพยาบาลไทรนครินทร์ จำกัด (มหาชน)

345 Dabaratna Road (Bangna-Trad) km.3.5, Bangna Nuea, Bangna, Bangkok 10260
Telephone: 0 2340 7777, 0 2340 6488, 0 2340 6499, 0 2361 2727, 0 2361 2828 Facsimile: 0 2340 6431
Email: info@thainakarin.co.th www.thainakarin.co.th

